Revised International Prognostic Scoring System for My

Blood

120, 2454-2465

DOI: 10.1182/blood-2012-03-420489

Citation Report

#	Article	IF	Citations
1	Azacitidine in the management of patients with myelodysplastic syndromes. Therapeutic Advances in Hematology, 2012, 3, 355-373.	1.1	42
3	Comment on â€œExpansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndromeâ€• Journal of Immunology, 2012, 189, 4199.1-4199.	0.4	0
4	Response to Comment on â€œExpansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndromeâ€• Journal of Immunology, 2012, 189, 4199.2-4200.	0.4	0
5	CD8+ T cells far predominate over CD4+ T cells in healthy immune response to Epstein-Barr virus infected lymphoblastoid cell lines. Blood, 2012, 120, 5085-5087.	0.6	6
6	The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood, 2012, 120, 5084-5085.	0.6	50
7	Treatment of Low-Risk Myelodysplastic Syndrome: Hematopoietic Growth Factors Erythropoietins and Thrombopoietins. Seminars in Hematology, 2012, 49, 295-303.	1.8	10
8	Prognostic scoring systems in MDS. Leukemia Research, 2012, 36, 1463-1469.	0.4	20
9	Historical perspectives on myelodysplastic syndromes. Leukemia Research, 2012, 36, 1441-1452.	0.4	17
10	Molecular genetics in myelodysplastic syndromes. Leukemia Research, 2012, 36, 1459-1462.	0.4	25
12	Signal transduction inhibitors in treatment of myelodysplastic syndromes. Journal of Hematology and Oncology, 2013, 6, 50.	6.9	40
13	Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. American Journal of Hematology, 2013, 88, 566-570.	2.0	59
14	Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion. Drugs, 2013, 73, 1183-1196.	4.9	8
15	Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia, 2013, 27, 1803-1812.	3.3	115
16	Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. British Journal of Haematology, 2013, 162, 587-605.	1.2	41
17	Verifying HellstrÃ¶m-Lindberg score as predictive tool for response to erythropoietin therapy according to the â€œInternational Working Groupâ€•criteria, in anemic patients affected by myelodysplastic syndrome: a monocentric experience. International Journal of Hematology, 2013, 97, 472-479.	0.7	4
18	Therapy-related MDS: the importance of repeating cytogenetics and immunophenotyping in â€œrelapsedâ€• AML. Journal of Hematopathology, 2013, 6, 207-211.	0.2	3
19	Myelodysplastic syndromes: What do hospitalists need to know?. Journal of Hospital Medicine, 2013, 8, 351-357.	0.7	21
20	The myelodysplastic syndromes: a personal recollection of four decades of classification and prognostic scoring systems. Leukemia and Lymphoma, 2013, 54, 2588-2591.	0.6	3

#	Article	IF	Citations
21	Monosomal karyotype improves IPSSâ€R stratification in MDS and AML patients treated with Azacitidine. American Journal of Hematology, 2013, 88, 780-783.	2.0	15
22	Clinical Prognostic Factors for Survival and Risk of Progression to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndromes With < 10% Marrow Blasts and Non-Unfavorable Cytogenetic Categories. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 144-152.	0.2	18
23	The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Annals of Hematology, 2013, 92, 1335-1343.	0.8	22
24	Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS. Annals of Hematology, 2013, 92, 1201-1206.	0.8	12
25	Efficacy and safety of deferasirox in myelodysplastic syndromes. Annals of Hematology, 2013, 92, 863-870.	0.8	28
26	High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Annals of Hematology, 2013, 92, 621-631.	0.8	40
28	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. Leukemia Research, 2013, 37, 769-776.	0.4	11
29	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. American Journal of Hematology, 2013, 88, 581-588.	2.0	61
30	Myeloid Neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Surgical Pathology Clinics, 2013, 6, 677-692.	0.7	2
31	Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine. Leukemia Research, 2013, 37, 1516-1521.	0.4	9
32	Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Critical Reviews in Oncology/Hematology, 2013, 88, 231-245.	2.0	26
33	Hypomethylating agents and chemotherapy in MDS. Best Practice and Research in Clinical Haematology, 2013, 26, 411-419.	0.7	7
34	Myelodysplastic syndromes: toward a risk-adapted treatment approach. Expert Review of Hematology, 2013, 6, 611-624.	1.0	23
35	Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?. Expert Review of Hematology, 2013, 6, 539-542.	1.0	5
36	Current therapy of myelodysplastic syndromes. Blood Reviews, 2013, 27, 243-259.	2.8	75
37	Monosomal karyotype in MDS: explaining the poor prognosis?. Leukemia, 2013, 27, 1988-1995.	3.3	42
38	Identification of Gene Expressionâ€"Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2013, 31, 3557-3564.	0.8	45
39	Standardizing the Initial Evaluation for Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2013, 8, 361-369.	1.2	4

#	Article	IF	Citations
40	The euphoria of hypomethylating agents in MDS and AML: Is it justified?. Best Practice and Research in Clinical Haematology, 2013, 26, 275-278.	0.7	8
41	Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S282-S288.	0.2	12
42	Morphology, cytogenetics and classification of MDS. Best Practice and Research in Clinical Haematology, 2013, 26, 337-353.	0.7	37
43	Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2013, 88, 967-974.	2.0	23
44	Myelodysplastic disorders. Medicine, 2013, 41, 261-264.	0.2	0
45	The biology and clinical impact of genetic lesions in myeloid malignancies. Blood, 2013, 122, 3741-3748.	0.6	47
46	Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes. International Journal of Hematology, 2013, 98, 687-693.	0.7	4
47	Thereâ€™s Risk, and Then Thereâ€™s RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2013, 8, 351-360.	1.2	37
48	Emerging patterns of somatic mutations in cancer. Nature Reviews Genetics, 2013, 14, 703-718.	7.7	442
49	Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia, 2013, 27, 1981-1987.	3.3	78
50	Iron chelation therapy in myelodysplastic syndromes: where do we stand?. Expert Review of Hematology, 2013, 6, 397-410.	1.0	46
51	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia, 2013, 27, 1504-1510.	3.3	190
52	Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leukemia Research, 2013, 37, 510-515.	0.4	18
53	Is it time for 5-azacytidine combinations in high-risk myelodysplastic syndrome patients?. Expert Review of Hematology, 2013, 6, 39-42.	1.0	0
54	Acquisition of cytogenetic abnormalities in patients with IPSS defined lowerâ€risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. American Journal of Hematology, 2013, 88, 831-837.	2.0	43
55	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. American Journal of Hematology, 2013, 88, 690-693.	2.0	30
56	Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood, 2013, 122, 3616-3627.	0.6	1,562
57	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 2013, 122, 2943-2964.	0.6	567

#	Article	IF	Citations
58	Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood, 2013, 121, 260-269.	0.6	124
59	Nextâ€generation sequencing â€“ feasibility and practicality in haematology. British Journal of Haematology, 2013, 160, 736-753.	1.2	54
60	Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine. Annals of Hematology, 2013, 92, 411-412.	0.8	15
61	Validation of the new comprehensive cytogenetic scoring system (<scp>NCCSS</scp>) on 630 consecutive de novo <scp>MDS</scp> patients from a single institution. American Journal of Hematology, 2013, 88, 120-129.	2.0	14
62	Prognostic Factors and Risk Models in Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S295-S299.	0.2	13
63	Challenges in Consolidated Reporting of Hematopoietic Neoplasms. Surgical Pathology Clinics, 2013, 6, 795-806.	0.7	7
64	Current pathology practices in and barriers to MDS diagnosis. Leukemia Research, 2013, 37, 1656-1661.	0.4	11
65	Update on Myelodysplastic Syndromes Classification and Prognosis. Surgical Pathology Clinics, 2013, 6, 693-728.	0.7	1
66	Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS). American Journal of Medicine, 2013, 126, e25.	0.6	26
67	A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Leukemia Research, 2013, 37, 1612-1615.	0.4	27
68	Erythropoiesis stimulating agents and other growth factors in low-risk MDS. Best Practice and Research in Clinical Haematology, 2013, 26, 401-410.	0.7	26
69	Allogeneic stem cell transplantation in MDS: How? When?. Best Practice and Research in Clinical Haematology, 2013, 26, 421-429.	0.7	13
70	Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3011-3016.	3.3	225
71	New Strategies in Myelodysplastic Syndromes: Application of Molecular Diagnostics to Clinical Practice. Clinical Cancer Research, 2013, 19, 1637-1643.	3.2	16
72	The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?. Expert Review of Hematology, 2013, 6, 59-68.	1.0	16
73	Correlation between the low marrow blast cutpoint and <scp>WHO</scp> classification for myelodysplastic syndromes. European Journal of Haematology, 2013, 90, 79-80.	1.1	1
74	Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Modern Pathology, 2013, 26, 751-761.	2.9	39
75	Myelodysplasia: New Approaches. Current Treatment Options in Oncology, 2013, 14, 156-169.	1.3	4

#	Article	IF	Citations
76	Decreased 5-hydroxymethylcytosine levels are associated withTET2mutation and unfavorable overall survival in myelodysplastic syndromes. Leukemia and Lymphoma, 2013, 54, 2466-2473.	0.6	46
77	Review of therapeutic options and the management of patients with myelodysplastic syndromes. Expert Review of Hematology, 2013, 6, 165-189.	1.0	3
78	Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy. Immunotherapy, 2013, 5, 621-637.	1.0	17
79	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	3.3	653
81	Prognostic models in myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2013, 2013, 504-510.	0.9	28
82	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British Journal of Haematology, 2013, 162, 74-86.	1.2	73
83	Refractory anemia with ring sideroblasts. Best Practice and Research in Clinical Haematology, 2013, 26, 377-385.	0.7	37
84	Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica, 2013, 98, 1856-1864.	1.7	29
85	5-azacitidine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. International Journal of Hematologic Oncology, 2013, 2, 419-428.	0.7	1
86	Chronic myelomonocytic leukemia: a review of the molecular biology, prognostic models and treatment. International Journal of Hematologic Oncology, 2013, 2, 151-162.	0.7	0
87	Heterogeneity in the myelodysplastic syndromes: moving toward a better understanding. Leukemia and Lymphoma, 2013, 54, 907-908.	0.6	0
88	THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013050.	0.5	8
89	Transplantation for myelodysplastic syndromes 2013. Current Opinion in Hematology, 2013, 20, 494-500.	1.2	11
91	Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. Current Opinion in Hematology, 2013, 20, 150-156.	1.2	13
92	Bone Marrow Transplantation (BMT) in Myelodysplastic Syndromes: To BMT or Not to BMTâ€"That Is the Question. Journal of Clinical Oncology, 2013, 31, 2643-2644.	0.8	5
93	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. Journal of Clinical Oncology, 2013, 31, 2662-2670.	0.8	265
94	Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opinion on Investigational Drugs, 2013, 22, 1495-1509.	1.9	8
95	Serum Ferritin Is an Independent Prognostic Factor in Chinese with Myelodysplastic Syndromes Classified as IPSS Intermediate-1. Acta Haematologica, 2013, 129, 243-250.	0.7	9

#	Article	IF	Citations
96	Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. Journal of Clinical Oncology, 2013, 31, 1669-1676.	0.8	69
97	Importance of Genetics in the Clinical Management of Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 2374-2376.	0.8	9
98	Phase <scp>I</scp> clinical trial of oral rigosertib in patients with myelodysplastic syndromes. British Journal of Haematology, 2013, 162, 517-524.	1.2	48
99	Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes and Cancer, 2013, 52, 1167-1177.	1.5	44
100	Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights. Hematology American Society of Hematology Education Program, 2013, 2013, 522-528.	0.9	14
101	The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany. European Journal of Haematology, 2013, 91, 473-482.	1.1	19
102	Specific Plasma Autoantibody Reactivity in Myelodysplastic Syndromes. Scientific Reports, 2013, 3, 3311.	1.6	8
103	Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine. Blood Cancer Journal, 2013, 3, e155-e155.	2.8	21
104	Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. Journal of Clinical Oncology, 2013, 31, 2671-2677.	0.8	121
105	Absent or Extremely Low Neutrophil Alkaline Phosphatase Activity Levels in Patients with Myelodysplastic Syndromes. Internal Medicine, 2013, 52, 479-482.	0.3	1
106	Components of the revised International Prognostic Scoring System and outcome after hematopoietic cell transplantation for myelodysplastic syndrome. Blood, 2013, 121, 4007-4008.	0.6	5
107	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood, 2013, 122, 1974-1982.	0.6	92
108	The genetic basis of myelodysplasia and its clinical relevance. Blood, 2013, 122, 4021-4034.	0.6	294
109	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood, 2013, 121, 3005-3015.	0.6	251
110	How we treat lower-risk myelodysplastic syndromes. Blood, 2013, 121, 4280-4286.	0.6	126
111	Impact of lead intoxication in children with iron deficiency anemia in low- and middle-income countries. Blood, 2013, 122, 2288-2289.	0.6	4
112	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. Blood, 2013, 122, 2286-2288.	0.6	67
113	Flying without a net in MDS. Blood, 2013, 122, 2925-2926.	0.6	1

#	Article	IF	Citations
114	Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary?. Haematologica, 2013, 98, 490-491.	1.7	13
115	Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica, 2013, 98, 568-575.	1.7	63
116	What lies beyond del(5q) in myelodysplastic syndrome?. Haematologica, 2013, 98, 1819-1821.	1.7	13
117	Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia. Cancers, 2013, 5, 857-874.	1.7	12
118	The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 877-885.	2.3	29
119	Cutting Edge: Flow Cytometry in Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 892-902.	2.3	22
120	Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 838-874.	2.3	181
121	Myelodysplastic Syndromes. Deutsches Ärzteblatt International, 2013, 110, 783-90.	0.6	47
122	Hematopoietic Stem Cell Transplantation for Older Patients With Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1227-1233.	2.3	8
123	Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations. Blood Research, 2013, 48, 87.	0.5	13
124	Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores. PLoS ONE, 2013, 8, e81048.	1.1	22
125	Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica, 2014, 99, 1868-1875.	1.7	19
126	Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia. PLoS ONE, 2014, 9, e100245.	1.1	7
127	CD34 and p53 Immunohistochemical Stains Differentiate Hypocellular Myelodysplastic Syndrome (hMDS) from Aplastic Anemia and a CD34 Immunohistochemical Stain Provides Useful Survival Information for hMDS. Annals of Laboratory Medicine, 2014, 34, 426-432.	1.2	8
128	Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Research, 2014, 49, 216.	0.5	51
129	MicroRNA Dysregulation in the Myelodysplastic Syndromes. MicroRNA (Shariqah, United Arab) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.6	3
130	Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine. Blood Research, 2014, 49, 234.	0.5	15
131	Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy. Stem Cells and Cloning: Advances and Applications, 2014, 7, 101.	2.3	1

#	Article	IF	Citations
132	HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014056.	0.5	2
133	Developments in the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes: epidemiology, etiology, genetics, and targeted therapies. Advances in Genomics and Genetics, 0, , 95.	0.8	2
137	Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks. Current Hematologic Malignancy Reports, 2014, 9, 421-431.	1.2	3
138	Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leukemia Research, 2014, 38, 1381-1391.	0.4	27
139	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a <scp>M</scp>ayo <scp>C</scp>linicâ€<scp>F</scp>rench <scp>C</scp>onsortium <scp>S</scp>tudy. American Journal of Hematology, 2014, 89, 1111-1115.	2.0	129
140	Myelodysplastic syndromes (MDS). Memo - Magazine of European Medical Oncology, 2014, 7, 134-137.	0.3	1
141	Clinical challenge: fatal mucormycotic osteomyelitis caused by Rhizopus microsporus despite aggressive multimodal treatment. BMC Infectious Diseases, 2014, 14, 488.	1.3	9
142	International MDS Working Groups: a model of success to improve diagnosis and treatment in rare diseases: 10-year jubilee of the Austrian MDS platform. Memo - Magazine of European Medical Oncology, 2014, 7, 194-195.	0.3	0
143	Resuscitating a Dying Marrow: the Role of Hematopoietic Growth Factors. Current Hematologic Malignancy Reports, 2014, 9, 412-420.	1.2	0
144	Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia, 2014, 28, 241-247.	3.3	1,291
145	Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer Journal, 2014, 4, e177-e177.	2.8	80
146	Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). Blood Cancer Journal, 2014, 4, e242-e242.	2.8	24
147	Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica, 2014, 99, 28-36.	1.7	42
149	Impact of the revised International Prognostic Scoring System on the outcome of patients with acute myeloid leukemia with or without antecedent myelodysplastic syndrome. Leukemia, 2014, 28, 723-725.	3.3	3
150	Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Modern Pathology, 2014, 27, 681-689.	2.9	50
151	Feedback Signals in Myelodysplastic Syndromes: Increased Self-Renewal of the Malignant Clone Suppresses Normal Hematopoiesis. PLoS Computational Biology, 2014, 10, e1003599.	1.5	34
152	Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia. Haematologica, 2014, 99, e8-e10.	1.7	16
153	Established and novel agents for myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2014, 2014, 82-89.	0.9	8

#	Article	IF	Citations
154	Application of the International Prognostic Scoring System-Revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia, 2014, 28, 185-189.	3.3	50
155	Chromothripsis: Basis of a Concurrent Unusual Association between Myelodysplastic Syndrome and Primary Ciliary Dyskinesia. Case Reports in Hematology, 2014, 2014, 1-5.	0.3	2
156	Cytogenetic as an Important Tool for Diagnosis and Prognosis for Patients with Hypocellular Primary Myelodysplastic Syndrome. BioMed Research International, 2014, 2014, 1-10.	0.9	10
157	Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. Journal of Blood Medicine, 2014, 6, 1.	0.7	14
158	Optimizing Outcomes with Azacitidine: Recommendations from Canadian Centres of Excellence. Current Oncology, 2014, 21, 44-50.	0.9	15
159	PP2A: The Achilles Heal in MDS with 5q Deletion. Frontiers in Oncology, 2014, 4, 264.	1.3	24
160	Limited utility of fluorescencein situhybridization for common abnormalities of myelodysplastic syndrome at first presentation and follow-up of myeloid neoplasms. Leukemia and Lymphoma, 2014, 55, 601-605.	0.6	21
162	Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-ÎºB Gene Network. Cell Reports, 2014, 8, 1328-1338.	2.9	64
163	Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. American Journal of Hematology, 2014, 89, 813-818.	2.0	66
164	Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia. British Journal of Haematology, 2014, 166, 720-728.	1.2	8
165	De novo acute myeloid leukemia with 20â€“29% blasts is less aggressive than acute myeloid leukemia with â‰¥30% blasts in older adults: a <scp>B</scp>one <scp>M</scp>arrow <scp>P</scp>athology <scp>G</scp>roup study. American Journal of Hematology, 2014, 89, E193-9.	2.0	22
166	Comparison of the prognostic utility of the revised International Prognostic Scoring System and the <scp>F</scp>rench Prognostic Scoring System in azacitidineâ€treated patients with myelodysplastic syndromes. British Journal of Haematology, 2014, 166, 352-359.	1.2	31
167	IPSSâ€R in 555 <scp>Taiwanese</scp> patients with primary MDS: Integration of monosomal karyotype can better riskâ€stratify the patients. American Journal of Hematology, 2014, 89, E142-9.	2.0	16
168	Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). Leukemia Research, 2014, 38, 1420-1424.	0.4	9
169	IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. American Journal of Hematology, 2014, 89, 137-144.	2.0	76
170	Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy. Expert Opinion on Pharmacotherapy, 2014, 15, 1621-1630.	0.9	3
171	Transplants in Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America, 2014, 28, 1011-1022.	0.9	3
172	Monosomal karyotype is an independent predictor of survival in patients with higherâ€risk myelodysplastic syndrome. American Journal of Hematology, 2014, 89, E163-8.	2.0	16

#	Article	IF	Citations
173	A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by nextâ€generation sequencing can be revealed by comparative bioinformatic analyses. British Journal of Haematology, 2014, 167, 278-281.	1.2	2
174	Impact of comorbidities by ACEâ€27 in the revisedâ€IPSS for patients with myelodysplastic syndromes. American Journal of Hematology, 2014, 89, 509-516.	2.0	30
175	Clinical Implications of the SETBP1 Mutation in Patients With Primary Myelodysplastic Syndrome and its Stability During Disease Progression. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S153.	0.2	29
176	Should Patients With High-Risk or Transformed Myelodysplastic Syndrome Proceed Directly toÂAllogeneic Transplant Without Prior Cytoreduction by Remission-Induction Chemotherapy or Hypomethylating AgentÂTherapy?. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S42-S45.	0.2	6
177	Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology, 2014, 89, 181-186.	2.0	56
178	Outcomes in <scp>RBC</scp> transfusionâ€dependent patients with <scp>L</scp>owâ€/<scp>I</scp>ntermediateâ€1â€risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the <scp>MDS</scp>â€004 study. European Journal of Haematology, 2014, 93, 429-438.	1.1	32
179	Successful treatment of myelodysplastic syndrome and chronic hepatitis <scp>C</scp> using combined peginterferonâ€±â€2b and ribavirin therapy. Hepatology Research, 2014, 44, 1159-1164.	1.8	1
180	Diagnostic molÃ©culaire des hÃ©mopathies malignes. , 2014, , 57-80.		0
181	End-of-Life Care for Blood Cancers: A Series of Focus Groups With Hematologic Oncologists. Journal of Oncology Practice, 2014, 10, e396-e403.	2.5	142
182	Lessons from the Atomic Bomb About Secondary MDS. Current Hematologic Malignancy Reports, 2014, 9, 407-411.	1.2	1
183	Allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes. Current Opinion in Oncology, 2014, 26, 642-649.	1.1	4
184	Pediatric Myelodysplastic Syndromes. Journal of Pediatric Hematology/Oncology, 2014, 36, 1-7.	0.3	34
185	Mesenchymal Stromal Cell Density Is Increased in Higher Grade Myelodysplastic Syndromes and Independently Predicts Survival. American Journal of Clinical Pathology, 2014, 142, 795-802.	0.4	14
186	Myelodysplastic syndromes in the United States: an update for clinicians. Annals of Medicine, 2014, 46, 283-289.	1.5	22
187	Current Current and novel therapeutic approaches in myelodysplastic syndromes. Journal of Community and Supportive Oncology, 2014, 12, 236-249.	0.1	3
188	Genetic Stratification in Myeloid Diseases: From Risk Assessment to Clinical Decision Support Tool. Rambam Maimonides Medical Journal, 2014, 5, e0025.	0.4	1
189	Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere. Leukemia and Lymphoma, 2014, 55, 2221-2222.	0.6	4
190	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 2691-2698.	0.8	359

#	Article	IF	Citations
191	Validation of the Revised International Prognostic Scoring System for Patients with Myelodysplastic Syndromes. Acta Haematologica, 2014, 131, 231-238.	0.7	15
192	Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current Opinion in Hematology, 2014, 21, 123-130.	1.2	41
193	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. Annals of Oncology, 2014, 25, 447-454.	0.6	38
194	NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia Research, 2014, 38, 619-624.	0.4	3
195	Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. Leukemia Research, 2014, 38, 57-64.	0.4	68
196	High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome. Leukemia Research, 2014, 38, 874-881.	0.4	16
197	Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis. Leukemia Research, 2014, 38, 537-544.	0.4	24
198	Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 196-201.	0.7	10
199	Application of the revised International Prognostic Scoring System for myelodysplastic syndromes in Argentinean patients. Annals of Hematology, 2014, 93, 705-707.	0.8	2
200	Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia. International Journal of Hematology, 2014, 99, 53-56.	0.7	6
201	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. American Journal of Hematology, 2014, 89, 604-609.	2.0	36
202	The characteristics and prognostic analysis in 213 myeloid malignancy patients with del(20q): a report of a single-center case series. Cancer Genetics, 2014, 207, 51-56.	0.2	6
204	Evaluation of epidemiological factors in survival of patients with de novo myelodysplastic syndromes. Cancer Causes and Control, 2014, 25, 425-435.	0.8	3
205	High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome. Tumor Biology, 2014, 35, 2211-2218.	0.8	12
206	Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). Current Hematologic Malignancy Reports, 2014, 9, 57-65.	1.2	11
207	Myelodysplastic syndromes. Lancet, The, 2014, 383, 2239-2252.	6.3	352
208	Guidelines for the diagnosis and management of adult myelodysplastic syndromes. British Journal of Haematology, 2014, 164, 503-525.	1.2	89
209	Myelodysplastic syndromes: 2014 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2014, 89, 97-108.	2.0	118

#	Article	IF	Citations
210	Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. , 2014, 86, 207-215.		25
211	Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. British Journal of Haematology, 2014, 165, 49-56.	1.2	8
212	Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. British Journal of Haematology, 2014, 164, 822-833.	1.2	44
213	Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. Annals of Hematology, 2014, 93, 57-64.	0.8	16
214	Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. European Journal of Cancer, 2014, 50, 1004-1012.	1.3	55
215	Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience. Leukemia Research, 2014, 38, 161-165.	0.4	4
216	Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia, 2014, 28, 958-961.	3.3	59
218	Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. Journal of Geriatric Oncology, 2014, 5, 299-306.	0.5	24
219	Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome. International Journal of Clinical Oncology, 2014, 19, 10-15.	1.0	11
220	Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. Leukemia and Lymphoma, 2014, 55, 1725-1734.	0.6	18
221	Inactivating CUX1 mutations promote tumorigenesis. Nature Genetics, 2014, 46, 33-38.	9.4	111
222	Improved risk stratification by the integration of the revised International Prognostic Scoring System with the Myelodysplastic Syndromes Comorbidity Index. European Journal of Cancer, 2014, 50, 3198-3205.	1.3	26
223	Development and validation of a model to predict platelet response to romiplostim in patients with lowerâ€risk myelodysplastic syndromes. British Journal of Haematology, 2014, 167, 337-345.	1.2	19
224	Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein. Leukemia, 2014, 28, 961-964.	3.3	10
225	Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica, 2014, 99, 613-619.	1.7	61
227	High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes. British Journal of Haematology, 2014, 167, 100-109.	1.2	32
228	Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised <scp>IPSS</scp>. British Journal of Haematology, 2014, 167, 62-68.	1.2	27
229	Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. Biology of Blood and Marrow Transplantation, 2014, 20, 1566-1572.	2.0	24

#	Article	IF	Citations
230	Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica, 2014, 99, 956-964.	1.7	91
231	Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes. Bone Marrow Transplantation, 2014, 49, 1022-1028.	1.3	7
232	Update on the pharmacotherapy for myelodysplastic syndromes. Expert Opinion on Pharmacotherapy, 2014, 15, 1811-1825.	0.9	7
233	Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults. Journal of Clinical Oncology, 2014, 32, 2541-2552.	0.8	132
234	Chronic Myelomonocytic Leukemia Prognostic Classification and Management: Evidence Base and Current Practice. Current Hematologic Malignancy Reports, 2014, 9, 301-310.	1.2	2
235	Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii57-iii69.	0.6	108
236	Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome. Stem Cells Translational Medicine, 2014, 3, 1188-1198.	1.6	7
237	I Walk the Other Line: Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndromes. Current Hematologic Malignancy Reports, 2014, 9, 400-406.	1.2	7
238	I Walk the Line: How to Tell MDS From Other Bone Marrow Failure Conditions. Current Hematologic Malignancy Reports, 2014, 9, 389-399.	1.2	9
239	Epidemiologic study of myelodysplastic syndromes in a multiethnic, inner city cohort. Experimental Hematology and Oncology, 2014, 3, 22.	2.0	7
240	Section II: Hematolymphoid malignancies. Current Problems in Cancer, 2014, 38, 159-174.	1.0	3
241	Identification of acquired mutations by whole-genome sequencing in GATA-2 deficiency evolving into myelodysplasia and acute leukemia. Annals of Hematology, 2014, 93, 1515-1522.	0.8	14
243	Artesunate induces apoptosis through caspase-dependent and -independent mitochondrial pathways in human myelodysplastic syndrome SKM-1 cells. Chemico-Biological Interactions, 2014, 219, 28-36.	1.7	16
244	Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica, 2014, 99, 821-829.	1.7	61
245	Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases. International Journal of Hematology, 2014, 99, 721-725.	0.7	10
246	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. BMC Cancer, 2014, 14, 396.	1.1	10
247	A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies. Clinical Cancer Research, 2014, 20, 5255-5264.	3.2	82
248	The Challenging World of Cytopenias: Distinguishing Myelodysplastic Syndromes From Other Disorders of Marrow Failure. Oncologist, 2014, 19, 735-745.	1.9	27

#	Article	IF	Citations
249	Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1618-1625.	2.0	46
250	Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes. Expert Review of Anticancer Therapy, 2014, 14, 817-829.	1.1	7
251	Proteins related to the spindle and checkpoint mitotic emphasize the different pathogenesis of hypoplastic MDS. Leukemia Research, 2014, 38, 218-224.	0.4	14
252	The GNAS1 gene in myelodysplastic syndromes (MDS). Leukemia Research, 2014, 38, 804-807.	0.4	4
253	Scientific comment on tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 175-177.	0.7	2
254	Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis. Leukemia Research, 2014, 38, 304-309.	0.4	4
255	Total Lymphoid Irradiationâ€“Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation, 2014, 20, 837-843.	2.0	18
256	The Genetic Basis and Expanding Role of Molecular Analysis in the Diagnosis, Prognosis, and Therapeutic Design for Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2014, 16, 145-158.	1.2	32
257	Genomic landscape of CD34 ⁺ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8589-8594.	3.3	52
258	Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromesâ€”proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia, 2014, 28, 1793-1798.	3.3	124
259	Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer, 2014, 120, 1670-1676.	2.0	33
261	Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients. Haematologica, 2014, 99, 951-953.	1.7	0
262	The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. Haematologica, 2014, 99, e31-e32.	1.7	34
263	Multiple Myeloma and Evolution of Novel Biomarkers and Therapies. , 2014, , 895-934.		0
264	Recent developments in myelodysplastic syndromes. Blood, 2014, 124, 2793-2803.	0.6	147
265	How we treat higher-risk myelodysplastic syndromes. Blood, 2014, 123, 829-836.	0.6	91
266	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood, 2014, 123, 2333-2342.	0.6	162
267	Stem cell transplants for myelodysplastic syndromes: refining the outcome predictions. Haematologica, 2014, 99, 1536-1537.	1.7	1

#	Article	IF	Citations
268	Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. , 2014, , n/a-n/a.		21
269	Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. Haematologica, 2014, 99, 1582-1590.	1.7	36
270	Use of deferasirox in transfusion-dependent myelodysplastic syndromes with iron overload. International Journal of Hematologic Oncology, 2014, 3, 211-221.	0.7	0
271	Myelodysplastic syndromes and acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) abnormality. Medicina ClÃnica (English Edition), 2015, 145, 224-226.	0.1	0
272	Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism. Lancet Haematology,the, 2015, 2, e396-e397.	2.2	3
273	Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?. Hematology American Society of Hematology Education Program, 2015, 2015, 308-316.	0.9	16
274	Do somatic mutations in de novo MDS predict for response to treatment?. Hematology American Society of Hematology Education Program, 2015, 2015, 317-328.	0.9	5
275	Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?. Hematology American Society of Hematology Education Program, 2015, 2015, 349-354.	0.9	9
276	Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study. Advances in Therapy, 2015, 32, 1140-1159.	1.3	27
277	A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Experimental Hematology and Oncology, 2015, 5, 12.	2.0	18
278	Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. , 2015, 3, .		14
279	Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. Hematology American Society of Hematology Education Program, 2015, 2015, 294-298.	0.9	34
280	Deferasirox in a refractory anemia after other treatment options: case report and literature review. Clinical Case Reports (discontinued), 2015, 3, 361-367.	0.2	2
282	Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome. Scientific Reports, 2014, 4, 7310.	1.6	22
283	Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. The Cochrane Library, 2015, , CD011577.	1.5	12
285	Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood, 2015, 126, 1699-1706.	0.6	52
286	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood, 2015, 125, 1857-1865.	0.6	153
287	Splicing up the classification of myelodysplasia. Blood, 2015, 126, 128-129.	0.6	1

#	Article	IF	Citations
289	The Level of Bone Marrow WT1 Message is a Useful Marker to Differentiate Myelodysplastic Syndromes with Low Blast Percentage from Cytopenia due to Other Reasons. Internal Medicine, 2015, 54, 445-451.	0.3	5
290	Microsatellite Instability. , 2015, , 2842-2845.		0
291	Acute myeloid leukaemia and myelodysplastic syndromes with 50% or greater erythroblasts: a diagnostic conundrum. Pathology, 2015, 47, 289-293.	0.3	7
292	High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia. Haematologica, 2015, 100, e223-e225.	1.7	12
293	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica, 2015, 100, 205-213.	1.7	20
295	Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a <scp>G</scp>erman diagnostic study in comparison with an international control group. Genes Chromosomes and Cancer, 2015, 54, 809-817.	1.5	8
296	Myelodysplastic syndromes in <scp>S</scp>outh <scp>A</scp>merica: A multinational study of 1080 patients. American Journal of Hematology, 2015, 90, 851-858.	2.0	14
297	Monosomal karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes. Cancer, 2015, 121, 2892-2899.	2.0	22
298	Leukemia diagnosis: today and tomorrow. European Journal of Haematology, 2015, 95, 365-373.	1.1	21
299	Myelodysplastic Syndromes, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 261-272.	2.3	40
300	Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 829-832.	2.3	4
301	Increased glycosylphosphatidylinositolâ€anchored proteinâ€deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8. European Journal of Haematology, 2015, 95, 230-238.	1.1	18
302	Myelodysplastic syndromes: update and nursing considerations. Cancer Nursing Practice, 2015, 14, 28-37.	0.2	0
303	Chronic relapsing remitting Sweet syndrome â€“ a harbinger of myelodysplastic syndrome. British Journal of Haematology, 2015, 170, 649-656.	1.2	38
304	Myelodysplastic syndromes: 2015 Update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2015, 90, 831-841.	2.0	101
305	Comparing the prognostic value of risk stratifying models for patients with lowerâ€risk myelodysplastic syndromes: Is one model better?. American Journal of Hematology, 2015, 90, 1036-1040.	2.0	23
306	Validation of the revised international prognostic scoring system (<scp>IPSS</scp>â€R) in patients with lowerâ€risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet <scp>MDS</scp> (<scp>EUMDS</scp>) registry. British Journal of Haematology, 2015, 170, 372-383.	1.2	72
307	Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes. Haematologica, 2015, 100, e220-e222.	1.7	19

#	Article	IF	Citations
308	Monthly blood transfusions decrease after fourÂmonths of azacitidine. Vox Sanguinis, 2015, 109, 163-167.	0.7	2
309	Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. Transplantation, 2015, 99, 1672-1680.	0.5	19
310	7. HÃmatologische Diagnostik. , 2015, , 125-278.		0
311	Diagnostik von myelodysplastischen Syndromen (MDS) und akuten myeloischen LeukÃmien (AML). Laboratoriums Medizin, 2015, 39, .	0.1	0
312	Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes. Cardiovascular & Hematological Disorders Drug Targets, 2015, 15, 148-161.	0.2	1
313	IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015035.	0.5	22
314	Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q). International Journal of Medical Sciences, 2015, 12, 719-726.	1.1	16
315	Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms: An Update on Risk Stratification, Molecular Genetics, and Therapeutic Approaches Including Allogeneic Hematopoietic Stem Cell Transplantation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e398-e412.	1.8	11
316	REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015018.	0.5	7
317	Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome. Case Reports in Hematology, 2015, 2015, 1-5.	0.3	2
318	Sonic Hedgehog Produced by Bone Marrow-Derived Mesenchymal Stromal Cells Supports Cell Survival in Myelodysplastic Syndrome. Stem Cells International, 2015, 2015, 1-13.	1.2	15
319	Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy. Case Reports in Hematology, 2015, 2015, 1-7.	0.3	10
321	Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e375-e380.	1.8	13
322	RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015034.	0.5	22
323	Eritropoietina SÃ©rica como Marcador PrognÃ³stico em SÃndrome MielodisplÃ¡sica. Acta Medica Portuguesa, 2015, 28, 720.	0.2	6
324	Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia, 2015, 29, 1502-1513.	3.3	106
325	MicroRNA-194-5p could serve as a diagnostic and prognostic biomarker in myelodysplastic syndromes. Leukemia Research, 2015, 39, 763-768.	0.4	30
326	High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia, 2015, 29, 1928-1938.	3.3	36

#	Article	IF	Citations
327	Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. American Journal of Hematology, 2015, 90, 411-416.	2.0	50
328	Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and highâ€risk myelodysplastic syndrome. American Journal of Hematology, 2015, 90, 483-486.	2.0	21
329	Question prompt list responds to information needs of myelodysplastic syndromes patients and caregivers. Leukemia Research, 2015, 39, 599-605.	0.4	17
330	Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes. Expert Opinion on Investigational Drugs, 2015, 24, 725-733.	1.9	30
331	Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors. Diagnostic Pathology, 2015, 10, 44.	0.9	14
332	Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia, 2015, 29, 1875-1881.	3.3	93
333	Correlation of myelodysplastic syndromes with i(17)(q10) and <scp>TP</scp>53 and <scp>SETBP</scp>1 mutations. British Journal of Haematology, 2015, 171, 137-141.	1.2	11
334	A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2015, 21, 985-994.	3.2	47
335	A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. International Journal of Hematology, 2015, 102, 401-412.	0.7	13
336	Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 489-495.	0.2	4
337	Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. Journal of Geriatric Oncology, 2015, 6, 288-298.	0.5	29
338	Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes. Nature Communications, 2015, 6, 8806.	5.8	30
339	CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. Biology of Blood and Marrow Transplantation, 2015, 21, 2106-2114.	2.0	49
340	Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: AÂSingle Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S14-S18.	0.2	7
341	Microarray-based genomic profiling and in situ hybridization on fibrotic bone marrow biopsies for the identification of numerical chromosomal abnormalities in myelodysplastic syndrome. Molecular Cytogenetics, 2015, 8, 33.	0.4	3
342	Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. Leukemia Research, 2015, 39, 52-57.	0.4	18
343	More is better: Combination therapies for myelodysplastic syndromes. Best Practice and Research in Clinical Haematology, 2015, 28, 22-31.	0.7	21
344	Rigosertib induces cell death of a myelodysplastic syndromeâ€derived cell line by <scp>DNA</scp> damageâ€induced G2/M arrest. Cancer Science, 2015, 106, 287-293.	1.7	31

#	Article	IF	Citations
345	Darbepoetin alfa for anemia with myelodysplastic syndrome. Expert Review of Hematology, 2015, 8, 139-146.	1.0	1
346	Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes. European Journal of Haematology, 2015, 95, 181-189.	1.1	27
347	Results of phase 2 randomized study of lowâ€dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer, 2015, 121, 556-561.	2.0	122
348	The molecular pathogenesis of the myelodysplastic syndromes. European Journal of Haematology, 2015, 95, 3-15.	1.1	92
349	â^'7/7qâ^' syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity. Oncogene, 2015, 34, 2413-2425.	2.6	41
350	Transplant for MDS: Challenges and emerging strategies. Best Practice and Research in Clinical Haematology, 2015, 28, 43-54.	0.7	5
351	Mutational profiling in patients with MDS: Ready for every-day use in the clinic?. Best Practice and Research in Clinical Haematology, 2015, 28, 32-42.	0.7	23
352	Immunophenotyping for diagnosis and prognosis in MDS: Ready for general application?. Best Practice and Research in Clinical Haematology, 2015, 28, 14-21.	0.7	9
353	Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years. Biology of Blood and Marrow Transplantation, 2015, 21, 517-525.	2.0	15
354	MDS prognostic scoring systems â€" Past, present, and future. Best Practice and Research in Clinical Haematology, 2015, 28, 3-13.	0.7	42
355	Genetic and epigenetic alterations of bone marrow stromal cells in myelodysplastic syndrome and acute myeloid leukemia patients. Stem Cell Research, 2015, 14, 177-184.	0.3	40
356	Tenâ€Elevenâ€Translocation 2 (<scp>TET</scp>2) is downregulated in myelodysplastic syndromes. European Journal of Haematology, 2015, 94, 413-418.	1.1	18
357	Overexpression of GYS1, MIF, and MYC Is Associated With Adverse Outcome and Poor Response to Azacitidine in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 236-244.	0.2	31
358	Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2015, 21, 866-872.	2.0	19
359	The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leukemia Research, 2015, 39, 177-182.	0.4	39
360	Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. Annals of Hematology, 2015, 94, 23-34.	0.8	12
361	Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients. Cytometry Part B - Clinical Cytometry, 2015, 88, 154-164.	0.7	23
362	Thrombopoiesisâ€stimulating agents and myelodysplastic syndromes. British Journal of Haematology, 2015, 169, 309-323.	1.2	22

#	Article	IF	Citations
364	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Haematologica, 2015, 100, 400-408.	1.7	50
365	Metaphase cytogenetics and single nucleotide polymorphism arrays in myeloid malignancies. Revista Brasileira De Hematologia E Hemoterapia, 2015, 37, 71-72.	0.7	2
366	Clonal origin and evolution of myelodysplastic syndrome analyzed by dysplastic morphology and fluorescence in situ hybridization. International Journal of Hematology, 2015, 101, 58-66.	0.7	1
367	Interobserver variance in myelodysplastic syndromes with less than 5Â% bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2Â% blasts. Annals of Hematology, 2015, 94, 565-573.	0.8	62
368	WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients. Annals of Hematology, 2015, 94, 761-769.	0.8	3
369	Therapy-related myelodysplastic syndrome. Expert Opinion on Drug Safety, 2015, 14, 655-665.	1.0	9
370	Differential profile of PIP4K2A expression in hematological malignancies. Blood Cells, Molecules, and Diseases, 2015, 55, 228-235.	0.6	6
371	Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. Lancet Haematology,the, 2015, 2, e260-e266.	2.2	24
372	Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?. Current Hematologic Malignancy Reports, 2015, 10, 329-333.	1.2	3
373	Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. Oncologist, 2015, 20, 1069-1076.	1.9	20
374	Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML. Leukemia Research, 2015, 39, 1146-1153.	0.4	15
375	Biology of the bone marrow microenvironment and myelodysplastic syndromes. Molecular Genetics and Metabolism, 2015, 116, 24-28.	0.5	22
376	Outcome of patients with lowâ€risk and intermediateâ€1â€risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium. Cancer, 2015, 121, 876-882.	2.0	93
377	Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing. Biology of Blood and Marrow Transplantation, 2015, 21, 1565-1575.	2.0	20
378	Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 556-562.	0.2	8
380	HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia, 2015, 29, 1496-1501.	3.3	65
381	Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes. Leukemia Research, 2015, 39, 846-852.	0.4	22
382	Change of prognosis of patients with myelodysplastic syndromes during the last 30 years. Leukemia Research, 2015, 39, 679-683.	0.4	19

#	Article	IF	Citations
383	Advances in the diagnosis and classification of myelodysplastic syndromes. Diagnostic Histopathology, 2015, 21, 203-211.	0.2	2
384	Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents. Leukemia and Lymphoma, 2015, 56, 3267-3269.	0.6	3
385	Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics. American Journal of Clinical Pathology, 2015, 144, 44-60.	0.4	43
386	Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota. Annals of Hematology, 2015, 94, 1667-1675.	0.8	8
387	New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide. Experimental Hematology, 2015, 43, 661-672.	0.2	7
388	Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2015, 90, 969-983.	1.4	78
389	Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation. Bone Marrow Transplantation, 2015, 50, 1180-1186.	1.3	17
390	Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy. Annals of Medicine, 2015, 47, 209-217.	1.5	20
391	Which prognostic score in MDS? Both!. Leukemia, 2015, 29, 1447-1447.	3.3	1
392	Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leukemia and Lymphoma, 2015, 56, 1718-1722.	0.6	18
394	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. Wiener Klinische Wochenschrift, 2015, 127, 12-15.	1.0	1
395	Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients. Cancer Epidemiology, 2015, 39, 222-228.	0.8	14
396	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood, 2015, 126, 233-241.	0.6	361
397	Cyclosporine Combined with Levamisole for Lower-Risk Myelodysplastic Syndromes. Acta Haematologica, 2015, 134, 138-145.	0.7	10
398	Annotation of Sequence Variants in Cancer Samples. Journal of Molecular Diagnostics, 2015, 17, 339-351.	1.2	9
399	Genetics factors associated with myelodysplastic syndromes. Blood Cells, Molecules, and Diseases, 2015, 55, 76-81.	0.6	8
400	Fluorescencein situhybridization ofTP53for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 3183-3188.	0.6	2
401	Proteins of the mitotic checkpoint and spindle are related to chromosomal instability and unfavourable prognosis in patients with myelodysplastic syndrome. Journal of Clinical Pathology, 2015, 68, 381-387.	1.0	16

#	Article	IF	Citations
402	Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment. Leukemia and Lymphoma, 2015, 56, 3022-3030.	0.6	7
403	Management of chronic myeloid leukemia in blast crisis. Annals of Hematology, 2015, 94, 159-165.	0.8	61
404	Current state of prognostication and risk stratification in myelodysplastic syndromes. Current Opinion in Hematology, 2015, 22, 146-154.	1.2	25
405	Cutting the cord from myelodysplastic syndromes. Current Opinion in Hematology, 2015, 22, 163-170.	1.2	22
406	Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S43-S49.	0.2	5
407	Flow cytometric detection of altered signaling in myelodysplastic syndrome and cytopenia. Leukemia Research, 2015, 39, 1396-1404.	0.4	5
409	The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 3437-3439.	0.6	20
410	Refractory anemia with ring sideroblasts and <scp>RARS</scp> with thrombocytosis. American Journal of Hematology, 2015, 90, 549-559.	2.0	41
411	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer Journal, 2015, 5, e333-e333.	2.8	117
412	Primary Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2015, 90, 1623-1638.	1.4	16
413	Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia, 2015, 29, 2263-2266.	3.3	32
414	Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management. Drugs and Aging, 2015, 32, 891-905.	1.3	15
415	Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Oncologist, 2015, 20, 1404-1412.	1.9	32
416	Dasatinib-induced immunosuppression and recurrent respiratory tract infections. Leukemia and Lymphoma, 2015, 56, 2484-2485.	0.6	7
417	Albumin as a prognostic marker in myelodysplastic syndromes: still relevant after all these years. Leukemia and Lymphoma, 2015, 56, 2491-2492.	0.6	5
418	The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts. BMC Cancer, 2015, 15, 484.	1.1	24
419	Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome. Acta Haematologica, 2015, 134, 40-48.	0.7	12
420	Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. American Journal of Hematology, 2015, 90, 859-863.	2.0	17

#	Article	IF	Citations
421	<scp>TP</scp>53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. British Journal of Haematology, 2015, 171, 91-99.	1.2	43
423	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncology, The, 2015, 16, 1506-1514.	5.1	76
424	Whole-exome sequencing enhances prognostic classification of myeloid malignancies. Journal of Biomedical Informatics, 2015, 58, 104-113.	2.5	9
426	Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients. Bone Marrow Transplantation, 2015, 50, 1145-1149.	1.3	9
427	Incidence and Burden of the Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2015, 10, 272-281.	1.2	108
428	Anemia as the Main Manifestation of Myelodysplastic Syndromes. Seminars in Hematology, 2015, 52, 348-356.	1.8	40
429	Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Modern Pathology, 2015, 28, 1014-1022.	2.9	20
430	The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Review of Anticancer Therapy, 2015, 15, 1019-1036.	1.1	17
431	Guadecitabine for AML and MDS: hype or hope?. Lancet Oncology, The, 2015, 16, 1009-1011.	5.1	5
432	Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S56-S59.	0.2	16
433	Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S60-S63.	0.2	6
434	Time to revise the revised-International Prognostic Scoring System?. Leukemia and Lymphoma, 2015, 56, 3248-3249.	0.6	0
435	Infection Rate and Risk Factors in Patients Treated With Azacitidine. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e141-e142.	0.2	7
436	Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 705-710.	0.2	36
437	Does the concept of lower-risk myelodysplastic syndrome need to be revisited?. Leukemia Research, 2015, 39, 1003-1005.	0.4	4
438	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research, 2015, 39, 1367-1374.	0.4	48
439	Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6359-68.	3.3	45
440	Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes. Leukemia Research, 2015, 39, 866-873.	0.4	11

#	Article	IF	Citations
441	An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States. Journal of Medical Economics, 2015, 18, 341-348.	1.0	14
442	Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy. Immunological Reviews, 2015, 263, 257-278.	2.8	43
443	Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes ä¿ƒçº¢ç»†èƒžç”Ÿæˆç´ æ²»ç——éª¨é«“å¢žç”Ÿå¼ Diabetes, 2015, 7, 493-496.	0.8	0
444	High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Modern Pathology, 2015, 28, 552-563.	2.9	42
447	Treatment of Myelodysplastic Syndrome with Thrombomimetic Drugs. Seminars in Hematology, 2015, 52, 38-45.	1.8	13
448	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern Pathology, 2015, 28, 373-382.	2.9	28
449	Deacetylase inhibitors for the treatment of myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 1205-1212.	0.6	5
450	Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia, 2015, 29, 66-75.	3.3	122
451	Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematological Oncology, 2015, 33, 57-66.	0.8	44
452	Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes. European Journal of Haematology, 2015, 94, 519-525.	1.1	2
453	The myelodysplastic syndromes: the era of understanding. European Journal of Haematology, 2015, 94, 379-390.	1.1	9
454	Introductory Chapter: Myelodysplastic Syndromes. , 0, , .		0
456	Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogÃ©nÃ©tique hÃ©matologique (GFCH). Annales De Biologie Clinique, 2016, 74, 525-534.	0.2	4
457	Treatment of refractory anemia with ring sideroblasts associated with marked thrombocytosis with lenalidomide in a patient testing negative for 5q deletion and JAK2 V617F and MPL W515K/L mutations. Hematology Reports, 2016, 8, 6592.	0.3	8
458	Clinico-pathological spectrum and novel karyotypic findings in myelodysplastic syndrome: Experience of tertiary care centre in India. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017048.	0.5	6
459	Should every patient with MDS get iron chelation â€" probably yes.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017055.	0.5	1
460	Myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017066.	0.5	4
461	Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes. Haematologica, 2016, 101, e177-e181.	1.7	10

#	Article	IF	Citations
462	Clinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience. Yonsei Medical Journal, 2016, 57, 358.	0.9	5
463	Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R. Oncotarget, 2016, 7, 68023-68032.	0.8	7
465	Myelodysplastic Syndromes and Other Precursor Myeloid Neoplasms in the Era of Genomic Medicine (Mini Review). Journal of Leukemia (Los Angeles, Calif), 2016, 04, .	0.1	0
466	Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e337-e344.	1.8	12
467	Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e345-e352.	1.8	1
468	TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes. Oncotarget, 2016, 7, 36266-36279.	0.8	47
469	A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017046.	0.5	3
470	Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis. Oncotarget, 2016, 7, 30492-30503.	0.8	41
471	Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. International Journal of Molecular Sciences, 2016, 17, 440.	1.8	50
472	Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic. International Journal of Molecular Sciences, 2016, 17, 553.	1.8	12
473	Immune Mechanisms in Myelodysplastic Syndrome. International Journal of Molecular Sciences, 2016, 17, 944.	1.8	48
474	SNP Array in Hematopoietic Neoplasms: A Review. Microarrays (Basel, Switzerland), 2016, 5, 1.	1.4	16
475	Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes. PLoS ONE, 2016, 11, e0164370.	1.1	28
476	Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients. PLoS ONE, 2016, 11, e0165582.	1.1	16
477	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. PLoS ONE, 2016, 11, e0166245.	1.1	6
478	Myelodysplastic/myeloproliferative neoplasm overlap syndromes. , 0, , 120-128.		0
479	Myelodysplastic syndromes: Where do we stand?. Asian Journal of Oncology, 0, 02, 014-022.	0.2	0
480	Allogeneic stem cell transplantation in myelodysplastic syndromes. Current Opinion in Hematology, 2016, 23, 167-174.	1.2	16

#	Article	IF	Citations
481	Detection of erythroblast antibodies in mitogenâ€stimulated bone marrow cultures from patients with myelodysplastic syndromes. Transfusion, 2016, 56, 2037-2041.	0.8	12
482	Clinical course of patients with incidental finding of 20qâ€in the bone marrow without a morphologic evidence of myeloid neoplasm. American Journal of Hematology, 2016, 91, 556-559.	2.0	9
483	Novel therapeutic strategies in myelodysplastic syndromes. Current Opinion in Hematology, 2016, 23, 79-87.	1.2	2
484	Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy. British Journal of Haematology, 2016, 173, 49-58.	1.2	27
485	Patientâ€related factors independently impact overall survival in patients with myelodysplastic syndromes: an <scp>MDS</scp>â€<scp>CAN</scp> prospective study. British Journal of Haematology, 2016, 174, 88-101.	1.2	78
486	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a realâ€world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. European Journal of Haematology, 2016, 96, 344-351.	1.1	31
487	The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer, 2016, 122, 681-692.	2.0	17
488	Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy. International Journal of Cancer, 2016, 139, 1402-1413.	2.3	10
489	Long Dayâ€™s Journey Into Night for Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2016, 34, 2956-2957.	0.8	2
490	The World Health Organization revisits the classification of the myelodysplastic syndromes: Improvement and insufficiencies. Blood Cells, Molecules, and Diseases, 2016, 60, 12-15.	0.6	2
491	Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization. American Journal of Clinical Pathology, 2016, 146, 86-94.	0.4	22
492	Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2016, 22, 1615-1620.	2.0	46
493	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (<scp>AML</scp>) and myelodysplastic syndrome (<scp>MDS</scp>). American Journal of Hematology, 2016, 91, 227-232.	2.0	46
494	Chronic neutrophilic leukemia in a child with a CSF3R T618I germ line mutation. Blood, 2016, 128, 2097-2099.	0.6	14
495	Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis. Internal Medicine, 2016, 55, 3351-3356.	0.3	0
496	Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica, 2016, 101, e232-e236.	1.7	13
497	Short telomere length and its correlation with gene mutations in myelodysplastic syndrome. Journal of Hematology and Oncology, 2016, 9, 62.	6.9	23
498	Myelodysplastic Syndromes: Going Gently Into That Good Night. Journal of Oncology Practice, 2016, 12, 795-796.	2.5	0

#	Article	IF	Citations
499	Treatment of low-risk myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2016, 2016, 462-469.	0.9	41
500	Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematology American Society of Hematology Education Program, 2016, 2016, 478-484.	0.9	39
501	Myeloid Cell Leukemia Sequence 1. , 2016, , 2989-2989.		0
502	Anemia and other hematological problems in the elderly. , 2016, , 523-536.		0
503	SÃndromes mielodisplÃ¡sicos. Medicine, 2016, 12, 1224-1234.	0.0	0
504	Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genetics, 2016, 209, 205-214.	0.2	6
505	Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation?. Leukemia, 2016, 30, 1797-1799.	3.3	4
506	Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. Blood Reviews, 2016, 30, 349-356.	2.8	16
507	Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia. Drugs, 2016, 76, 889-900.	4.9	49
508	Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia, 2016, 30, 2214-2220.	3.3	141
509	Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. Modern Pathology, 2016, 29, 727-734.	2.9	8
510	Azacitidine versus decitabine in patients with refractory anemia with excess blastâ€"Results of multicenter study. Leukemia Research, 2016, 45, 82-89.	0.4	14
511	GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome. Experimental Hematology, 2016, 44, 590-595.e1.	0.2	11
512	Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2016, 22, 1227-1233.	2.0	36
513	Myelodysplastic syndrome macrophages have aberrant iron storage and heme oxygenase-1 expression. Leukemia and Lymphoma, 2016, 57, 1893-1902.	0.6	14
514	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 2016, 34, 1864-1871.	0.8	61
515	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusionâ€"dependent anemia and thrombocytopenia. BMC Hematology, 2016, 16, 12.	2.6	31
516	Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia, 2016, 30, 2055-2063.	3.3	99

#	Article	IF	Citations
517	Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia. American Journal of Clinical Pathology, 2016, 145, 497-506.	0.4	36
518	Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course. American Journal of Clinical Pathology, 2016, 145, 459-466.	0.4	4
519	A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. Leukemia and Lymphoma, 2016, 57, 2535-2540.	0.6	11
520	Selective quantitation of microvessel density reveals sinusoidal expansion in myelodysplastic syndromes. Leukemia and Lymphoma, 2016, 57, 2923-2926.	0.6	6
521	Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?). Leukemia Research, 2016, 47, 63-69.	0.4	17
522	Oligonucleotide Arrayâ€"based Comparative Genomic Hybridization Approach in Hematologic Malignancies With Normal/Failed Conventional Cytogenetics and Fluorescent In Situ Hybridization. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 120-127.	0.6	1
523	Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?. Blood Reviews, 2016, 30, 381-388.	2.8	3
524	How I treat MDS and AML in Fanconi anemia. Blood, 2016, 127, 2971-2979.	0.6	77
525	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood, 2016, 127, 2742-2750.	0.6	145
526	Time-dependent changes in mortality and transformation risk in MDS. Blood, 2016, 128, 902-910.	0.6	140
527	Defining risk in MDS over time. Blood, 2016, 128, 885-886.	0.6	3
528	The grade of neoangiogenesis and the bone marrow blast count predict leukemic transformation-free survival in myelodysplastic syndromes. Romanian Journal of Laboratory Medicine, 2016, 24, 228-231.	0.1	0
530	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2016, 34, 3627-3637.	0.8	204
531	Section E6.1â€"6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrowâ€"acquired chromosomal abnormalities. Genetics in Medicine, 2016, 18, 635-642.	1.1	35
532	Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood, 2016, 128, 1408-1417.	0.6	249
533	Jumping translocations in myelodysplastic syndromes. Cancer Genetics, 2016, 209, 395-402.	0.2	7
534	Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S49-S52.	0.2	4
535	Repositioning of bromocriptine for treatment of acute myeloid leukemia. Journal of Translational Medicine, 2016, 14, 261.	1.8	18

#	Article	IF	Citations
536	Molecular Testing in Patients with Suspected Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2016, 11, 441-448.	1.2	6
537	Palliative and End-of-Life Care in Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2016, 11, 434-440.	1.2	7
538	Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. Haematologica, 2016, 101, e427-e428.	1.7	13
539	Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report. Molecular and Clinical Oncology, 2016, 5, 227-230.	0.4	0
540	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer, 2016, 16, 652.	1.1	12
541	Influence of functional polymorphisms in DNA repair genes of myelodysplastic syndrome. Leukemia Research, 2016, 48, 62-72.	0.4	13
542	Rigosertib in myelodysplastic syndromes (MDS). Expert Opinion on Orphan Drugs, 2016, 4, 981-988.	0.5	2
543	Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion on Emerging Drugs, 2016, 21, 283-300.	1.0	15
545	Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. Rna, 2016, 22, 1535-1549.	1.6	40
546	Improving Prognostic Modeling in Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2016, 11, 395-401.	1.2	4
547	Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Medicine, 2016, 5, 1694-1701.	1.3	5
548	Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. British Journal of Haematology, 2016, 175, 975-979.	1.2	15
549	The role of microRNA in myelodysplastic syndromes: beyond DNA methylation and histone modification. European Journal of Haematology, 2016, 96, 553-563.	1.1	9
550	Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 59-63.	0.7	9
551	Myelodysplastic syndromes: Contemporary review and how we treat. American Journal of Hematology, 2016, 91, 76-89.	2.0	153
552	Myelodysplastic Syndromes and Myeloproliferative Disorders. , 2016, , 348-366.		0
553	Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S39-S43.	0.2	10
554	Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes. Annals of Hematology, 2016, 95, 1795-1804.	0.8	1

#	Article	IF	Citations
555	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. Modern Pathology, 2016, 29, 1541-1551.	2.9	11
556	Therapy-related myelodysplastic syndrome following primary breast cancer. Leukemia Research, 2016, 47, 178-184.	0.4	14
557	Matched unrelated donor transplantsâ€"State of the art in the 21st century. Seminars in Hematology, 2016, 53, 221-229.	1.8	7
558	Trends in Clinical Investigation for Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S57-S63.	0.2	11
559	Acute Megakaryoblastic Leukemia with Myelodysplasia-related Changes Associated with ATM Gene Deletion. Internal Medicine, 2016, 55, 1625-1629.	0.3	1
560	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. Journal of Clinical Oncology, 2016, 34, 3284-3292.	0.8	20
561	The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016, 127, 2391-2405.	0.6	7,429
562	Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study. Leukemia and Lymphoma, 2016, 57, 1491-1493.	0.6	3
563	Established and emerging targeted therapies in the myelodysplastic syndromes. Expert Review of Hematology, 2016, 9, 997-1005.	1.0	2
564	Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome. British Journal of Haematology, 2016, 175, 393-401.	1.2	24
565	Monosomal karyotype of chromosome 5/7 was an independent poor prognostic factor for Chinese myelodysplastic syndrome patients. Cancer Genetics, 2016, 209, 423-429.	0.2	5
566	Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Modern Pathology, 2016, 29, 1221-1231.	2.9	22
567	The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapy, 2016, 16, 805-810.	1.1	8
568	Epidemiology, pathogenesis, and etiology of acute leukemia. , 2016, , 3-13.		8
570	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood, 2016, 128, 2096-2097.	0.6	46
571	Clofarabine versus fludarabineâ€based reducedâ€intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. Cancer Medicine, 2016, 5, 3068-3076.	1.3	13
572	Identification of microRNA-regulated pathways using an integration of microRNA-mRNA microarray and bioinformatics analysis in CD34+ cells of myelodysplastic syndromes. Scientific Reports, 2016, 6, 32232.	1.6	11
573	Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki. Cancer Science, 2016, 107, 1484-1491.	1.7	9

#	Article	IF	Citations
574	Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Cancer Biomarkers, 2016, 17, 21-32.	0.8	10
575	Diagnostics of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Laboratoriums Medizin, 2016, 39, .	0.1	1
576	Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis. Acta Haematologica, 2016, 136, 23-42.	0.7	23
577	Natural killer cell (<scp>NK</scp>) subsets and <scp>NK</scp>â€like <scp>T</scp>â€cell populations in acute myeloid leukemias and myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2016, 90, 349-357.	0.7	42
578	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. Genes Chromosomes and Cancer, 2016, 55, 322-327.	1.5	7
579	Azacitidine with or without Entinostat for the treatment of therapyâ€related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. British Journal of Haematology, 2016, 172, 384-391.	1.2	63
580	Efficacy and safety of a 5â€day regimen of azacitidine for patients with highâ€risk myelodysplastic syndromes. European Journal of Haematology, 2016, 97, 228-231.	1.1	6
581	Correlation of somatic mutations with outcome after FLAMSAâ€busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes. European Journal of Haematology, 2016, 97, 288-296.	1.1	14
582	High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. Journal of Translational Medicine, 2016, 14, 66.	1.8	17
583	Causes of death in 2877 patients with myelodysplastic syndromes. Annals of Hematology, 2016, 95, 937-944.	0.8	74
584	Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica, 2016, 101, 781-788.	1.7	50
585	Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Modern Pathology, 2016, 29, 996-1003.	2.9	12
586	Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. Blood Cancer Journal, 2016, 6, e414-e414.	2.8	23
587	The prevalence of chromosomal aberrations associated with myelodysplastic syndromes in China. Annals of Hematology, 2016, 95, 1241-1248.	0.8	7
588	Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5Â%â€”a feasibility study. Annals of Hematology, 2016, 95, 1151-1161.	0.8	4
589	Never too old to treat cancer?. Memo - Magazine of European Medical Oncology, 2016, 9, 2-3.	0.3	0
590	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biology of Blood and Marrow Transplantation, 2016, 22, 1431-1439.	2.0	26
591	Awareness of acute myeloid leukaemia risk induced by diagnosis of a myelodysplastic syndrome. Leukemia Research, 2016, 46, 79-84.	0.4	1

#	Article	IF	Citations
592	Genomic imbalances in peripheral blood confirm the diagnosis of myelodysplastic syndrome in a patient presenting with non-immune hemolytic anemia. Leukemia Research Reports, 2016, 5, 23-26.	0.2	5
593	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. Journal of Hematology and Oncology, 2016, 9, 39.	6.9	36
594	Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clinical Epigenetics, 2016, 8, 68.	1.8	62
595	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica, 2016, 101, e224-e227.	1.7	36
596	Mutations of myelodysplastic syndromes (MDS): An update. Mutation Research - Reviews in Mutation Research, 2016, 769, 47-62.	2.4	87
597	MicroRNA-205-5p is upregulated in myelodysplastic syndromes and induces cell proliferation via PTEN suppression. Leukemia Research, 2016, 47, 172-177.	0.4	15
598	Autoimmune diseases and myelodysplastic syndromes. American Journal of Hematology, 2016, 91, E280-3.	2.0	99
599	Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Current Oncology Reports, 2016, 18, 4.	1.8	17
600	Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias. European Journal of Cancer, 2016, 54, 49-56.	1.3	36
601	Killer Cell Immunoglobulin-Like Receptor Ligand Mismatching: To Match or Mismatch?. Biology of Blood and Marrow Transplantation, 2016, 22, 192-194.	2.0	4
602	Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System. European Journal of Cancer, 2016, 56, 10-20.	1.3	8
603	Helpful Tool or Oversimplification? Concept of the Monosomal Karyotype from the Clinical and Cytogenetic Point of View. Biology of Blood and Marrow Transplantation, 2016, 22, 191-192.	2.0	2
604	Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia, 2016, 30, 1580-1582.	3.3	30
605	Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center. Archives of Pathology and Laboratory Medicine, 2016, 140, 932-949.	1.2	12
606	Improving accuracy of prognosis in patients with myelodysplastic syndromes using self-reported quality of life data. Opportunities for a new research agenda in developing prognostic models. Expert Review of Hematology, 2016, 9, 415-417.	1.0	2
607	Laboratory and clinical risk assessment to treat myelodysplatic syndromes. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1411-1426.	1.4	12
608	Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the â€˜real lifeâ€™ setting: A single center observational study. Hematology, 2016, 21, 34-41.	0.7	13
609	The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the â€œRete Ematologica Lombardaâ€• Leukemia Research, 2016, 42, 21-27.	0.4	7

#	Article	IF	Citations
610	Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO). Hematology, 2016, 21, 162-169.	0.7	1
611	Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clinic Proceedings, 2016, 91, 259-272.	1.4	23
612	Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome. Bone Marrow Transplantation, 2016, 51, 199-204.	1.3	7
613	Current Role of Genetics in Hematologic Malignancies. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 18-31.	0.3	22
614	Immune checkpoint pathways: perspectives on myeloid malignancies. Leukemia and Lymphoma, 2016, 57, 995-1001.	0.6	4
615	Laboratory Test Utilization Management. Surgical Pathology Clinics, 2016, 9, 1-10.	0.7	4
616	Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Surgical Pathology Clinics, 2016, 9, 143-163.	0.7	14
617	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 496-508.	5.1	142
618	Costâ€“effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 275-284.	0.7	4
619	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. Bone Marrow Transplantation, 2016, 51, 194-198.	1.3	22
620	Myelodysplastic syndrome. Cmaj, 2016, 188, 751-751.	0.9	1
621	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leukemia Research, 2016, 41, 43-47.	0.4	27
622	Graphical representation of clinical outcomes for patients with myelodysplastic syndromes. Leukemia and Lymphoma, 2016, 57, 17-20.	0.6	22
623	Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly. Clinics in Geriatric Medicine, 2016, 32, 155-173.	1.0	38
624	New insights into transfusion-related iron toxicity: Implications for the oncologist. Critical Reviews in Oncology/Hematology, 2016, 99, 261-271.	2.0	46
625	Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Annals of Hematology, 2016, 95, 191-199.	0.8	84
626	Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged â‰¥70ÂYears. Biology of Blood and Marrow Transplantation, 2016, 22, 390-393.	2.0	28
627	Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions. Leukemia, 2016, 30, 259-261.	3.3	15

#	Article	IF	Citations
628	Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes. Tumor Biology, 2016, 37, 4633-4640.	0.8	43
629	The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system. Leukemia, 2016, 30, 658-665.	3.3	40
630	Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Annals of Oncology, 2016, 27, 62-68.	0.6	21
631	Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia, 2016, 30, 897-905.	3.3	109
632	Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. Leukemia, 2016, 30, 536-544.	3.3	43
633	Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. Journal of Medical Economics, 2016, 19, 77-83.	1.0	9
634	Isolated trisomy 13 in refractory anemia with excess blasts: report of two cases and a brief literature review of this possible association. Leukemia and Lymphoma, 2016, 57, 493-495.	0.6	0
635	Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leukemia and Lymphoma, 2016, 57, 812-819.	0.6	7
636	Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia, 2016, 30, 649-657.	3.3	66
637	Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia, 2016, 30, 243-247.	3.3	6
638	The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. Blood Reviews, 2016, 30, 1-10.	2.8	32
639	Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leukemia and Lymphoma, 2017, 58, 298-307.	0.6	12
640	Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome. Leukemia and Lymphoma, 2017, 58, 569-577.	0.6	12
641	Phase 2, randomized, doubleâ€blind study of pracinostat in combination with azacitidine in patients with untreated, higherâ€risk myelodysplastic syndromes. Cancer, 2017, 123, 994-1002.	2.0	88
642	Modifying the Phenotypic Frailty Model in Predicting Risk of Major Osteoporotic Fracture in the Elderly. Journal of the American Medical Directors Association, 2017, 18, 414-419.	1.2	6
643	Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia, 2017, 31, 1391-1397.	3.3	51
644	Increase of IRF-1 gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year study. Leukemia Research, 2017, 55, 6-17.	0.4	4
645	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. American Journal of Hematology, 2017, 92, 351-358.	2.0	13

#	Article	IF	Citations
646	Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease. Leukemia Research, 2017, 55, 58-64.	0.4	5
647	MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 2144-2155.	0.6	26
649	Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood, 2017, 129, 2266-2279.	0.6	152
650	Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes. Scientific Reports, 2017, 7, 43113.	1.6	37
651	Myelodysplastic Syndromes. Medical Clinics of North America, 2017, 101, 333-350.	1.1	9
652	Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes. Blood Cancer Journal, 2017, 7, e533-e533.	2.8	12
653	A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers. Leukemia, 2017, 31, 2303-2314.	3.3	64
654	Selfâ€reported sleep disturbance and survival in myelodysplastic syndromes. British Journal of Haematology, 2017, 177, 562-566.	1.2	16
655	Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Annals of Hematology, 2017, 96, 1421-1434.	0.8	33
656	Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Review of Hematology, 2017, 10, 345-364.	1.0	12
657	Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial. Genes Chromosomes and Cancer, 2017, 56, 524-534.	1.5	15
658	New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. Leukemia Research, 2017, 57, 78-84.	0.4	30
659	Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood, 2017, 129, 1685-1690.	0.6	53
660	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematology,the, 2017, 4, e127-e136.	2.2	132
661	Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. Journal of Clinical Pathology, 2017, 70, 435-442.	1.0	19
662	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood, 2017, 129, 1753-1762.	0.6	278
664	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (<scp>RARS</scp>â€<scp>T</scp>): 2017 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2017, 92, 297-310.	2.0	61
665	Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer, 2017, 123, 1703-1713.	2.0	43

#	Article	IF	Citations
666	New polymorphisms of Xeroderma Pigmentosum DNA repair genes in myelodysplastic syndrome. Leukemia Research, 2017, 58, 73-82.	0.4	10
667	An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. American Journal of Hematology, 2017, 92, 674-682.	2.0	24
668	Ironâ€chelating therapy with deferasirox in transfusionâ€dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. British Journal of Haematology, 2017, 177, 741-750.	1.2	23
669	The 2016 revised World Health Organization definition of â€˜myelodysplastic syndrome with isolated del(5q)â€™; prognostic implications of single versus double cytogenetic abnormalities. British Journal of Haematology, 2017, 178, 57-60.	1.2	7
670	Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. International Journal of Hematology, 2017, 106, 375-384.	0.7	17
671	A retrospective study evaluating the impact of infectious complications during azacitidine treatment. Annals of Hematology, 2017, 96, 1097-1104.	0.8	15
672	73-Year-Old Asymptomatic Woman With Anemia. Mayo Clinic Proceedings, 2017, 92, e89-e93.	1.4	0
673	Telomere length is an independent prognostic marker in <scp>MDS</scp> but not in de novo <scp>AML</scp>. British Journal of Haematology, 2017, 178, 240-249.	1.2	21
674	Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica, 2017, 102, 1511-1518.	1.7	35
675	Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes. Methods in Molecular Biology, 2017, 1541, 209-222.	0.4	5
676	5qâ^' syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10). International Journal of Hematology, 2017, 105, 692-696.	0.7	1
677	Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome. Bone Marrow Transplantation, 2017, 52, 522-531.	1.3	11
678	Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Annals of Hematology, 2017, 96, 1361-1372.	0.8	49
680	Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. Annals of Hematology, 2017, 96, 1105-1112.	0.8	11
681	A singleâ€tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes. International Journal of Laboratory Hematology, 2017, 39, 577-584.	0.7	8
682	Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes. Journal of Leukocyte Biology, 2017, 102, 209-219.	1.5	12
683	DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome. Journal of Clinical Pathology, 2017, 70, 970-980.	1.0	10
684	Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes. Annals of Hematology, 2017, 96, 1287-1295.	0.8	4

#	Article	IF	Citations
685	Hematological Disorders in Children. , 2017, , .		2
686	Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. American Journal of Clinical Pathology, 2017, 148, 49-57.	0.4	18
687	Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. Blood, 2017, 130, 832-835.	0.6	55
688	Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. American Journal of Hematology, 2017, 92, E534-E541.	2.0	6
689	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer Journal, 2017, 7, e550-e550.	2.8	21
691	Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies. Critical Reviews in Oncology/Hematology, 2017, 113, 156-170.	2.0	33
692	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer, 2017, 123, 2661-2670.	2.0	14
693	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia, 2017, 31, 2449-2457.	3.3	51
694	Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias. Leukemia Research, 2017, 57, 112-118.	0.4	29
695	Myelodysplastic disorders. Medicine, 2017, 45, 270-274.	0.2	0
696	Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leukemia and Lymphoma, 2017, 58, 2379-2386.	0.6	21
697	Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications. BMC Medical Genomics, 2017, 10, 16.	0.7	34
698	Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5â€azacitidine. European Journal of Haematology, 2017, 99, 112-118.	1.1	13
699	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Annals of Oncology, 2017, 28, 1547-1553.	0.6	46
700	Anemia is present years before myelodysplastic syndrome diagnosis: Results from the preâ€diagnostic period. American Journal of Hematology, 2017, 92, E130-E132.	2.0	5
701	Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. Annals of Hematology, 2017, 96, 887-894.	0.8	7
702	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSSâ€R). American Journal of Hematology, 2017, 92, 614-621.	2.0	12
703	Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure. Leukemia and Lymphoma, 2017, 58, 2532-2539.	0.6	8

#	Article	IF	Citations
704	Dynamic assessment of RBCâ€transfusion dependency improves the prognostic value of the revisedâ€IPSS in MDS patients. American Journal of Hematology, 2017, 92, 508-514.	2.0	25
705	The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. Oncologist, 2017, 22, 379-385.	1.9	16
707	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2017, 23, 971-979.	2.0	16
708	Iron chelation therapy in low risk myelodysplastic syndrome. British Journal of Haematology, 2017, 177, 375-387.	1.2	12
709	Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. American Journal of Hematology, 2017, 92, E117-E119.	2.0	3
710	Clinical significance of isolated del(7p) in myeloid neoplasms. Leukemia Research, 2017, 55, 18-22.	0.4	6
711	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	0.6	4,375
712	The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome*. Leukemia and Lymphoma, 2017, 58, 1893-1902.	0.6	9
713	Therapy-related myelodysplastic syndromes, or are they?. Blood Reviews, 2017, 31, 119-128.	2.8	28
714	Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate. Expert Review of Hematology, 2017, 10, 53-64.	1.0	4
715	Repeated adjuvant antiâ€CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and longâ€term efficacy results of a prospective phase 2 study. Cancer, 2017, 123, 638-649.	2.0	30
716	MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes. Bone Marrow Transplantation, 2017, 52, 532-538.	1.3	5
717	p53 â^'/â^' synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia. Blood, 2017, 129, 358-370.	0.6	29
718	Models of Prognostication in Chronic Myelomonocytic Leukemia. Current Hematologic Malignancy Reports, 2017, 12, 513-521.	1.2	9
719	Diagnostic and Prognostic Utility of Fluorescence In situ Hybridization (FISH) Analysis in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2017, 12, 568-573.	1.2	12
720	Personalized treatment strategies for elderly patients with myelodysplastic syndromes. Expert Review of Hematology, 2017, 10, 1077-1086.	1.0	5
721	Phase 1/2 study of the <scp>WT</scp>1 peptide cancer vaccine <scp>WT</scp>4869 in patients with myelodysplastic syndrome. Cancer Science, 2017, 108, 2445-2453.	1.7	27
722	Individual risk assessment in MDS in the era of genomic medicine. Seminars in Hematology, 2017, 54, 133-140.	1.8	2

#	Article	IF	Citations
723	Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies. Cancer Genetics, 2017, 216-217, 128-141.	0.2	13
724	The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. Journal of Translational Internal Medicine, 2017, 5, 139-143.	1.0	50
725	Gene expression and risk of leukemic transformation in myelodysplasia. Blood, 2017, 130, 2642-2653.	0.6	64
726	The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes. Best Practice and Research in Clinical Haematology, 2017, 30, 295-300.	0.7	7
727	Flow Cytometric Assessment of Chronic Myeloid Neoplasms. Clinics in Laboratory Medicine, 2017, 37, 803-819.	0.7	3
728	Should Molecular Genetics Guide the Decision for Allogeneic Transplant? - Con. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S83-S84.	0.2	0
729	SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 613-620.	0.2	8
730	Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells. Blood, 2017, 130, 2762-2773.	0.6	52
732	A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry. Annals of Hematology, 2017, 96, 2025-2029.	0.8	12
733	A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis. Annals of Hematology, 2017, 96, 1811-1823.	0.8	8
734	Ring chromosome in myeloid neoplasms is associated with complex karyotype and disease progression. Human Pathology, 2017, 68, 40-46.	1.1	5
735	Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study. Leukemia Research, 2017, 60, 135-144.	0.4	8
736	Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. Advances in Therapy, 2017, 34, 2104-2119.	1.3	9
737	MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands. Cancer Epidemiology, 2017, 50, 137-140.	0.8	4
738	Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2017, 12, 478-483.	1.2	7
739	Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. Bone Marrow Transplantation, 2017, 52, 1519-1525.	1.3	19
740	Management of Lower Risk Non-del(5q) MDS. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S35-S36.	0.2	0
741	Characterization of <scp>TP</scp>53 mutations in lowâ€grade myelodysplastic syndromes and myelodysplastic syndromes with a nonâ€complex karyotype. European Journal of Haematology, 2017, 99, 536-543.	1.1	20

#	Article	IF	Citations
742	Screening of mutations in the additional sex combs like 1, transcriptional regulator, tumor protein p53, and KRAS proto-oncogene, GTPase/NRAS proto-oncogene, GTPase genes of patients with myelodysplastic syndrome. Biomedical Reports, 2017, 7, 343-348.	0.9	3
743	Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncology, The, 2017, 18, 1338-1347.	5.1	241
744	Defeating anaemia in myelodysplastic syndromes: another step forward. Lancet Oncology, The, 2017, 18, 1290-1292.	5.1	1
745	Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome. Medical Oncology, 2017, 34, 168.	1.2	15
746	Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes. Blood Cancer Journal, 2017, 7, e602-e602.	2.8	8
747	IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes. Acta Haematologica, 2017, 138, 143-151.	0.7	18
748	High frequency of RUNX1 mutation in myelodysplastic syndrome patients with whole-arm translocation of der(1;7)(q10;p10). Leukemia, 2017, 31, 2257-2260.	3.3	11
749	ITACA: A new validated international erythropoietic stimulating agentâ€response score that further refines the predictive power of previous scoring systems. American Journal of Hematology, 2017, 92, 1037-1046.	2.0	20
751	Overall survival in lower <scp>IPSS</scp> risk <scp>MDS</scp> by receipt of iron chelation therapy, adjusting for patientâ€related factors and measuring from time of first red blood cell transfusion dependence: an <scp>MDS</scp>â€<scp>CAN</scp> analysis. British Journal of Haematology, 2017, 179, 83-97.	1.2	48
752	Diagnosis of Acquired Aplastic Anemiaa. , 2017, , 35-50.		0
753	Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis. Cancer, 2017, 123, 4608-4616.	2.0	18
755	Differential expression of homologous recombination <scp>DNA</scp> repair genes in the early and advanced stages of myelodysplastic syndrome. European Journal of Haematology, 2017, 99, 323-331.	1.1	7
756	Monosomy 7/del (7q) in inherited bone marrow failure syndromes: A systematic review. Pediatric Blood and Cancer, 2017, 64, e26714.	0.8	16
757	Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes. American Journal of Hematology, 2017, 92, E631-E634.	2.0	4
758	First-line Therapeutic Strategies for Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S31-S36.	0.2	7
759	Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and ImmuneÂCheckpoints. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S16-S25.	0.2	6
760	Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?. Leukemia, 2017, 31, 2539-2541.	3.3	10
761	Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Seminars in Hematology, 2017, 54, 159-166.	1.8	32

#	Article	IF	Citations
762	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood, 2017, 130, 1514-1522.	0.6	151
763	The Complexities of Defining a Complex Karyotype in Hematological Malignancies: A Need for Standardization?. Acta Haematologica, 2017, 138, 65-66.	0.7	4
764	Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. Leukemia, 2017, 31, 2848-2850.	3.3	62
765	Introduction. Seminars in Hematology, 2017, 54, 129-132.	1.8	0
766	Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence. Leukemia Research, 2017, 60, 123-128.	0.4	8
767	Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leukemia Research, 2017, 63, 72-77.	0.4	14
768	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leukemia Research, 2017, 63, 85-89.	0.4	9
769	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 753-758.	0.2	18
770	Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report. Oncology Letters, 2017, 14, 97-102.	0.8	11
771	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood, 2017, 130, 1156-1164.	0.6	210
772	How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome. Current Research in Translational Medicine, 2017, 65, 65-69.	1.2	25
773	Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings. Expert Opinion on Pharmacotherapy, 2017, 18, 1213-1224.	0.9	13
774	Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22). American Journal of Clinical Pathology, 2017, 147, 411-419.	0.4	6
775	Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes. Pathology, 2017, 49, 526-533.	0.3	3
776	Calcium Pyrophosphate Crystal Inflammatory Arthritis (Pseudogout) with Myelodysplastic Syndrome: A New Paraneoplastic Syndrome?. Journal of Rheumatology, 2017, 44, 1101-1102.	1.0	8
777	Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 743-752.e5.	0.2	1
779	Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes. Seminars in Hematology, 2017, 54, 154-158.	1.8	7
780	Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents. Biology of Blood and Marrow Transplantation, 2017, 23, 1509-1514.	2.0	33

#	Article	IF	Citations
781	Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity. Seminars in Hematology, 2017, 54, 147-153.	1.8	8
782	What Is the Clinical Utility of Repeat SNP Array Testing in the Follow-up of Myeloid Neoplasms?. American Journal of Clinical Pathology, 2017, 147, 278-284.	0.4	1
783	SIVA, a target of p53, is downregulated in myelodysplastic syndromes. Applied Cancer Research, 2017, 37, .	1.0	0
784	Preclinical modeling of myelodysplastic syndromes. Leukemia, 2017, 31, 2702-2708.	3.3	34
785	Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients. International Journal of Clinical Oncology, 2017, 22, 380-386.	1.0	1
786	The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nature Reviews Cancer, 2017, 17, 5-19.	12.8	542
787	Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia. Genes Chromosomes and Cancer, 2017, 56, 243-252.	1.5	10
788	Excess mortality in the myelodysplastic syndromes. American Journal of Hematology, 2017, 92, 149-154.	2.0	15
789	Chromosomes and Chromosomal Instability in Human Cancer. , 2017, , 241-262.		0
790	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8. Biology of Blood and Marrow Transplantation, 2017, 23, 75-80.	2.0	6
791	Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes. Therapeutic Advances in Hematology, 2017, 8, 21-27.	1.1	9
792	Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*. Leukemia and Lymphoma, 2017, 58, 1325-1331.	0.6	23
793	MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. Cellular Oncology (Dordrecht), 2017, 40, 97-103.	2.1	65
794	Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplantation, 2017, 52, 209-215.	1.3	37
795	A replicable CD271+ mesenchymal stromal cell density score: bringing the dysfunctional myelodysplastic syndrome niche to the diagnostic laboratory. Leukemia and Lymphoma, 2017, 58, 1730-1732.	0.6	5
796	Clinical significance of <scp>TFR</scp>2 and <scp>EPOR</scp> expression in bone marrow cells in myelodysplastic syndromes. British Journal of Haematology, 2017, 176, 491-495.	1.2	8
797	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leukemia and Lymphoma, 2017, 58, 872-881.	0.6	29
798	Validation of the <scp>WHO</scp> 2016 proposals for Myelodysplastic syndromes patients with the presence of ring sideroblasts but without excess blasts. British Journal of Haematology, 2017, 178, 813-816.	1.2	7

#	Article	IF	Citations
799	Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. International Journal of Hematology, 2017, 105, 44-51.	0.7	15
800	Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leukemia and Lymphoma, 2017, 58, 1022-1036.	0.6	53
801	Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 7-13.	0.2	5
802	Phase 2 study of lowâ€dose clofarabine plus cytarabine for patients with higherâ€risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer, 2017, 123, 629-637.	2.0	31
803	Allogeneic Stem Cell Transplantation for Patients Age â‰¥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biology of Blood and Marrow Transplantation, 2017, 23, 44-52.	2.0	49
804	Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome. Acta Haematologica, 2017, 137, 32-39.	0.7	19
805	Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leukemia Research, 2017, 52, 50-57.	0.4	25
806	Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusionâ€dependent patients with myelodysplastic syndromes. Vox Sanguinis, 2017, 112, 79-86.	0.7	36
807	Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience. Blood Cancer Journal, 2017, 7, 655.	2.8	3
808	Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer Journal, 2017, 7, 644.	2.8	15
811	Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2017, 38, 157-162.	0.2	0
812	Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach. BMC Clinical Pathology, 2017, 17, 28.	1.8	3
813	Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS. Current Hematologic Malignancy Reports, 2017, 12, 461-467.	1.2	25
814	Hematopoietic cell transplants for myelodysplastic syndromes. , 0, , 328-338.		0
815	New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 480-494.	1.8	9
817	25 BlutbildverÃnderungen (II). , 2017, , .		0
818	Successful treatment of donor cell derived myelodysplastic syndrome with 5-azacytidine. Annales De Biologie Clinique, 2017, 75, 713-714.	0.2	1
819	Diagnostics and Prognostication of Myelodysplastic Syndromes. Annals of Laboratory Medicine, 2017, 37, 465-474.	1.2	18

#	Article	IF	Citations
820	The Use of Flow Cytometry in Myelodysplastic Syndromes: A Review. Frontiers in Oncology, 2017, 7, 270.	1.3	29
821	Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia. Case Reports in Hematology, 2017, 2017, 1-5.	0.3	5
822	Acute Myeloid Leukemia with Basophilic Differentiation Transformed from Myelodysplastic Syndrome. Case Reports in Hematology, 2017, 2017, 1-6.	0.3	2
823	The uniqueness of morphological features of pure erythroid leukemia in myeloid neoplasm with erythroid predominance: A reassessment using criteria revised in the 2016 World Health Organization classification. PLoS ONE, 2017, 12, e0172029.	1.1	3
824	Hematopoietic cell transplants for children with acute lymphoblastic leukemia. , 0, , 291-297.		0
825	Epoetin Î² pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report. Journal of Medical Case Reports, 2017, 11, 296.	0.4	2
826	TET2 is upregulated during erythroid differentiation of CD34+ cells from healthy donors and myelodysplastic syndrome patients. Applied Cancer Research, 2017, 37, .	1.0	0
827	Myelodysplasia. , 0, , 156-166.		0
828	Methylation and expression of mismatch repair gene human mutS homolog 2 in myelodysplastic syndromes. Experimental and Therapeutic Medicine, 2018, 15, 500-505.	0.8	0
829	Patient with a short history of hemoptysis, fever and melena. Bangabandhu Sheikh Mujib Medical University Journal, 2017, 10, 157.	0.0	0
830	A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes. Blood Advances, 2017, 1, 1505-1516.	2.5	19
831	THROMBOCYTOPENIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - STILL AN UNSOLVED PROBLEM. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, e2018046.	0.5	13
832	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 2017, 8, 73483-73500.	0.8	153
833	INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, e2018039.	0.5	14
834	Monosomal karyotype in myeloid neoplasias: a literature review. OncoTargets and Therapy, 2017, Volume 10, 2163-2171.	1.0	13
835	Techniques for detecting chromosomal aberrations in myelodysplastic syndromes. Oncotarget, 2017, 8, 62716-62729.	0.8	6
836	Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. Journal of Clinical Oncology, 2017, 35, 2745-2753.	0.8	205
837	Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Advances, 2017, 1, 2032-2040.	2.5	53

#	Article	IF	Citations
838	Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. Journal of Clinical Oncology, 2017, 35, 968-974.	0.8	117
839	Current treatment algorithm for the management of lower-risk MDS. Hematology American Society of Hematology Education Program, 2017, 2017, 453-459.	0.9	24
840	Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLIâ€"a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Annals of Hematology, 2018, 97, 335-342.	0.8	67
841	Prognostic implication of appendicular skeleton bone marrow abnormalities detected using low-dose multidetector computed tomography in patients with myelodysplastic syndrome. Leukemia, 2018, 32, 2069-2073.	3.3	3
842	(In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes. Leukemia, 2018, 32, 1264-1266.	3.3	1
843	Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience. Biology of Blood and Marrow Transplantation, 2018, 24, 1209-1215.	2.0	14
844	Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia. Seminars in Hematology, 2018, 55, 202-208.	1.8	6
845	Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders. Blood Cancer Journal, 2018, 8, 28.	2.8	19
846	U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. American Journal of Hematology, 2018, 93, E146-E148.	2.0	15
847	Cytogenetic features in primary myelodysplastic syndrome Egyptian patients. Journal of Advanced Research, 2018, 10, 77-83.	4.4	9
848	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E164-E167.	2.0	1
849	Monocyte function in patients with myelodysplastic syndrome. Journal of Leukocyte Biology, 2018, 104, 641-647.	1.5	21
850	The prognostic value of monosomal karyotype (MK) in higherâ€risk patients with myelodysplastic syndromes treated with 5â€Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. American Journal of Hematology, 2018, 93, 895-901.	2.0	10
851	Final results of a phase 2, openâ€label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and highâ€risk myelodysplastic syndrome. Cancer, 2018, 124, 2758-2765.	2.0	78
852	Azacitidine improves outcome in higherâ€risk <scp>MDS</scp> patients with chromosome 7 abnormalities: a retrospective comparison of <scp>GESMD</scp> and <scp>GFM</scp> registries. British Journal of Haematology, 2018, 181, 350-359.	1.2	11
853	The enigma of monosomy 7. Blood, 2018, 131, 2891-2898.	0.6	63
854	Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies. Leukemia and Lymphoma, 2018, 59, 2836-2841.	0.6	28
855	Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leukemia and Lymphoma, 2018, 59, 2801-2811.	0.6	9

#	Article	IF	Citations
856	Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood, 2018, 131, 2782-2788.	0.6	18
857	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer Journal, 2018, 8, 39.	2.8	68
858	How I investigate Clonal cytogenetic abnormalities of undetermined significance. International Journal of Laboratory Hematology, 2018, 40, 385-391.	0.7	16
859	Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leukemia and Lymphoma, 2018, 59, 2952-2962.	0.6	16
860	MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia. Cancer Biomarkers, 2018, 22, 101-110.	0.8	19
861	PAS positivity of erythroid precursor cells is associated with a poor prognosis in newly diagnosed myelodysplastic syndrome patients. International Journal of Hematology, 2018, 108, 30-38.	0.7	0
862	Prognosis in myelodysplastic syndromes: The attractions and limitations of simplicity. American Journal of Hematology, 2018, 93, 605-606.	2.0	0
864	Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematology,the, 2018, 5, e63-e72.	2.2	95
865	Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. Leukemia Research, 2018, 67, 21-26.	0.4	4
866	Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy. Leukemia Research, 2018, 67, 75-81.	0.4	19
867	Establishment and validation of aÂnovel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wiener Klinische Wochenschrift, 2018, 130, 115-125.	1.0	0
868	Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leukemia and Lymphoma, 2018, 59, 2135-2143.	0.6	5
869	Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. Genes Chromosomes and Cancer, 2018, 57, 252-259.	1.5	48
870	Mutations and prognosis in myelodysplastic syndromes: karyotypeâ€adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. American Journal of Hematology, 2018, 93, 691-697.	2.0	50
871	Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. Leukemia Research, 2018, 67, 56-59.	0.4	16
873	Partial tandem duplication of KMT2A (MLL) may predict a subset of myelodysplastic syndrome with unique characteristics and poor outcome. Haematologica, 2018, 103, e131-e134.	1.7	12
874	Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. British Journal of Haematology, 2018, 180, 381-390.	1.2	5
875	IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. Hematology, Transfusion and Cell Therapy, 2018, 40, 92-95.	0.1	0

#	Article	IF	Citations
876	Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes. Expert Review of Precision Medicine and Drug Development, 2018, 3, 23-31.	0.4	1
877	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biology of Blood and Marrow Transplantation, 2018, 24, 997-1004.	2.0	18
878	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 956-963.	2.0	18
879	AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo. Leukemia, 2018, 32, 900-910.	3.3	27
880	Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know. Current Opinion in Hematology, 2018, 25, 120-128.	1.2	4
881	Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1079-1087.	2.0	20
882	The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nature Reviews Clinical Oncology, 2018, 15, 219-233.	12.5	120
883	Management of older adults with myelodysplastic syndromes (MDS). Journal of Geriatric Oncology, 2018, 9, 302-307.	0.5	12
884	Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic model. Leukemia and Lymphoma, 2018, 59, 2227-2232.	0.6	2
885	Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. Expert Review of Hematology, 2018, 11, 109-116.	1.0	3
886	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clinical Epigenetics, 2018, 10, 42.	1.8	36
887	Implications of high EVI1 expression in high-risk myelodysplastic syndromes. Leukemia and Lymphoma, 2018, 59, 2765-2766.	0.6	0
888	Current status and trends in the diagnostics of AML and MDS. Blood Reviews, 2018, 32, 508-519.	2.8	35
889	Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Annals of Hematology, 2018, 97, 1349-1356.	0.8	34
890	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia, 2018, 32, 1380-1392.	3.3	66
891	Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1037-1047.	1.2	18
892	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
893	The current and future role of stem cells in myelodysplastic syndrome therapies. Expert Review of Hematology, 2018, 11, 411-422.	1.0	9

#	Article	IF	Citations
894	To chelate or not to chelate in MDS: That is the question!. Blood Reviews, 2018, 32, 368-377.	2.8	25
895	Bone marrow fibrosis at diagnosis is associated with <scp>TP</scp>53 overexpression and adverse prognosis in lowâ€risk myelodysplastic syndrome. British Journal of Haematology, 2018, 181, 547-549.	1.2	11
896	Multicenter comparison of CD34+ myeloid cell count by flow cytometry in lowâ€risk myelodysplastic syndrome. Is it feasible?. Cytometry Part B - Clinical Cytometry, 2018, 94, 527-535.	0.7	9
897	A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia, 2018, 32, 413-418.	3.3	58
898	Effect of initial body mass index on survival outcome of patients with myelodysplastic syndrome: a single-center retrospective study. Leukemia and Lymphoma, 2018, 59, 129-137.	0.6	5
899	Model-free Scoring System for Risk Prediction with Application to Hepatocellular Carcinoma Study. Biometrics, 2018, 74, 239-248.	0.8	3
900	Verification of Survival Predictors in Elderly Patients with Myelodysplastic Syndrome from Outpatient Clinical Practice. International Journal of Gerontology, 2018, 12, 27-31.	0.7	1
901	Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS. Blood Cells, Molecules, and Diseases, 2018, 69, 90-100.	0.6	24
902	Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches. Advances in Biological Regulation, 2018, 67, 13-29.	1.4	21
903	NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clinical Cancer Research, 2018, 24, 1019-1029.	3.2	87
904	Therapy relatedâ€chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. American Journal of Hematology, 2018, 93, 65-73.	2.0	49
905	Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome. Clinical Chemistry and Laboratory Medicine, 2018, 56, 485-491.	1.4	5
906	Nuclear translocation of PKCâ€Î± is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). FASEB Journal, 2018, 32, 681-692.	0.2	24
907	Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia. Leukemia and Lymphoma, 2018, 59, 1095-1104.	0.6	15
908	Myelodysplastic syndromes (MDS) in regular care in Germany â€“ the oldest patients come to the fore. Leukemia and Lymphoma, 2018, 59, 1244-1247.	0.6	3
909	The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. Annals of Hematology, 2018, 97, 247-254.	0.8	12
910	Myelodysplastic syndromes: 2018 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2018, 93, 129-147.	2.0	154
911	Prognostic importance of Aurora Kinases and mitotic spindle genes transcript levels in Myelodysplastic syndrome. Leukemia Research, 2018, 64, 61-70.	0.4	14

#	Article	IF	Citations
912	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. Biology of Blood and Marrow Transplantation, 2018, 24, 507-513.	2.0	10
913	Patientâ€reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. Cancer, 2018, 124, 1251-1259.	2.0	31
914	The usefulness of mutational data on prognosis of myelodysplastic syndromes: alone or incorporated into the <scp>IPSS</scp>â€R?. British Journal of Haematology, 2018, 183, 815-819.	1.2	13
915	Frailty and the management of hematologic malignancies. Blood, 2018, 131, 515-524.	0.6	146
916	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. American Journal of Hematology, 2018, 93, 277-285.	2.0	54
917	Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?. Leukemia Research, 2018, 64, 24-29.	0.4	10
918	DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. Seminars in Cancer Biology, 2018, 51, 68-79.	4.3	42
919	A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia. Leukemia Research, 2018, 64, 10-16.	0.4	37
920	Epigenetics in myelodysplastic syndromes. Seminars in Cancer Biology, 2018, 51, 170-179.	4.3	45
921	The Wilmsâ€™ tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis. Oncotarget, 2018, 9, 16205-16212.	0.8	7
922	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Advances, 2018, 2, 1765-1772.	2.5	100
923	Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy. Journal of Clinical Investigation, 2018, 128, 5383-5398.	3.9	25
924	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus ¹³¹I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of Clinical Oncology, 2018, 36, 697-703.	0.8	68
926	Treatments targeting MDS genetics: a foolâ€™s errand?. Hematology American Society of Hematology Education Program, 2018, 2018, 277-285.	0.9	5
927	Mining Heterogeneous Information Graph for Health Status Classification. , 2018, , .		5
928	Managing anaemia in bone marrow failure syndromes. Current Opinion in Supportive and Palliative Care, 2018, 12, 538-541.	0.5	1
929	A novel complete blood countâ€based score to screen for myelodysplastic syndrome in cytopenic patients. British Journal of Haematology, 2018, 183, 736-746.	1.2	15
930	The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q). Blood Cancer Journal, 2018, 8, 90.	2.8	8

#	Article	IF	Citations
931	The role of hypomethylating agents prior to hematopoietic cell transplantation in myelodysplastic syndromes. Best Practice and Research in Clinical Haematology, 2018, 31, 346-350.	0.7	0
932	The prognostic impact of loss of chromosome 7 material detected by fluorescence in situ hybridization (FISH) in myeloid malignancies. Journal of the Egyptian National Cancer Institute, 2018, 30, 133-138.	0.6	1
933	Myelodysplastic syndrome from theoretical review to clinical application view. Oncology Reviews, 2018, 12, 397.	0.8	18
934	Utilization of CMA in myeloid, lymphoid and plasma cell disorders. Cancer Genetics, 2018, 228-229, 181-183.	0.2	0
935	The Clinical and Laboratory Features of Clonal Hematopoiesis of Indeterminate Potential. Advances in Molecular Pathology, 2018, 1, 37-42.	0.2	1
936	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. HemaSphere, 2018, 2, e150.	1.2	91
937	Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget, 2018, 9, 27882-27894.	0.8	60
938	Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML. Frontiers in Pharmacology, 2018, 9, 1279.	1.6	15
939	Significance of Cytogenetics in Leukemia Diagnostics. Current Genetic Medicine Reports, 2018, 6, 165-175.	1.9	1
940	Mutational landscape of myelodysplastic/myeloproliferative neoplasmâ€“unclassifiable. Blood, 2018, 132, 2100-2103.	0.6	40
941	Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation. International Journal of Molecular Sciences, 2018, 19, 2991.	1.8	26
942	Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML. Scientific Reports, 2018, 8, 13883.	1.6	11
943	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes and Cancer, 2018, 57, 547-556.	1.5	3
944	Recent Updates on Chronic Myelomonocytic Leukemia. Current Hematologic Malignancy Reports, 2018, 13, 446-454.	1.2	6
945	Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes. International Journal of Hematology, 2018, 108, 598-606.	0.7	14
946	Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. Stem Cell Research and Therapy, 2018, 9, 271.	2.4	63
947	Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. Current Treatment Options in Oncology, 2018, 19, 67.	1.3	26
948	Improving Treatment for Myelodysplastic Syndromes Patients. Current Treatment Options in Oncology, 2018, 19, 66.	1.3	12

#	Article	IF	Citations
949	Genetic Aspects of Hematopoietic Malignancies. , 2018, , 201-234.		1
950	Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion. International Journal of Molecular Sciences, 2018, 19, 3269.	1.8	8
951	Improving Prognostic Tools for Patients With Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2018, 93, 1340-1342.	1.4	1
952	Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. Current Hematologic Malignancy Reports, 2018, 13, 467-476.	1.2	4
953	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Cancer Genetics, 2018, 228-229, 197-217.	0.2	25
954	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research, 2018, 73, 51-57.	0.4	20
955	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leukemia Research, 2018, 73, 78-85.	0.4	9
956	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E398-E401.	2.0	1
957	A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. Systematic Reviews, 2018, 7, 144.	2.5	15
958	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 1028-1041.	13.9	93
959	Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nature Communications, 2018, 9, 3694.	5.8	66
960	Sequential HLAâ€haploidentical transplantation utilizing postâ€transplantation cyclophosphamide for GvHD prophylaxis in highâ€risk and relapsed/refractory AML/MDS. American Journal of Hematology, 2018, 93, 1524-1531.	2.0	17
962	Fiveâ€day regimen of azacitidine for lowerâ€risk myelodysplastic syndromes (refractory anemia or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2018, 109, 3209-3215.	1.7	15
963	Extended Abstract: Treatment of Lower-Risk Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S17-S18.	0.2	0
964	Selecting the Right Lower Risk Patient For Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S25-S27.	0.2	0
965	Mutations and karyotype predict treatment response in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, 1420-1426.	2.0	25
966	Molecular Genetics of MDS. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S45-S47.	0.2	0
967	The MDS genomics-prognosis symbiosis. Hematology American Society of Hematology Education Program, 2018, 2018, 270-276.	0.9	17

#	Article	IF	Citations
968	Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy. Blood Advances, 2018, 2, 2787-2797.	2.5	20
969	161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. Blood Advances, 2018, 2, 1459-1469.	2.5	85
970	Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes. Blood Advances, 2018, 2, 1393-1402.	2.5	20
971	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Advances, 2018, 2, 1807-1816.	2.5	34
972	Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. Blood Advances, 2018, 2, 2079-2089.	2.5	18
973	Present status and perspective of laboratory hematology in Japan: On the standardization of blood cell morphology including myelodysplasia: On behalf of the Japanese Society for Laboratory Hematology. International Journal of Laboratory Hematology, 2018, 40, 120-125.	0.7	3
974	Azacitidine in the â€˜realâ€worldâ€™: an evaluation of 1101 higherâ€risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. British Journal of Haematology, 2018, 181, 803-815.	1.2	45
975	Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Intâ€1â€risk <scp>MDS</scp> patients: Results of the phase <scp>II KALLISTO</scp> trial. European Journal of Haematology, 2018, 101, 208-215.	1.1	3
976	Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 47.	2.8	107
977	Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 495-500.	0.2	1
978	Comparison of transplantâ€specific prognostic scoring systems in haploidentical transplantation for myelodysplastic syndrome. European Journal of Haematology, 2018, 101, 200-207.	1.1	0
979	Shifting of erythroleukemia to myelodysplastic syndrome according to the revised WHO classification: Biologic and cytogenetic features of shifted erythroleukemia. Leukemia Research, 2018, 70, 13-19.	0.4	3
980	An increased percentage of myeloid CD34+ bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups. International Journal of Laboratory Hematology, 2018, 40, 549-555.	0.7	4
981	Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 469-474.e1.	0.2	4
982	EVI1 expression predicts outcome in higher-risk myelodysplastic syndrome patients. Leukemia and Lymphoma, 2018, 59, 2929-2940.	0.6	3
983	Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. British Journal of Haematology, 2018, 182, 830-842.	1.2	16
984	Diagnostic algorithm for lower-risk myelodysplastic syndromes. Leukemia, 2018, 32, 1679-1696.	3.3	10
985	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. European Journal of Haematology, 2018, 101, 502-507.	1.1	6

#	Article	IF	Citations
986	Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia. Current Hematologic Malignancy Reports, 2018, 13, 341-347.	1.2	4
987	Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts. Annals of Hematology, 2018, 97, 2309-2317.	0.8	4
988	Impact of lenalidomide use among nonâ€transfusion dependent patients with myelodysplastic syndromes. American Journal of Hematology, 2018, 93, 1119-1126.	2.0	8
989	The IPSS-R has prognostic impact in untreated patients with MDS del(5q). Leukemia Research, 2018, 72, 27-33.	0.4	3
990	The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms. American Journal of Clinical Pathology, 2018, 150, 375-384.	0.4	13
991	Prognosis of patients with intermediate risk IPSSâ€R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSSâ€R. American Journal of Hematology, 2018, 93, 1245-1253.	2.0	34
993	Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition. Current Hematologic Malignancy Reports, 2018, 13, 256-264.	1.2	19
994	Diagnosis and Prognosis: Molecular. Hematologic Malignancies, 2018, , 15-37.	0.2	0
995	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10Âyears and future perspectives. Wiener Klinische Wochenschrift, 2018, 130, 517-529.	1.0	3
996	Myelodysplastic Syndromes/Neoplasmsâ€”An Overview. , 2018, , 145-163.		0
997	Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. Leukemia Research, 2018, 71, 67-74.	0.4	4
998	Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology, 2018, 23, 785-792.	0.7	23
999	Myelodysplastic syndrome (<scp>MDS</scp>) with isolated trisomy 8: a type of <scp>MDS</scp> frequently associated with myeloproliferative features? A report by the Groupe Francophone des MyÂ©lodysplasies. British Journal of Haematology, 2018, 182, 843-850.	1.2	18
1000	Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment. , 2018, , 563-563.		0
1001	The role of T2*-weighted gradient echo in the diagnosis of tumefactive intrahepatic extramedullary hematopoiesis in myelodysplastic syndrome and diffuse hepatic iron overload: a case report and review of the literature. Journal of Medical Case Reports, 2018, 12, 9.	0.4	8
1002	A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the â€œMDS thermometerâ€. BMC Hematology, 2018, 18, 6.	2.6	7
1003	Applications of Bayesian network models in predicting types of hematological malignancies. Scientific Reports, 2018, 8, 6951.	1.6	48
1004	The genetic and molecular pathogenesis of myelodysplastic syndromes. European Journal of Haematology, 2018, 101, 260-271.	1.1	58

#	Article	IF	Citations
1005	Prognostic scoring systems for myelodysplastic syndromes (<scp>MDS</scp>) in a populationâ€based setting: a report from the Swedish <scp>MDS</scp> register. British Journal of Haematology, 2018, 181, 614-627.	1.2	34
1006	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica, 2018, 103, 1278-1287.	1.7	129
1007	Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). European Journal of Haematology, 2018, 101, 766-773.	1.1	10
1008	SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 629-635.	0.2	5
1009	CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leukemia Research, 2018, 72, 79-85.	0.4	20
1010	Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Cancer Discovery, 2018, 8, 1438-1457.	7.7	38
1011	Part 2: Myelodysplastic syndromes â€“ classification systems. Hematology, Transfusion and Cell Therapy, 2018, 40, 262-266.	0.1	3
1012	Cytopenias: Reactive and Neoplastic. , 2018, , 17-79.		1
1014	Treatment with Hypomethylating Agents (HMA). Hematologic Malignancies, 2018, , 131-139.	0.2	0
1015	Allogeneic Stem Cell Transplantation for MDS. Hematologic Malignancies, 2018, , 141-157.	0.2	0
1016	Chronic Myelomonocytic Leukemia (CMML). Hematologic Malignancies, 2018, , 65-79.	0.2	0
1017	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clinic Proceedings, 2018, 93, 1363-1374.	1.4	20
1018	Iron overload in patients with myelodysplastic syndromes: An updated overview. Cancer, 2018, 124, 3979-3989.	2.0	24
1019	Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. Leukemia Research, 2018, 74, 137-143.	0.4	7
1020	Cytogenetics of MDS. Hematologic Malignancies, 2018, , 43-64.	0.2	0
1021	Myelodysplastic Syndrome Updated. Pathobiology, 2019, 86, 7-13.	1.9	37
1022	The Molecular Pathology of Myelodysplastic Syndrome. Pathobiology, 2019, 86, 24-29.	1.9	30
1023	Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report. Journal of Oncology Pharmacy Practice, 2019, 25, 1248-1252.	0.5	8

#	Article	IF	Citations
1024	The current approach to the diagnosis of myelodysplastic syndromesâ˜†. Seminars in Hematology, 2019, 56, 15-21.	1.8	22
1025	Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications. Seminars in Hematology, 2019, 56, 69-82.	1.8	45
1026	Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care. Leukemia and Lymphoma, 2019, 60, 49-59.	0.6	7
1027	Prognostic significance of monosomal karyotype in myelodysplastic syndrome: a meta-analysis. Hematology, 2019, 24, 60-69.	0.7	2
1028	Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia, 2019, 33, 205-216.	3.3	39
1029	Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma. Leukemia and Lymphoma, 2019, 60, 3577-3580.	0.6	1
1030	Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients. Blood Cancer Journal, 2019, 9, 63.	2.8	23
1031	Novel therapies in low- and high-risk myelodysplastic syndrome. Expert Review of Hematology, 2019, 12, 893-908.	1.0	13
1032	HIV portends a poor prognosis in myelodysplastic syndromes. Leukemia and Lymphoma, 2019, 60, 3529-3535.	0.6	15
1033	The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A populationâ€based study. Hematological Oncology, 2019, 37, 438-446.	0.8	11
1034	A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of Patient-Reported Outcomes, 2019, 3, 35.	0.9	13
1035	Enhanced polo-like kinase 1 expression in myelodysplastic syndromes. Blood Research, 2019, 54, 102-107.	0.5	0
1036	Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes. Expert Review of Hematology, 2019, 12, 821-831.	1.0	6
1037	Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation. Drugs, 2019, 79, 1305-1319.	4.9	36
1038	Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer Genetics, 2019, 238, 18-22.	0.2	10
1039	Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis. Annals of Laboratory Medicine, 2019, 39, 509-514.	1.2	10
1040	Cytogenomic array detects a subset of myelodysplastic syndrome with increased risk that is invisible to conventional karyotype. Genes Chromosomes and Cancer, 2019, 58, 756-774.	1.5	3
1041	Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome. , 2019, , 191-201.		0

#	Article	IF	Citations
1042	Effect of L-Leucine Therapy on Hematopoietic Function in Elderly Myelodysplastic Syndrome Patients. Biological and Pharmaceutical Bulletin, 2019, 42, 1651-1657.	0.6	3
1043	Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. International Journal of Hematology, 2019, 110, 533-542.	0.7	6
1044	Myelodysplastic Syndromes: An Update on Pathophysiology and Management. , 0, , .		0
1045	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. Blood Reviews, 2019, 37, 100587.	2.8	23
1046	Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). American Journal of Clinical Pathology, 2019, 152, 302-321.	0.4	5
1047	Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder (é•é»„æ•£) in Patients with Myelodysplastic Syndrome. Chinese Journal of Integrative Medicine, 2019, 25, 497-501.	0.7	5
1048	Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies. Cancers, 2019, 11, 1493.	1.7	9
1050	Design of a Soft Wearable Device for Hip and Knee Extension Assistance. , 2019, , .		4
1051	Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression. Cancer Immunology, Immunotherapy, 2019, 68, 2015-2027.	2.0	33
1052	EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer Journal, 2019, 9, 85.	2.8	24
1053	HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia. Journal of Translational Medicine, 2019, 17, 366.	1.8	14
1054	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematology,the, 2019, 6, e480-e488.	2.2	103
1055	Combination of Frailty Status and Comorbidity Score Improves the Stratification of Survival in Patients With Myelodysplastic Syndrome Owing to Good Predictive Capability for Infection-related Mortality. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 799-805.	0.2	17
1057	Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS. Blood Cancer Journal, 2019, 9, 86.	2.8	25
1058	Isolated isochromosomes i(X)(p10) and idic(X)(q13) are associated with myeloid malignancies and dysplastic features. American Journal of Hematology, 2019, 94, E285-E288.	2.0	2
1059	Comparison of nonâ€myeloablative and reducedâ€intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. American Journal of Hematology, 2019, 94, 1344-1352.	2.0	7
1060	Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis. Annals of Hematology, 2019, 98, 2523-2531.	0.8	10
1061	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. Mayo Clinic Proceedings, 2019, 94, 1467-1474.	1.4	12

#	Article	IF	Citations
1062	Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Surgical Pathology Clinics, 2019, 12, 651-669.	0.7	1
1063	Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity scoreâ€matched analysis. Cancer Medicine, 2019, 8, 7567-7576.	1.3	5
1064	Prognostic value of DNMT3A mutations in myelodysplastic syndromes: a meta-analysis. Hematology, 2019, 24, 613-622.	0.7	14
1065	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. Leukemia Research, 2019, 84, 106191.	0.4	5
1066	Neut-X can be successfully used as diagnostic and prognostic tool in MDS. Leukemia Research, 2019, 86, 106224.	0.4	1
1067	Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. JCO Precision Oncology, 2019, 3, 1-11.	1.5	29
1068	The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 and Clinical Oncology, 2019, 145, 3089-3097.	1.2	2
1069	Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leukemia Research, 2019, 86, 106227.	0.4	2
1070	Banking on a cooperative effort. Leukemia and Lymphoma, 2019, 60, 3102-3103.	0.6	0
1071	The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Annals of Hematology, 2019, 98, 541-559.	0.8	34
1072	Presence of CD34⁺ in Megakaryocytes in Association With p53 Expression Predicts Unfavorable Prognosis in Low-risk Myelodysplastic Syndrome Patients. In Vivo, 2019, 33, 277-280.	0.6	3
1073	Rethinking clinical trial endpoints in myelodysplastic syndromes. Leukemia, 2019, 33, 570-575.	3.3	18
1074	European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia, 2019, 33, 1851-1867.	3.3	92
1075	Combined Pathology-Driven Algorithmic Testing and Integrated Reporting for Bone Marrow Examination. Archives of Pathology and Laboratory Medicine, 2019, 143, 732-737.	1.2	2
1076	The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood, 2019, 133, 1039-1048.	0.6	172
1077	MDS overlap disorders and diagnostic boundaries. Blood, 2019, 133, 1086-1095.	0.6	58
1078	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica, 2019, 104, 929-936.	1.7	23
1079	Wilms tumor 1 expression: addressing the â€˜elephantâ€™ in MDS. Leukemia and Lymphoma, 2019, 60, 566-567.	0.6	0

#	Article	IF	Citations
1080	Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States. PharmacoEconomics - Open, 2019, 3, 237-245.	0.9	12
1081	Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. Leukemia Research, 2019, 82, 19-23.	0.4	0
1082	A post-transplant optimized transplant-specific risk score in myelodysplastic syndromes. Haematologica, 2019, 104, 859-861.	1.7	1
1083	Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. Leukemia and Lymphoma, 2019, 60, 3058-3062.	0.6	4
1084	Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS. Current Hematologic Malignancy Reports, 2019, 14, 346-351.	1.2	12
1085	Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS. International Journal of Hematology, 2019, 110, 347-354.	0.7	3
1086	Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5â€azacytidine: Identification of responding patients. European Journal of Haematology, 2019, 103, 208-214.	1.1	9
1087	Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy. Leukemia Research, 2019, 83, 106170.	0.4	12
1088	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. Annals of Hematology, 2019, 98, 1919-1925.	0.8	8
1089	Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. Critical Reviews in Oncology/Hematology, 2019, 141, 54-72.	2.0	18
1090	CD123 CAR T cells for the treatment of myelodysplastic syndrome. Experimental Hematology, 2019, 74, 52-63.e3.	0.2	25
1091	Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC). Genetics in Medicine, 2019, 21, 1903-1916.	1.1	39
1092	Monosomal karyotypes apart from complex karyotypes independently predict the outcome of myelodysplastic syndrome patients using a fluorescence in situ hybridization panel and conventional cytogenetics. International Journal of Laboratory Hematology, 2019, 41, 519-529.	0.7	3
1093	Flow cytometry â€œOgata scoreâ€•for the diagnosis of myelodysplastic syndromes in a realâ€life setting. A Latin American experience. International Journal of Laboratory Hematology, 2019, 41, 536-541.	0.7	8
1094	Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e367-e373.	0.2	1
1095	Prognostic mutations in persons with isolated neutropenia myelodysplastic syndrome. Leukemia and Lymphoma, 2019, 60, 2835-2837.	0.6	0
1096	MicroRNA-661 upregulation in myelodysplastic syndromes induces apoptosis through p53 activation and associates with decreased overall survival. Leukemia and Lymphoma, 2019, 60, 2779-2786.	0.6	9
1097	Factors predicting early mortality after new diagnosis of myelodysplastic syndrome: A populationâ€based study. European Journal of Haematology, 2019, 103, 56-63.	1.1	6

#	Article	IF	Citations
1098	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia, 2019, 33, 2842-2853.	3.3	43
1099	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematology,the, 2019, 6, e317-e327.	2.2	71
1100	Management of myelodysplastic syndromes after failure of response to hypomethylating agents. Therapeutic Advances in Hematology, 2019, 10, 204062071984705.	1.1	29
1101	Genetic abnormalities and pathophysiology of MDS. International Journal of Clinical Oncology, 2019, 24, 885-892.	1.0	70
1102	Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment. Current Hematologic Malignancy Reports, 2019, 14, 154-163.	1.2	12
1103	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. Leukemia and Lymphoma, 2019, 60, 2483-2487.	0.6	3
1104	Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome. Leukemia and Lymphoma, 2019, 60, 2762-2770.	0.6	7
1105	Impact of the relative dose intensity on survival of patients with highâ€risk myelodysplastic syndromes treated with Azacitidine. Cancer Medicine, 2019, 8, 2188-2195.	1.3	8
1106	Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. Genes Chromosomes and Cancer, 2019, 58, 689-697.	1.5	8
1107	Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations. Genes Chromosomes and Cancer, 2019, 58, 698-704.	1.5	9
1108	Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes. Blood Reviews, 2019, 36, 57-69.	2.8	34
1110	The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile?. Haematologica, 2019, 104, e547-e550.	1.7	2
1111	Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood, 2019, 133, 2575-2585.	0.6	77
1112	A case of subacute-onset myelodysplastic syndrome with infection mimicking thrombotic thrombocytopenic purpura: a case report with literature review. Renal Replacement Therapy, 2019, 5, .	0.3	1
1113	A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2019, 60, 2404-2414.	0.6	15
1114	Establishment of a zebrafish hematological disease model induced by 1,4-benzoquinone. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	5
1115	Prognostic impact of red blood cell distribution width in myelodysplastic syndromes. British Journal of Haematology, 2019, 186, 352-355.	1.2	8
1116	Immunophenotypic Features of Myeloid Neoplasms Associated with Chromosome 7 Abnormalities. Cytometry Part B - Clinical Cytometry, 2019, 96, 300-309.	0.7	11

#	Article	IF	Citations
1117	Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. British Journal of Haematology, 2019, 185, 725-732.	1.2	17
1118	Dysregulation of interferon regulatory genes reinforces the concept of chronic immune response in myelodysplastic syndrome pathogenesis. Hematological Oncology, 2019, 37, 523-526.	0.8	3
1120	Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation. Blood Cancer Journal, 2019, 9, 31.	2.8	9
1121	Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60â€“69Âyears with myelodysplastic syndrome. Annals of Hematology, 2019, 98, 1367-1381.	0.8	13
1122	Use of a Blast Dominanceâ€“Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS). American Journal of Clinical Pathology, 2019, 151, 584-592.	0.4	2
1123	Gender disparity in the survival of patients with primary myelodysplastic syndrome. Journal of Cancer, 2019, 10, 1325-1332.	1.2	18
1124	Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review. Critical Reviews in Oncology/Hematology, 2019, 136, 37-47.	2.0	11
1125	Treatment of myelodysplastic syndrome in the era of nextâ€generation sequencing. Journal of Internal Medicine, 2019, 286, 41-62.	2.7	13
1126	Genetic Variant Screening of DNA Repair Genes in Myelodysplastic Syndrome Identifies a Novel Mutation in the <i>XRCC2</i> Gene. Oncology Research and Treatment, 2019, 42, 263-268.	0.8	3
1127	Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility. Oncology Reviews, 2019, 13, 389.	0.8	9
1128	Role of conventional cytogenetics in sequential karyotype analysis of myelodysplastic syndrome: a patient with der(1;7)(q10;p10). Hematology, Transfusion and Cell Therapy, 2019, 41, 91-94.	0.1	1
1129	ASXL1 gene alterations in patients with isolated 20q deletion. Neoplasma, 2019, 66, 627-630.	0.7	2
1130	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. Annals of Hematology, 2019, 98, 1383-1392.	0.8	9
1131	Comprehensive molecular characterization of myeloid malignancies with 9q deletion. Leukemia and Lymphoma, 2019, 60, 2591-2593.	0.6	4
1132	PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL P53 EXPRESSION IN BONE MARROW BIOPSY IN HIGHER RISK MDS: A PILOT STUDY. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019015.	0.5	5
1133	Transforming growth factor (TGF)-Î² pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia, 2019, 33, 1303-1312.	3.3	43
1134	The fraction of CD117/câ€KITâ€expressing erythroid precursors predicts ESA response in lowâ€risk myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2019, 96, 215-222.	0.7	10
1135	Serum Vitamin D Levels in Patients with Myelodysplastic Syndromes: A Retrospective Single-Center Analysis. Acta Haematologica, 2019, 141, 225-231.	0.7	2

#	Article	IF	Citations
1136	Getting personal with myelodysplastic syndromes: is now the right time?. Expert Review of Hematology, 2019, 12, 215-224.	1.0	9
1137	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	9.4	97
1138	Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies. Annals of Hematology, 2019, 98, 1225-1235.	0.8	22
1139	Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. Leukemia Research, 2019, 81, 35-42.	0.4	10
1140	Pretreatment CD34+/CD38â€“ Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1560-1566.	2.0	5
1141	Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms. Biology of Blood and Marrow Transplantation, 2019, 25, 1293-1303.	2.0	16
1142	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 390-395.	0.2	6
1143	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. Leukemia, 2019, 33, 2276-2290.	3.3	25
1144	Somatic mutation of HLAâ€ÐRB1*04:03 in a patient with myelodysplastic syndrome at diagnosis. Hla, 2019, 93, 216-219.	0.4	2
1145	Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?. Best Practice and Research in Clinical Haematology, 2019, 32, 104-113.	0.7	5
1146	Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1471-1481.	1.3	8
1147	BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Frontiers in Oncology, 2019, 9, 16.	1.3	34
1148	Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood, 2019, 133, 2069-2078.	0.6	47
1149	Additional information offered by single nucleotide polymorphism array advantages in two myelodysplastic syndromes with excess blasts cases and future perspectives. Hematology, Transfusion and Cell Therapy, 2019, 41, 181-184.	0.1	0
1150	Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics. Advances in Cell and Gene Therapy, 2019, 2, e48.	0.6	11
1151	Epidemiology, etiology and risk factors. , 2019, , .		0
1152	Research Article High diversity of chromosomal aberrations in a Brazilian myelodysplastic syndrome cohort. Genetics and Molecular Research, 2019, 18, .	0.3	1
1153	In MDS, is higher risk higher reward?. Hematology American Society of Hematology Education Program, 2019, 2019, 381-390.	0.9	7

#	Article	IF	Citations
1154	Integrating patient-centered factors in the risk assessment of MDS. Hematology American Society of Hematology Education Program, 2019, 2019, 373-380.	0.9	11
1155	Articles Title ch_3. , 2019, , .		0
1156	Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. HemaSphere, 2019, 3, e314.	1.2	21
1157	Inflammation in del(20q): a MST opportunity?. Blood, 2019, 134, 1685-1686.	0.6	0
1158	Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. Blood Advances, 2019, 3, 3449-3453.	2.5	7
1159	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Advances, 2019, 3, 922-933.	2.5	84
1160	Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Advances, 2019, 3, 980-983.	2.5	5
1161	Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 2019, 3, 2454-2464.	2.5	12
1162	Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. Blood Advances, 2019, 3, 3406-3418.	2.5	8
1163	Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Advances, 2019, 3, 4271-4279.	2.5	19
1164	Elevated TIM3 expression of T helper cells affects immune system in patients with myelodysplastic syndrome. Journal of Investigative Medicine, 2019, 67, 1125-1130.	0.7	6
1165	DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes. Blood Advances, 2019, 3, 2845-2858.	2.5	32
1166	Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern. Blood Advances, 2019, 3, 3111-3122.	2.5	6
1167	Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. Current Oncology Reports, 2019, 21, 101.	1.8	10
1169	Does mutational burden add to other prognostic factors in MDS?. Best Practice and Research in Clinical Haematology, 2019, 32, 101098.	0.7	3
1170	Mutation-Driven Therapy in MDS. Current Hematologic Malignancy Reports, 2019, 14, 550-560.	1.2	4
1171	Application of Genomics to Clinical Practice in Haematological Malignancy. Current Genetic Medicine Reports, 2019, 7, 236-252.	1.9	0
1172	Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes. Pathobiology, 2019, 86, 14-23.	1.9	23

#	Article	IF	Citations
1173	Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC. Current Research in Translational Medicine, 2019, 67, 8-15.	1.2	4
1174	Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome. Leukemia and Lymphoma, 2019, 60, 703-710.	0.6	7
1175	Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. European Journal of Haematology, 2019, 102, 203-209.	1.1	28
1176	The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study. Leukemia Research, 2019, 76, 76-81.	0.4	9
1177	Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy. Leukemia, 2019, 33, 1487-1500.	3.3	48
1178	Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 1-8.	0.2	9
1179	Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. Haematologica, 2019, 104, 700-709.	1.7	14
1180	Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes. Leukemia Research, 2019, 77, 8-13.	0.4	0
1181	Evaluation of SF3B1 Mutation Screening by High-Resolution Melting Analysis and its Clinical Utility for Myelodysplastic Syndrome with Ring Sideroblasts at the Point of Diagnosis. Laboratory Medicine, 2019, 50, 254-262.	0.8	5
1182	Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood, 2019, 133, 790-794.	0.6	75
1183	The Role of FLT3-ITD Mutation on de Novo MDS in Chinese Population. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e107-e115.	0.2	6
1184	Circulating microvesicles are less procoagulant and carry different miRNA cargo in myelodysplasia. Blood Cells, Molecules, and Diseases, 2019, 74, 37-43.	0.6	7
1185	Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review. Autoimmunity Reviews, 2019, 18, 36-42.	2.5	24
1186	Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood, 2019, 133, 1020-1030.	0.6	98
1187	What does good FISHing look like in MDS?. Leukemia and Lymphoma, 2019, 60, 571-572.	0.6	0
1188	Presenting signs and patient coâ€variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GEDâ€C) Delphi initiative. Internal Medicine Journal, 2019, 49, 578-591.	0.5	39
1189	Chronic myelomonocytic leukemia treated with 5-azacytidine â€“ results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. Leukemia and Lymphoma, 2019, 60, 1721-1730.	0.6	12
1190	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Annals of Hematology, 2019, 98, 331-337.	0.8	5

#	Article	IF	Citations
1191	Myelodysplastic Syndromes (MDS). , 2019, , 333-341.		0
1192	Genetics in Hematologic Disorders: Implications of Recurring Chromosome Abnormalities and Gene Mutations. , 2019, , 277-297.		0
1193	Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia. Annals of Hematology, 2019, 98, 1127-1133.	0.8	0
1194	Analysis of clinical and molecular features of MDS patients with complex karyotype in China. Blood Cells, Molecules, and Diseases, 2019, 75, 13-19.	0.6	8
1195	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplantation, 2019, 54, 1281-1286.	1.3	24
1196	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: â€œ2019 Update on Diagnosis, Riskâ€stratification, and Managementâ€• American Journal of Hematology, 2019, 94, 475-488.	2.0	35
1197	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	3.3	195
1198	BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leukemia and Lymphoma, 2019, 60, 1587-1590.	0.6	16
1199	A multicenter report on the natural history of myelodysplastic syndromes in very old patients (aged) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.6	0
1200	An update on treatment of higher risk myelodysplastic syndromes. Expert Review of Hematology, 2019, 12, 61-70.	1.0	1
1201	Evaluation of immature platelet fraction in patients with myelodysplastic syndromes. Association with poor prognosis factors. Clinical Chemistry and Laboratory Medicine, 2019, 57, e128-e130.	1.4	6
1202	The challenging task of enumerating blasts in the bone marrow. Seminars in Hematology, 2019, 56, 58-64.	1.8	21
1203	Clinical and biological characteristics of acute myeloid leukemia with 20â€“29% blasts: a retrospective single-center study. Leukemia and Lymphoma, 2019, 60, 1136-1145.	0.6	2
1204	Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nature Medicine, 2019, 25, 103-110.	15.2	169
1205	Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. Leukemia and Lymphoma, 2019, 60, 1522-1527.	0.6	2
1206	Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews, 2019, 34, 1-15.	2.8	117
1207	Is fluorescence in-situ hybridization sufficient in patients with myelodysplastic syndromes and insufficient cytogenetic testing?. Leukemia and Lymphoma, 2019, 60, 764-771.	0.6	3
1208	Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology. International Journal of Laboratory Hematology, 2019, 41, 109-117.	0.7	5

#	Article	IF	Citations
1209	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica, 2019, 104, 497-504.	1.7	17
1210	Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, e33-e38.	2.0	10
1211	The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes. Haematologica, 2019, 104, 485-496.	1.7	25
1212	Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. Journal of Geriatric Oncology, 2020, 11, 114-120.	0.5	27
1213	Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica, 2020, 105, 102-111.	1.7	31
1214	Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia and Lymphoma, 2020, 61, 397-408.	0.6	19
1215	Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia. Haematologica, 2020, 105, 652-660.	1.7	23
1216	Splicing factor mutant myelodysplastic syndromes: Recent advances. Advances in Biological Regulation, 2020, 75, 100655.	1.4	18
1218	Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 160-165.	0.6	8
1219	Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 114-121.	0.2	5
1220	Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1â€tube panel strategy for diagnosis and prognosis of patients with MDS. Cytometry Part B - Clinical Cytometry, 2020, 98, 226-237.	0.7	12
1221	The diagnostic and prognostic role of flow cytometry in idiopathic and clonal cytopenia of undetermined significance (ICUS/CCUS): A singleâ€center analysis of 79 patients. Cytometry Part B - Clinical Cytometry, 2020, 98, 250-258.	0.7	10
1223	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia, 2020, 34, 656-661.	3.3	32
1224	Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis. Clinical and Experimental Medicine, 2020, 20, 1-9.	1.9	11
1225	Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia, 2020, 34, 872-881.	3.3	22
1227	Low prevalence of the BCRâ€“ABL1 fusion gene in a normal population in southern Sarawak. International Journal of Hematology, 2020, 111, 217-224.	0.7	1
1228	Schizophyllum commune sinusitis after allogeneic bone marrow transplantation for myelodysplastic syndrome: A case report and literature review. Transplant Infectious Disease, 2020, 22, e13205.	0.7	4
1229	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematology,the, 2020, 7, e28-e39.	2.2	94

#	Article	IF	Citations
1230	The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Annals of Hematology, 2020, 99, 7-19.	0.8	13
1231	How we manage adults with myelodysplastic syndrome. British Journal of Haematology, 2020, 189, 1016-1027.	1.2	60
1232	The evolving role of next generation sequencing in myelodysplastic syndromes. British Journal of Haematology, 2020, 188, 224-239.	1.2	11
1234	Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population. Journal of Cancer, 2020, 11, 508-519.	1.2	8
1236	Moving towards a uniform risk stratification system in CMML - How far are we?. Best Practice and Research in Clinical Haematology, 2020, 33, 101131.	0.7	2
1237	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151.	13.9	335
1238	Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study. Scientific Reports, 2020, 10, 39.	1.6	13
1239	Autoimmune disease in CMML-the chicken or the egg?. Best Practice and Research in Clinical Haematology, 2020, 33, 101136.	0.7	16
1240	Targeting Aberrant Splicing in Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America, 2020, 34, 379-391.	0.9	10
1241	Recommendations for cytogenomic analysis of hematologic malignancies: comments from the Francophone Group of Hematological Cytogenetics (GFCH). Leukemia, 2020, 34, 1711-1713.	3.3	5
1242	Allogeneic stem cell transplant in myelodysplastic syndromeâ€factors impacting survival. European Journal of Haematology, 2020, 104, 116-124.	1.1	5
1243	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome. JAMA Oncology, 2020, 6, 486.	3.4	39
1244	An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. Leukemia, 2020, 34, 1394-1406.	3.3	23
1245	Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes. Leukemia and Lymphoma, 2020, 61, 919-926.	0.6	5
1246	Prognostic significance of U2AF1 mutations in myelodysplastic syndromes: a meta-analysis. Journal of International Medical Research, 2020, 48, 030006051989101.	0.4	12
1247	Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Frontiers in Oncology, 2019, 9, 1380.	1.3	187
1248	Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome. Internal Medicine, 2020, 59, 1081-1086.	0.3	4
1249	Knowledge of Secondary Pulmonary Alveolar Proteinosis Complicated with Myelodysplastic Syndrome. Internal Medicine, 2020, 59, 1019-1020.	0.3	1

#	Article	IF	Citations
1250	Novel Prognostic Models for Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America, 2020, 34, 369-378.	0.9	4
1251	Cytogenetic and cytokine profile in elderly patients with cytopenia. Experimental Hematology, 2020, 89, 80-86.	0.2	1
1252	LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome. Cancers, 2020, 12, 2726.	1.7	17
1253	Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins. International Journal of Molecular Sciences, 2020, 21, 7140.	1.8	14
1254	Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A singleâ€center retrospective study. Cancer Medicine, 2020, 9, 6244-6255.	1.3	9
1255	Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?. Leukemia, 2020, 34, 2552-2560.	3.3	9
1256	Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse. Blood Advances, 2020, 4, 3102-3108.	2.5	19
1257	No clear survival benefit of azacitidine for lowerâ€risk myelodysplastic syndromes: A retrospective study of Nagasaki. Cancer Science, 2020, 111, 4490-4499.	1.7	3
1258	Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?. Frontiers in Oncology, 2020, 10, 595838.	1.3	1
1260	The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications. Cells, 2020, 9, 2512.	1.8	15
1261	Emerging treatment options for patients with high-risk myelodysplastic syndrome. Therapeutic Advances in Hematology, 2020, 11, 204062072095500.	1.1	19
1262	Tissue methylation and demethylation influence translesion synthesis DNA polymerases (TLS) contributing to the genesis of chromosomal abnormalities in myelodysplastic syndrome. Journal of Clinical Pathology, 2022, 75, 85-93.	1.0	5
1263	Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts. Cancers, 2020, 12, 3520.	1.7	9
1264	Patient stratification in myelodysplastic syndromes: how a puzzle may become a map. Hematology American Society of Hematology Education Program, 2020, 2020, 418-425.	0.9	6
1265	A simple score derived from bone marrow immunophenotyping is important for prognostic evaluation in myelodysplastic syndromes. Scientific Reports, 2020, 10, 20281.	1.6	3
1266	Therapy for lower-risk MDS. Hematology American Society of Hematology Education Program, 2020, 2020, 426-433.	0.9	31
1267	Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers. Nature Communications, 2020, 11, 5660.	5.8	55
1268	Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes. Scientific Reports, 2020, 10, 19555.	1.6	7

#	Article	IF	Citations
1269	Identification of latent core genes and pathways associated with myelodysplastic syndromes based on integrated bioinformatics analysis. Hematology, 2020, 25, 299-308.	0.7	5
1270	Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome. Leukemia Research Reports, 2020, 14, 100215.	0.2	5
1271	Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2020, 26, 2047-2052.	2.0	6
1272	Improving the accuracy of prognostication in chronic myelomonocytic leukemia. Expert Review of Anticancer Therapy, 2020, 20, 703-714.	1.1	4
1273	TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood, 2020, 136, 2812-2823.	0.6	113
1274	Founder and subclonal mutations in myelodysplastic syndromes and related myeloid neoplasms. Best Practice and Research in Clinical Haematology, 2020, 33, 101189.	0.7	2
1275	The clinical impact of COVID-19 epidemic in the hematologic setting. Advances in Biological Regulation, 2020, 77, 100742.	1.4	14
1276	Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. American Journal of Hematology, 2020, 95, 1399-1420.	2.0	119
1277	Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia. Haematologica, 2021, 106, 2215-2223.	1.7	12
1278	Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia. Critical Reviews in Oncology/Hematology, 2020, 154, 103067.	2.0	4
1279	Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia. Leukemia Research, 2020, 97, 106430.	0.4	8
1280	Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The â€œSeed and Soilâ€• Crosstalk. International Journal of Molecular Sciences, 2020, 21, 5438.	1.8	20
1281	Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e566-e574.	2.2	13
1282	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
1283	Patients of Myelodysplastic Syndrome with Mild/Moderate Myelofibrosis and a Monosomal Karyotype are Independently Associated with an Adverse Prognosis: Long-Term Follow-Up Data . Cancer Management and Research, 2020, Volume 12, 5881-5891.	0.9	6
1285	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, 2139-2146.	2.0	14
1286	Low-risk myelodysplastic syndrome managed with an erythroid-stimulating agent for 10 years. BMJ Case Reports, 2020, 13, e232285.	0.2	0
1287	Controversies on the Consequences of Iron Overload and Chelation in MDS. HemaSphere, 2020, 4, e357.	1.2	19

#	Article	IF	Citations
1288	Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, e263-e264.	2.0	0
1289	Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS . OncoTargets and Therapy, 2020, Volume 13, 10143-10148.	1.0	0
1290	Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy. Cancers, 2020, 12, 3128.	1.7	12
1291	Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. Leukemia and Lymphoma, 2020, 61, 3476-3483.	0.6	2
1292	Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?. Expert Review of Hematology, 2020, 13, 1131-1142.	1.0	8
1293	The utility of fluorescence in situ hybridization testing in patients clinically suspected of myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm overlap is limited in the absence of significant morphological dysplasia. International Journal of Laboratory Hematology, 2020, 42, e287-e290.	0.7	1
1294	Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada. EJHaem, 2020, 1, 69-78.	0.4	1
1295	Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Advances, 2020, 4, 4029-4044.	2.5	12
1296	Revised 15-item MDS-specific frailty scale maintains prognostic potential. Leukemia, 2020, 34, 3434-3438.	3.3	8
1297	Relationship between p53 expression and prognosis of myelodysplastic syndrome treated with azacitidine. Journal of Hematopathology, 2020, 13, 213-219.	0.2	1
1298	Allogeneic hematopoietic stem cell transplantation in a prior lung transplant recipient. International Journal of Hematology, 2020, 112, 871-877.	0.7	0
1299	Development of Telintra as an Inhibitor of Glutathione S-Transferase P. Handbook of Experimental Pharmacology, 2020, 264, 71-91.	0.9	10
1300	Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome. International Journal of Hematology, 2020, 112, 825-834.	0.7	2
1301	Eat and be healthy: nutritional status in myelodysplastic syndromes. Leukemia and Lymphoma, 2020, 61, 2788-2789.	0.6	1
1302	Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation. Cancers, 2020, 12, 2255.	1.7	18
1303	Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre. Blood Cancer Journal, 2020, 10, 83.	2.8	1
1305	Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. Therapeutic Advances in Hematology, 2020, 11, 204062072096612.	1.1	9
1306	Predictors of vascular disease in myelodysplastic syndromes. EJHaem, 2020, 1, 467-472.	0.4	3

#	Article	IF	Citations
1307	Emerging drugs for the treatment of chronic myelomonocytic leukemia. Expert Opinion on Emerging Drugs, 2020, 25, 515-529.	1.0	4
1308	Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from Higher-Risk MDS Patients by Regulating the ROS-Related Wnt/Î²-Catenin Pathway. Stem Cells International, 2020, 2020, 1-16.	1.2	9
1309	Thrombocytopenia and platelet transfusion in myelodysplastic syndromes. Transfusion, 2020, 60, 2164-2167.	0.8	0
1310	TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings. International Journal of Molecular Sciences, 2020, 21, 3432.	1.8	25
1311	Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?. Leukemia and Lymphoma, 2020, 61, 2295-2312.	0.6	7
1312	Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. Current Hematologic Malignancy Reports, 2020, 15, 194-202.	1.2	7
1313	Are next-generation sequencing results knocking on Heavenâ€™s door for transplantation planning in chronic myelomonocytic leukemia?. Haematologica, 2020, 105, 530-533.	1.7	2
1314	Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years. Expert Review of Anticancer Therapy, 2020, 20, 465-482.	1.1	5
1315	Development of a core outcome set for myelodysplastic syndromes â€“ a Delphi study from the EUMDS Registry Group. British Journal of Haematology, 2020, 191, 405-417.	1.2	10
1316	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood, 2020, 136, 698-714.	0.6	28
1317	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	0.6	195
1318	Genetics of progression from MDS to secondary leukemia. Blood, 2020, 136, 50-60.	0.6	80
1319	How I Diagnose Low-Grade Myelodysplastic Syndromes. American Journal of Clinical Pathology, 2020, 154, 5-14.	0.4	9
1320	Cytogenetics in the genomic era. Best Practice and Research in Clinical Haematology, 2020, 33, 101196.	0.7	5
1321	Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia and Lymphoma, 2020, 61, 2700-2707.	0.6	21
1322	Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. Scientific Reports, 2020, 10, 9156.	1.6	9
1323	Characteristics of patients with myelodysplastic syndrome with balanced translocations. British Journal of Haematology, 2020, 190, 244-248.	1.2	1
1324	Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count. Leukemia and Lymphoma, 2020, 61, 1756-1759.	0.6	11

#	Article	IF	Citations
1325	Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. Leukemia and Lymphoma, 2020, 61, 1688-1694.	0.6	2
1326	Distinct mutational pattern of myelodysplastic syndromes with and without 5qâ€“ treated with lenalidomide. British Journal of Haematology, 2020, 189, e133-e137.	1.2	4
1327	Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. Leukemia and Lymphoma, 2020, 61, 1678-1687.	0.6	6
1328	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematology,the, 2020, 7, e309-e319.	2.2	70
1329	Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. Expert Review of Hematology, 2020, 13, 447-460.	1.0	2
1330	Novel combinations to improve hematopoiesis in myelodysplastic syndrome. Stem Cell Research and Therapy, 2020, 11, 132.	2.4	2
1331	Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax. Case Reports in Hematology, 2020, 2020, 1-4.	0.3	2
1332	Clinical significance of CD41â€positive blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine. British Journal of Haematology, 2020, 189, e144-e147.	1.2	3
1333	Myelodysplastic syndrome with clonal karyotype evolution associated with trisomy 8 and ASXL1 mutation in wellâ€controlled HIV patient: Case report and literature review. EJHaem, 2020, 1, 344-349.	0.4	1
1334	Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes. Frontiers in Immunology, 2020, 11, 1236.	2.2	33
1335	Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes. Frontiers in Oncology, 2020, 10, 962.	1.3	1
1336	Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. Genes, 2020, 11, 749.	1.0	30
1337	Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification. Journal of Hematopathology, 2020, 13, 79-88.	0.2	6
1338	Kinetics of <scp>preâ€myelodysplastic</scp> syndromes blood values correlate with disease risk and survival. Hematological Oncology, 2020, 38, 782-791.	0.8	1
1339	Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. Blood Advances, 2020, 4, 2768-2778.	2.5	24
1340	Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells. Leukemia, 2020, 34, 2460-2472.	3.3	7
1341	Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?. Expert Review of Hematology, 2020, 13, 233-239.	1.0	2
1342	A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data. Journal of Biomedical Informatics, 2020, 104, 103398.	2.5	5

#	Article	IF	Citations
1343	Integrating the â€œImmunomeâ€•in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design. Journal of Clinical Oncology, 2020, 38, 1723-1735.	0.8	56
1344	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia, 2020, 34, 2441-2450.	3.3	14
1345	Evolving therapies for lower-risk myelodysplastic syndromes. Annals of Hematology, 2020, 99, 677-692.	0.8	16
1346	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia, 2020, 34, 2451-2459.	3.3	14
1347	Abnormal Dendritic Cellâ€poiesis in Patients With Lowerâ€risk Myelodysplastic Syndromes. HemaSphere, 2020, 4, e335.	1.2	0
1348	Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. Current Hematologic Malignancy Reports, 2020, 15, 268-275.	1.2	6
1349	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. Biology of Blood and Marrow Transplantation, 2020, 26, 1160-1170.	2.0	9
1350	Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the â€˜real-worldâ€™. Leukemia and Lymphoma, 2020, 61, 1445-1454.	0.6	5
1351	Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span. Current Hematologic Malignancy Reports, 2020, 15, 149-154.	1.2	2
1352	Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 324-328.	0.2	13
1353	Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation. Current Oncology Reports, 2020, 22, 4.	1.8	9
1354	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. Annals of Hematology, 2020, 99, 513-518.	0.8	1
1355	Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy. Bone Marrow Transplantation, 2020, 55, 1220-1228.	1.3	1
1356	SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndromeâ€“Refractory Cytopenia With Multilineage Dysplasia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 329-339.e3.	0.2	3
1357	Clinical effects of the CD13/CD33 ratio on the prognosis of myelodysplastic syndrome treated with azacitidine. Leukemia and Lymphoma, 2020, 61, 1250-1253.	0.6	2
1358	Clonal selection in therapyâ€related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. European Journal of Haematology, 2020, 104, 488-498.	1.1	6
1359	PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes. European Journal of Haematology, 2020, 104, 526-537.	1.1	5
1360	Hematopathology. , 2020, , 1729-2141.		0

#	Article	IF	Citations
1361	The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome. International Journal of Molecular Sciences, 2020, 21, 3033.	1.8	3
1362	Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome. Cells, 2020, 9, 794.	1.8	26
1363	Risk of invasive fungal infections in patients with <scp>highâ€risk MDS</scp> and <scp>AML</scp> receiving hypomethylating agents. American Journal of Hematology, 2020, 95, 792-798.	2.0	20
1364	Decision Analysis of Transplantation for Patients with Myelodysplasia: â€œWho Should We Transplant Today?â€• Current Hematologic Malignancy Reports, 2020, 15, 305-315.	1.2	1
1365	Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e597-e605.	0.2	3
1366	Acute leukemia in the time of COVID-19. Leukemia Research, 2020, 92, 106353.	0.4	46
1367	Results of a Phase 1/2a doseâ€“escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leukemia and Lymphoma, 2020, 61, 1943-1953.	0.6	2
1368	Balanced translocations in myelodysplastic syndromes (MDS) â€“ an unrecognised MDS patient subgroup?. British Journal of Haematology, 2020, 190, 141-142.	1.2	4
1369	Synergistic effects of PRIMA-1^{Met} (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica, 2020, 105, 1539-1551.	1.7	101
1370	Identification of a metabolic gene panel to predict the prognosis of myelodysplastic syndrome. Journal of Cellular and Molecular Medicine, 2020, 24, 6373-6384.	1.6	6
1371	Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan. Biology of Blood and Marrow Transplantation, 2020, 26, 1543-1551.	2.0	10
1372	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Advances, 2020, 4, 482-495.	2.5	86
1373	A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. Blood Advances, 2020, 4, 644-654.	2.5	14
1374	Therapeutic strategies in low and high-risk MDS: What does the future have to offer?. Blood Reviews, 2021, 45, 100689.	2.8	21
1375	Treating Leukemia in the Time of COVID-19. Acta Haematologica, 2021, 144, 132-145.	0.7	57
1376	Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia. Annals of Hematology, 2021, 100, 63-78.	0.8	3
1377	Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide populationâ€based study. British Journal of Haematology, 2021, 192, 474-483.	1.2	10
1378	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica, 2021, 106, 1599-1607.	1.7	18

#	Article	IF	Citations
1379	Clinical value of nextâ€generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome. British Journal of Haematology, 2021, 192, 729-736.	1.2	8
1380	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratificationâ€"an approach to classification of patients with t-MDS. Leukemia, 2021, 35, 835-849.	3.3	54
1381	Perls Stain Grade in Bone Marrow Aspirate Correlates with Overall Survival in Low-Risk Myelodysplastic Patients. Acta Haematologica, 2021, 144, 332-336.	0.7	1
1382	Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia, 2021, 35, 1145-1155.	3.3	27
1383	Loss of 5q in myeloid malignancies â€" A gain in understanding of biological and clinical consequences. Blood Reviews, 2021, 46, 100735.	2.8	16
1384	Increased proportion and altered properties of intermediate monocytes in the peripheral blood of patients with lower risk Myelodysplastic Syndrome. Blood Cells, Molecules, and Diseases, 2021, 86, 102507.	0.6	4
1385	Aneuploidy in Cancer: Lessons from Acute Lymphoblastic Leukemia. Trends in Cancer, 2021, 7, 37-47.	3.8	20
1386	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer, 2021, 127, 609-618.	2.0	12
1387	Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 1-7.	0.2	9
1388	Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ€â˜†. Annals of Oncology, 2021, 32, 142-156.	0.6	75
1389	Costs associated with transfusion therapy in patients with myelodysplastic syndromes in Sweden: a nationwide retrospective cohort study. Vox Sanguinis, 2021, 116, 581-590.	0.7	4
1390	The expression levels of long nonâ€coding RNA KIAA0125 are associated with distinct clinical and biological features in myelodysplastic syndromes. British Journal of Haematology, 2021, 192, 589-598.	1.2	5
1391	Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome. Cytotherapy, 2021, 23, 236-241.	0.3	7
1392	Chronic myelomonocytic leukemia - a review. Expert Review of Hematology, 2021, 14, 59-77.	1.0	6
1393	Parsing the Paradox of Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 4-6.	0.8	0
1394	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. Leukemia, 2021, 35, 1166-1175.	3.3	5
1395	Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20Âyears of experiences: prognostic parameters and overall survival. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1390-1398.	3.3	16
1396	Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia. Transplantation and Cellular Therapy, 2021, 27, 286-291.	0.6	10

#	Article	IF	Citations
1397	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Leukemia, 2021, 35, 2371-2381.	3.3	17
1398	Validation of International Working Group response criteria in higherâ€risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. Cancer Medicine, 2021, 10, 447-453.	1.3	24
1399	Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e52-e56.	0.2	1
1400	Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019. Annals of Hematology, 2021, 100, 117-133.	0.8	2
1401	Highâ€level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome. International Journal of Laboratory Hematology, 2021, 43, 99-109.	0.7	7
1402	The effect of 5â€azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. British Journal of Haematology, 2021, 192, 978-987.	1.2	4
1403	Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2021, 62, 229-233.	0.6	0
1404	Clinical presentation, diagnosis and management of therapyâ€related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and polyâ€ADPâ€ribose polymerase inhibitors: A singleâ€center experience. International Journal of Cancer, 2021, 148, 170-177.	2.3	9
1406	Discontinuation of the reninâ€“angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes. Therapeutic Advances in Hematology, 2021, 12, 204062072095829.	1.1	0
1407	Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, 2021, 11, 1675.	1.6	2
1408	Magnetic Resonance Myocardial Feature Tracking in Transfusion-Dependent Myelodysplastic Syndrome. Journal of Cardiovascular Imaging, 2021, 29, 331.	0.2	2
1409	WT1-specific CD8â€‰+â€‰cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS. International Journal of Hematology, 2021, 113, 723-734.	0.7	1
1410	Integration Analysis of JAK2 or RUNX1 Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome. Frontiers in Oncology, 2020, 10, 610525.	1.3	4
1411	Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Journal of Medical Economics, 2021, 24, 234-243.	1.0	5
1413	Prognostic Factors in AML. Hematologic Malignancies, 2021, , 127-175.	0.2	1
1414	Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome. Current Opinion in Hematology, 2021, 28, 101-109.	1.2	1
1415	Reticulocytosis As a Whistleblower: A Rare Case of Acquired Elliptocytosis in a Myelodysplastic Syndrome Patient With Trisomy 8. HemaSphere, 2021, 5, e517.	1.2	2
1416	HSCT in Malignancies. Organ and Tissue Transplantation, 2021, , 99-114.	0.0	0

#	Article	IF	Citations
1417	Immunomodulatory Effect of Green Tea Treatment in Combination with Low-dose Chemotherapy in Elderly Acute Myeloid Leukemia Patients with Myelodysplasia-related Changes. Integrative Cancer Therapies, 2021, 20, 153473542110026.	0.8	8
1418	Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients â€“ results of the PALG study â€˜PolAZAâ€™. Hematology, 2021, 26, 556-564.	0.7	3
1419	Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation. Frontiers in Genetics, 2020, 11, 603956.	1.1	2
1420	Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?. Haematologica, 2020, 106, 7-9.	1.7	2
1421	Myelodysplastic syndromes with ring sideroblasts (<scp>MDSâ€RS</scp>) and <scp>MDS</scp>/myeloproliferative neoplasm with <scp>RS</scp> and thrombocytosis (<scp>MDS/MPNâ€RSâ€T</scp>) â€“ â€œ<scp>2021</scp> update on diagnosis, riskâ€stratification, and managementâ€. American Journal of Hematology, 2021, 96, 379-394.	2.0	29
1422	Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?. Cancers, 2021, 13, 132.	1.7	20
1423	Reduced miR-16 levels are associated with VEGF upregulation in high-risk myelodysplastic syndromes. Journal of Cancer, 2021, 12, 1967-1977.	1.2	0
1424	Post-transplant relapse of therapy-related MDS as gastric myeloid sarcoma: Case report and review of literature. Leukemia Research Reports, 2021, 15, 100244.	0.2	1
1425	Treatment options for lower-risk myelodysplastic syndromes. Where are we now?. Therapeutic Advances in Hematology, 2021, 12, 204062072098664.	1.1	4
1426	Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34+ Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia. Cancers, 2021, 13, 186.	1.7	8
1427	Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer Management and Research, 2021, Volume 13, 645-657.	0.9	5
1428	Myelodysplastic Syndrome. , 2021, , 101-118.		0
1429	Unique ethnic features of <I>DDX41</I> mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. Haematologica, 2022, 107, 510-518.	1.7	33
1430	Preâ€transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. Cancer Communications, 2021, 41, 333-344.	3.7	5
1431	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Advances, 2021, 5, 1110-1121.	2.5	33
1432	Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. Blood Cancer Journal, 2021, 11, 30.	2.8	2
1433	Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes. Cancer Medicine, 2021, 10, 1759-1771.	1.3	4
1434	A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS. BMC Cancer, 2021, 21, 134.	1.1	10

#	Article	IF	Citations
1436	Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia, 2021, 35, 2720-2724.	3.3	29
1437	Genomic variations in patients with myelodysplastic syndrome and karyotypes without numerical or structural changes. Scientific Reports, 2021, 11, 2783.	1.6	2
1438	Autophagy Gene Panel-Based Prognostic Model in Myelodysplastic Syndrome. Frontiers in Oncology, 2020, 10, 606928.	1.3	2
1439	Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach. Cancers, 2021, 13, 841.	1.7	5
1440	Asiaâ€inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. Clinical and Translational Science, 2021, 14, 1069-1081.	1.5	9
1441	Clinicopathologic Features of Myelodysplastic Syndromes Involving Lymph Nodes. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 930-938.	2.1	0
1442	Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes. Haematologica, 2022, 107, 655-667.	1.7	16
1443	Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study. Blood Advances, 2021, 5, 1344-1351.	2.5	11
1444	When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis. Journal of Clinical Medicine, 2021, 10, 1026.	1.0	6
1445	Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS. Blood Cancer Discovery, 2021, 2, 238-249.	2.6	25
1446	Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?. Best Practice and Research in Clinical Haematology, 2021, 34, 101245.	0.7	8
1447	Multicenter Next-Generation Sequencing Studies between Theory and Practice. Journal of Molecular Diagnostics, 2021, 23, 347-357.	1.2	1
1448	Expression of mRNA TNFÎ± and level of protein TNFÎ± after exposure sCD40L in bone marrow mononuclear cells of myelodysplastic syndromes. Stem Cell Investigation, 2021, 8, 6-6.	1.3	1
1449	Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. HemaSphere, 2021, 5, e549.	1.2	29
1450	Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Cancers, 2021, 13, 1610.	1.7	17
1451	Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia. Current Hematologic Malignancy Reports, 2021, 16, 247-255.	1.2	5
1452	The prognostic significance of singleâ€nucleotide polymorphism arrayâ€based wholeâ€genome analysis and uniparental disomy in myelodysplastic syndrome. International Journal of Laboratory Hematology, 2021, 43, 1062-1069.	0.7	3
1453	VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder. Experimental Hematology and Oncology, 2021, 10, 23.	2.0	42

#	Article	IF	Citations
1454	Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 328-350.	1.8	2
1455	Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome. Korean Journal of Internal Medicine, 2021, 36, 413-423.	0.7	4
1456	High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies. Aging, 2021, 13, 11120-11134.	1.4	3
1457	Development of luspatercept to treat ineffective erythropoiesis. Blood Advances, 2021, 5, 1565-1575.	2.5	39
1458	Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists. International Journal of Molecular Sciences, 2021, 22, 2525.	1.8	2
1459	Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. New England Journal of Medicine, 2021, 384, 924-935.	13.9	170
1460	Improved Variant Detection in Clinical Myeloid NGS Testing by Supplementing a Commercial Myeloid NGS Assay with Custom or Extended Data Filtering and Accessory Fragment Analysis. Molecular Diagnosis and Therapy, 2021, 25, 251-266.	1.6	5
1461	Combination of HDE and BIIB021 efficiently inhibits cell proliferation and induces apoptosis via downregulating hTERT in myelodysplastic syndromes. Experimental and Therapeutic Medicine, 2021, 21, 503.	0.8	2
1462	Comparative Study on Iron Content Detection by Energy Spectral CT and MRI in MDS Patients. Frontiers in Oncology, 2021, 11, 646946.	1.3	4
1463	Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia. Nature Communications, 2021, 12, 2482.	5.8	14
1464	Precision medicine in myeloid malignancies. Seminars in Cancer Biology, 2022, 84, 153-169.	4.3	18
1465	Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study. Annals of Hematology, 2021, 100, 1451-1457.	0.8	4
1466	Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?. Expert Opinion on Investigational Drugs, 2021, 30, 665-673.	1.9	2
1467	WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biomedicines, 2021, 9, 387.	1.4	9
1468	A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms. Cancers, 2021, 13, 1947.	1.7	5
1469	Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome. Pathology, 2021, 53, 328-338.	0.3	6
1470	Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome. Leukemia Research, 2021, 103, 106540.	0.4	1
1471	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1223-1233.	0.8	127

#	Article	IF	Citations
1472	Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia and Lymphoma, 2021, 62, 1-10.	0.6	0
1473	Successful use of allogeneic bone marrow transplantation in a patient with myelodysplastic syndrome presenting with autoimmune manifestations. British Journal of Haematology, 2021, 193, 1275-1277.	1.2	1
1474	Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy. Cancers, 2021, 13, 1746.	1.7	7
1475	Prognostic relevance of lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience. Leukemia and Lymphoma, 2021, 62, 2272-2275.	0.6	0
1476	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia, 2021, 35, 3329-3333.	3.3	6
1477	Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?. Leukemia Research, 2021, 103, 106543.	0.4	2
1478	Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and metaâ€analysis. European Journal of Haematology, 2021, 107, 3-23.	1.1	7
1479	Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Advances, 2021, 5, 2264-2271.	2.5	20
1480	Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS). Hemato, 2021, 2, 217-236.	0.2	2
1481	Clinical genetic description and analysis of the case of chromosomal mosaicism mos47,XY,+8/46,XY. Bulletin of Siberian Medicine, 2021, 20, 213-217.	0.1	0
1482	Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review. Annals of Hematology, 2021, 100, 1359-1376.	0.8	12
1483	Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine. Case Reports in Hematology, 2021, 2021, 1-8.	0.3	3
1484	Luspatercept in the treatment of lower-risk myelodysplastic syndromes. Future Oncology, 2021, 17, 1473-1481.	1.1	3
1485	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Advances, 2021, 5, 2272-2278.	2.5	19
1486	Computational flow cytometry as a diagnostic tool in suspectedâ€myelodysplastic syndromes. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 814-824.	1.1	17
1487	Treatment strategies for myelodysplastic syndrome in 2021. Vnitrni Lekarstvi, 2021, 67, 150-155.	0.1	0
1488	Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia, 2021, 35, 2182-2198.	3.3	46
1489	Risk factors for invasive fungal infection in 5â€azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome. European Journal of Haematology, 2021, 107, 181-189.	1.1	5

#	Article	IF	Citations
1490	Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1â€mRNA expression in patients with AML and MDS. European Journal of Haematology, 2021, 107, 283-292.	1.1	11
1491	Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes. European Journal of Haematology, 2021, 107, 219-228.	1.1	3
1492	Targeting CD47/SIRPÎ± in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab. Journal of Immunotherapy and Precision Oncology, 2021, 4, 67-71.	0.6	21
1493	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1426-1436.	0.8	49
1494	Current Therapy of the Patients with MDS: Walking towards Personalized Therapy. Journal of Clinical Medicine, 2021, 10, 2107.	1.0	9
1495	Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with <scp>MDSâ€EB</scp>â€1 or <scp>MDSâ€EB</scp>â€2. International Journal of Cancer, 2021, 149, 1109-1120.	2.3	6
1496	Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. Aging Cell, 2021, 20, e13366.	3.0	72
1497	A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leukemia Research, 2021, 104, 106555.	0.4	18
1498	Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients. Annals of Hematology, 2021, 100, 1701-1709.	0.8	3
1499	High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage. Leukemia and Lymphoma, 2021, 62, 1-9.	0.6	1
1500	Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients. Annals of Hematology, 2021, 100, 1439-1449.	0.8	2
1501	Multiplex ligation-dependent probe amplification identifies copy number changes in normal and undetectable karyotype MDS patients. Annals of Hematology, 2021, 100, 2207-2214.	0.8	1
1502	Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome: The first retrospective cross-sectional study in Iranian patients. Molecular Cytogenetics, 2021, 14, 24.	0.4	4
1504	Myelodysplastic syndrome and immunotherapy novel to next in-line treatments. Human Vaccines and Immunotherapeutics, 2021, 17, 2602-2616.	1.4	3
1505	Targeting health-related quality of life in patients with myelodysplastic syndromes â€“ Current knowledge and lessons to be learned. Blood Reviews, 2021, 50, 100851.	2.8	14
1506	Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration. Journal of Clinical Medicine, 2021, 10, 2052.	1.0	4
1507	Comparison of non-first-degree related donors and first-degree related donors in haploidentical HSCT: a multi-centre retrospective analysis. Bone Marrow Transplantation, 2021, 56, 2567-2574.	1.3	4
1508	Chronic Myelomonocytic Leukemia: Hematopathology Perspective. Journal of Immunotherapy and Precision Oncology, 2021, 4, 142-149.	0.6	1

#	Article	IF	Citations
1509	Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. Journal of Experimental Medicine, 2021, 218, .	4.2	88
1510	Survival Benefit and Efficiency of Low Dose Decitabine With CEG Regimen Compared to Decitabine Alone in the Elderly MDS â€“ A Multicenter, Retrospective Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e792-e800.	0.2	0
1511	What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. Leukemia and Lymphoma, 2021, 62, 2762-2767.	0.6	6
1512	Clinical Complications of Iron Overload in Patients with Myelodysplastic Syndromes: a literature review. Brazilian Journal of Case Reports, 2021, 1, 83-92.	0.0	0
1513	Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts. Expert Review of Hematology, 2021, 14, 509-516.	1.0	1
1514	Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. European Journal of Haematology, 2021, 107, 265-274.	1.1	10
1515	Plasma IL-33 levels are decreased in patients with high-risk myelodysplastic syndrome and show no correlation with pro-inflammatory IL-6 levels. Cytokine, 2021, 148, 155617.	1.4	0
1516	Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia. Future Oncology, 2021, 17, 2077-2087.	1.1	11
1517	Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes. Leukemia, 2022, 36, 236-247.	3.3	4
1518	Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome. Biomarker Research, 2021, 9, 46.	2.8	8
1519	A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia. Leukemia Research, 2021, 105, 106573.	0.4	5
1520	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood, 2022, 139, 323-332.	0.6	80
1521	Thrombopoietin receptor agonists for marrow failure: A concise clinical review. Best Practice and Research in Clinical Haematology, 2021, 34, 101274.	0.7	2
1522	Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome. Best Practice and Research in Clinical Haematology, 2021, 34, 101280.	0.7	11
1523	Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations. Cancers, 2021, 13, 3001.	1.7	2
1524	Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. Cancers, 2021, 13, 3296.	1.7	4
1525	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 2021, 35, 3542-3550.	3.3	97
1526	British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes. British Journal of Haematology, 2021, 194, 282-293.	1.2	10

#	Article	IF	Citations
1527	Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective realâ€life study. British Journal of Haematology, 2021, 194, 336-343.	1.2	12
1528	British Society for Haematology guidelines for the management of adult myelodysplastic syndromes. British Journal of Haematology, 2021, 194, 267-281.	1.2	14
1529	Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity. Blood Research, 2021, 56, 102-108.	0.5	0
1530	Sindromi mielodisplastiche. EMC - AKOS - Trattato Di Medicina, 2021, 23, 1-7.	0.0	0
1531	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer, 2021, 127, 3552-3565.	2.0	19
1532	The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia. HemaSphere, 2021, 5, e616.	1.2	2
1533	Stem Cells in the Myelodysplastic Syndromes. Frontiers in Aging, 2021, 2, .	1.2	4
1534	Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndromeÂ-Âa phase I clinical trial. Cancer Immunology, Immunotherapy, 2022, 71, 433-444.	2.0	8
1535	Chronic Myelomonocytic Leukemia Gold Jubilee. Hemato, 2021, 2, 403-428.	0.2	0
1536	Increased serum C-reactive protein is an adverse prognostic factor in low-risk myelodysplastic syndromes. International Journal of Hematology, 2021, 114, 441-448.	0.7	5
1537	Disulfiram/copper shows potent cytotoxic effects on myelodysplastic syndromes via inducing Bip-mediated apoptosis and suppressing autophagy. European Journal of Pharmacology, 2021, 902, 174107.	1.7	5
1538	The Genetics of Myelodysplastic Syndromes: Clinical Relevance. Genes, 2021, 12, 1144.	1.0	14
1539	On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 34-43.	0.2	4
1540	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). Journal of Clinical Oncology, 2021, 39, 3318-3327.	0.8	44
1541	Genetics of Myelodysplastic Syndromes. Cancers, 2021, 13, 3380.	1.7	9
1542	Targeting the Myeloid Lineages and the Immune Microenvironment in Myelodysplastic Syndromes: Novel and Evolving Therapeutic Strategies. Annals of Pharmacotherapy, 2021, , 106002802110361.	0.9	1
1543	The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. Bone Marrow Transplantation, 2021, 56, 2749-2754.	1.3	0
1545	Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae. Critical Reviews in Oncology/Hematology, 2021, 163, 103367.	2.0	15

#	Article	IF	Citations
1546	Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia. Pharmaceuticals, 2021, 14, 641.	1.7	13
1547	Characteristics and prognosis of patients with myelodysplastic syndromes admitted to the intensive care unit. Leukemia and Lymphoma, 2021, 62, 3057-3059.	0.6	0
1548	Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. Clinical Chemistry, 2021, 67, 1062-1070.	1.5	0
1549	A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia and Lymphoma, 2021, 62, 3181-3191.	0.6	4
1550	Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine. Epigenomics, 2021, 13, 1129-1143.	1.0	2
1551	Periâ€transfusion qualityâ€ofâ€life assessment for patients with myelodysplastic syndromes. Transfusion, 2021, 61, 2830-2836.	0.8	10
1552	Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients. Annals of Hematology, 2021, 100, 2575-2584.	0.8	5
1553	Current and emerging strategies for management of myelodysplastic syndromes. Blood Reviews, 2021, 48, 100791.	2.8	34
1554	Cytogenetic and Genetic Advances in Myelodysplasia Syndromes. , 0, , .		0
1555	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplantation and Cellular Therapy, 2021, 27, 913.e1-913.e12.	0.6	6
1556	Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. British Journal of Haematology, 2021, 194, 708-717.	1.2	7
1557	The impact of CD33/CD34 ratio in the prognosis of myelodysplastic syndrome treated with azacitidine for first-line therapy. Journal of Hematopathology, 2021, 14, 205-212.	0.2	0
1558	Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact. Cytometry Part B - Clinical Cytometry, 2023, 104, 141-150.	0.7	14
1559	Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome. Experimental Hematology and Oncology, 2021, 10, 44.	2.0	4
1560	Profile of patients with Myelodysplastic syndrome: A report from a tertiary care teaching hospital from Eastern India. , 0, .		0
1561	Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality. Blood Advances, 2021, 5, 3266-3278.	2.5	6
1562	Case Report: Diagnosis of Myelodysplastic Syndrome in a 72-Year-Old Female With Interstitial Lung Disease. Frontiers in Medicine, 2021, 8, 673573.	1.2	1
1563	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	0.6	11

#	Article	IF	Citations
1565	Expanding the immune armoury against myelodysplastic syndrome. British Journal of Haematology, 2021, 195, 301-303.	1.2	0
1566	Allogeneic Stem Cell Transplantation for MDS. Hemato, 2021, 2, 545-555.	0.2	3
1567	Effect Of Genetic Characteristics On Survival In Myelodysplastic Syndrome. BezmiÃ¢lem Science, 2021, .	0.1	0
1568	The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms. Medicina (Lithuania), 2021, 57, 813.	0.8	2
1569	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 3737-3746.	0.8	90
1570	Phase II study of azacitidine with pembrolizumab in patients with intermediateâ€1 or higherâ€risk myelodysplastic syndrome. British Journal of Haematology, 2021, 195, 378-387.	1.2	32
1571	Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in highâ€risk myelodysplastic syndromes: Challenges and opportunities in implementation. Cancer, 2021, 127, 4339-4347.	2.0	4
1572	GATA2 deficiency syndrome: A decade of discovery. Human Mutation, 2021, 42, 1399-1421.	1.1	30
1573	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 2021, 27, 923.e1-923.e12.	0.6	15
1574	Scopus Veri TabanÄ±na DayalÄ± Bibliyometrik DeÄŸerlendirme: Miyelodisplastik Sendrom Konulu YayÄ±nlarÄ±n Global Analizi ve TÃ¼rkiye KaynaklÄ± YayÄ±nlarÄ±n DeÄŸerlendirilmesi. Journal of Biotechnology and Strategic Health Research, 2021, 5, 125-131.	0.8	23
1575	Stem Cells in Myelodysplastic Syndromes and Acute Myeloid Leukemia: First Cousins or Unrelated Entities?. Frontiers in Oncology, 2021, 11, 730899.	1.3	5
1576	Management of the Older Patient with Myelodysplastic Syndrome. Drugs and Aging, 2021, 38, 751-767.	1.3	9
1577	TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy. Current Issues in Molecular Biology, 2021, 43, 917-931.	1.0	5
1578	Is race important in genomic classification of hematological neoplasms?. Hematological Oncology, 2021, 39, 728-732.	0.8	4
1579	Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 659.e1-659.e6.	0.6	5
1580	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia and Lymphoma, 2022, 63, 199-204.	0.6	3
1581	SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 1-16.	0.2	20
1582	Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S73-S76.	0.2	0

#	Article	IF	Citations
1583	BCL-2 Inhibition in MDS. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S104-S106.	0.2	0
1584	Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome. Bone Marrow Transplantation, 2021, 56, 3016-3023.	1.3	1
1585	Higherâ€risk myelodysplastic syndrome in an elderly patient: Longâ€term partial remission with lowâ€dose prednisone, Gâ€CSF, and epoetin alfa. Clinical Case Reports (discontinued), 2021, 9, e04752.	0.2	1
1586	Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. Bone Marrow Transplantation, 2021, 56, 3008-3015.	1.3	4
1587	Molecular Pathology of Myeloid Neoplasms. Surgical Pathology Clinics, 2021, 14, 517-528.	0.7	3
1588	The anemia-independent impact of myelodysplastic syndromes on health-related quality of life. Annals of Hematology, 2021, 100, 2921-2932.	0.8	7
1589	Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome. British Journal of Haematology, 2021, , .	1.2	2
1590	Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A populationâ€based study. Transfusion, 2021, 61, 2877-2884.	0.8	5
1591	Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center. Leukemia Research, 2021, 108, 106611.	0.4	4
1592	Coexisting primary tumors from esophageal cancer and myelodysplastic syndromes: A case report. Clinical Case Reports (discontinued), 2021, 9, e04872.	0.2	0
1593	Flow Cytometric Findings in Clonal Cytopenia of Undetermined Significance. American Journal of Clinical Pathology, 2021, , .	0.4	3
1594	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. Journal of Clinical Epidemiology, 2021, 137, 31-44.	2.4	11
1595	Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome. Bone Marrow Transplantation, 2021, 56, 2975-2980.	1.3	3
1596	Functional polymorphisms of DNA repair genes in Latin America reinforces the heterogeneity of Myelodysplastic Syndrome. Hematology, Transfusion and Cell Therapy, 2021, , .	0.1	1
1598	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leukemia Research, 2021, 110, 106713.	0.4	9
1599	Diagnostic approach to myelodysplastic syndromes and related neoplasms. Diagnostic Histopathology, 2021, 27, 380-389.	0.2	0
1600	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 771.e1-771.e10.	0.6	17
1601	Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies. Trends in Molecular Medicine, 2021, 27, 990-999.	3.5	1

#	Article	IF	Citations
1602	A machine learning approach to predicting risk of myelodysplastic syndrome. Leukemia Research, 2021, 109, 106639.	0.4	11
1603	Significance of Y Chromosome Loss in Hematologic Malignancies. Laboratory Medicine Online, 2021, 11, 230-234.	0.0	0
1604	Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. Leukemia Research, 2021, 109, 106625.	0.4	0
1605	Acute Myeloid Leukemia. , 2021, , 39-99.		0
1606	Pretransplant Assessment for Hematopoietic Cell Transplantation Recipients and Donors. , 2021, , 55-72.		0
1607	Prognostic impact of peripheral blood Wilmsâ€™ tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysis. Leukemia Research Reports, 2021, 15, 100231.	0.2	1
1608	Clinical features ofDDX41mutation-related diseases: a systematic review with individual patient data. Therapeutic Advances in Hematology, 2021, 12, 204062072110324.	1.1	15
1609	Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. Annals of Hematology, 2021, 100, 1995-2004.	0.8	9
1610	Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations. Cancers, 2021, 13, 481.	1.7	22
1611	Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Leukemia and Lymphoma, 2021, 62, 1411-1421.	0.6	8
1613	SF3B1 mutant myelodysplastic syndrome: Recent advances. Advances in Biological Regulation, 2021, 79, 100776.	1.4	8
1614	Hebrew Psychological Lexicons. , 2021, , .		0
1616	Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?. American Journal of Hematology, 2015, 90, n/a-n/a.	2.0	2
1617	Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: <scp>CD45RA</scp> and <scp>CD371</scp> improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy. Cytometry Part B - Clinical Cytometry, 2021, 100, 574-589.	0.7	10
1618	Biology and Pathophysiology of MDS with del(5q). , 2020, , 43-54.		1
1619	Prognostic Models in Myelodysplastic Syndromes. , 2020, , 109-127.		2
1620	Myelodysplastic Syndrome. Molecular Pathology Library, 2018, , 83-98.	0.1	1
1621	Neoplastische BildungsstÃ¶rungen der HÃmatopoiese mit erhaltener Ausreifung. , 2019, , 47-87.		2

#	Article	IF	Citations
1622	Biomarkers and Methodologies for Monitoring Epigenetic Drug Effects in Cancer. , 2016, , 91-118.		2
1623	Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 2143-2150.	2.0	19
1624	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1607-1611.	2.0	6
1625	Current concepts and future directions for hemato-oncologic diagnostics. Critical Reviews in Oncology/Hematology, 2020, 151, 102977.	2.0	14
1626	Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 383, 1358-1374.	13.9	274
1627	Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. Leukemia and Lymphoma, 2020, 61, 1475-1483.	0.6	4
1628	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 1226-1233.	0.6	24
1630	Mutation status and burden can improve prognostic prediction of patients with lowerâ€risk myelodysplastic syndromes. Cancer Science, 2020, 111, 580-591.	1.7	33
1631	Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. Journal of Clinical Investigation, 2015, 125, 1043-1055.	3.9	79
1632	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. Journal of Clinical Investigation, 2017, 127, 2206-2221.	3.9	69
1633	Novel therapeutic strategies: hypomethylating agents and beyond. Hematology American Society of Hematology Education Program, 2012, 2012, 65-73.	0.9	16
1634	Novel therapeutic strategies: hypomethylating agents and beyond. Hematology American Society of Hematology Education Program, 2012, 2012, 65-73.	0.9	26
1635	How I treat anemia in heart failure. Blood, 2020, 136, 790-800.	0.6	14
1636	Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes. Blood, 2013, 122, 521-521.	0.6	14
1637	Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome. Hematology American Society of Hematology Education Program, 2019, 2019, 97-104.	0.9	25
1638	Lowering the boom on lower-risk myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2019, 2019, 367-372.	0.9	4
1639	Tandem triplication of the long arm of chromosome 1, trp(1)(q21q32), in two cases with myelodysplastic syndromes. Tenri Medical Bulletin, 2015, 18, 23-30.	0.1	1
1640	Establishment and Validation of an Updated Diagnostic FCM Scoring System Based on Pooled Immunophenotyping in CD34+ Blasts and Its Clinical Significance for Myelodysplastic Syndromes. PLoS ONE, 2014, 9, e88706.	1.1	15

#	Article	IF	Citations
1641	Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis. PLoS ONE, 2014, 9, e100206.	1.1	47
1642	Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?. PLoS ONE, 2015, 10, e0129375.	1.1	19
1643	Targeting the Sonic Hedgehog-Gli1 Pathway as a Potential New Therapeutic Strategy for Myelodysplastic Syndromes. PLoS ONE, 2015, 10, e0136843.	1.1	16
1644	Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0165948.	1.1	10
1645	Myelodysplastic syndrome patients present more severe respiratory muscle impairment and reduced forced vital capacity: Is disordered inflammatory signaling the culprit?. PLoS ONE, 2017, 12, e0184079.	1.1	3
1646	Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis. PLoS ONE, 2017, 12, e0185053.	1.1	18
1647	Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e256-e270.	1.8	2
1648	Rare Respiratory and Neurologic Adverse Reactions to Azacitidine in the Treatment of Myelodysplastic Syndrome of Patients Treated at the Ottawa Hospital. Journal of Hematology (Brossard, Quebec), 2015, 4, 231-234.	0.4	4
1649	HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML. Aging, 2020, 12, 16759-16774.	1.4	9
1650	Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. Oncotarget, 2016, 7, 55264-55275.	0.8	62
1651	Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Oncotarget, 2016, 7, 63177-63188.	0.8	21
1652	Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality. Oncotarget, 2016, 7, 72685-72698.	0.8	21
1653	Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes. Oncotarget, 2017, 8, 1603-1612.	0.8	6
1654	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget, 2017, 8, 37866-37874.	0.8	10
1655	Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup. Oncotarget, 2017, 8, 79188-79200.	0.8	5
1656	Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. Oncotarget, 2014, 5, 4384-4391.	0.8	17
1657	Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. Oncotarget, 2017, 8, 103274-103282.	0.8	12
1658	Prognostic factors for histiocytic and dendritic cell neoplasms. Oncotarget, 2017, 8, 98723-98732.	0.8	20

#	Article	IF	Citations
1659	Reactive oxygen species levels control NF-ÎºB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. Oncotarget, 2017, 8, 105510-105524.	0.8	35
1660	Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes. Oncotarget, 2017, 8, 115002-115017.	0.8	6
1661	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget, 2018, 9, 9714-9727.	0.8	56
1662	Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. Oncotarget, 2018, 9, 19342-19355.	0.8	15
1663	Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia. Oncotarget, 2018, 9, 34398-34412.	0.8	11
1664	Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients. Oncotarget, 2018, 9, 36929-36944.	0.8	18
1665	The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells. Oncotarget, 2019, 10, 3462-3471.	0.8	8
1666	Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget, 2016, 7, 6609-6619.	0.8	16
1667	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget, 2016, 7, 14172-14187.	0.8	86
1668	Prognostic Value of Next-Generation Sequencing Data in Patients with Myelodysplastic Syndrome. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 170-175.	0.1	2
1669	Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes. Current Bioinformatics, 2014, 9, 408-413.	0.7	3
1670	The Indications for Allogeneic Stem Cell Transplantation in Myeloid Malignancies. Deutsches Ärzteblatt International, 2015, 112, 262-70.	0.6	14
1671	Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. Haematologica, 2021, 106, 701-707.	1.7	10
1672	Myelodysplastic syndromes: moving towards personalized management. Haematologica, 2020, 105, 1765-1779.	1.7	52
1673	Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome. Haematologica, 2020, 105, 2785-2794.	1.7	41
1674	Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations. Haematologica, 2021, 106, 2906-2917.	1.7	21
1675	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. Haematologica, 2020, 105, 2516-2523.	1.7	12
1676	Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. International Journal of Environmental Research and Public Health, 2020, 17, 9562.	1.2	3

#	Article	IF	Citations
1680	Downregulation of extracellular vesicle microRNAâ€'101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progression. Oncology Letters, 2020, 19, 2053-2061.	0.8	5
1681	Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome. Korean Journal of Internal Medicine, 2019, 34, 390-400.	0.7	14
1682	No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. Korean Journal of Internal Medicine, 2018, 33, 1194-1202.	0.7	1
1683	Clinical Effects of Hypomethylating Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome Who Received DNA-Damaging Chemotherapy for Metastatic Breast Cancer. Journal of Breast Cancer, 2019, 22, 647.	0.8	3
1684	A Primary Care Approach to Myelodysplastic Syndromes. Korean Journal of Family Medicine, 2014, 35, 111.	0.4	5
1685	Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems. Turkish Journal of Haematology, 2016, 33, 119-126.	0.2	4
1686	Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification. Turkish Journal of Haematology, 2018, 35, 109-115.	0.2	4
1687	Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Archives of Pathology and Laboratory Medicine, 2021, 145, 176-190.	1.2	3
1688	Response and survival in acute myeloid leukemia patients not candidates to transplantation treated with azacitidine versus palliative treatment: a retrospective study. Medwave, 2015, 15, e6207-e6207.	0.2	2
1689	Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil. Clinics, 2019, 74, e771.	0.6	2
1690	Current Management and New Developments in the Treatment of Myelodysplastic Syndrome. Cancer Treatment and Research, 2021, 181, 115-132.	0.2	2
1691	Impact of next generation sequencing results on clinical management in patients with hematological disorders. Leukemia and Lymphoma, 2021, 62, 1702-1710.	0.6	4
1692	Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine. Journal of Clinical Medicine, 2021, 10, 4809.	1.0	0
1693	TheCADM1tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11. Blood Advances, 2022, 6, 386-398.	2.5	3
1694	Impaired formation of neutrophil extracellular traps in patients with MDS. Blood Advances, 2022, 6, 129-137.	2.5	7
1695	Central Nervous System-related Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Internal Medicine, 2021, 60, 3299-3304.	0.3	4
1696	Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 236-250.	0.2	10
1697	Azacitidine for patients with Vacuoles, E1 Enzyme, Xâ€linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. British Journal of Haematology, 2022, 196, 969-974.	1.2	85

#	Article	IF	Citations
1698	A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes. Blood Advances, 2021, 5, 4535-4548.	2.5	19
1699	Meaningful response criteria for myelodysplastic syndromes. British Journal of Haematology, 2022, 196, 1137-1148.	1.2	12
1700	Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancers, 2021, 13, 5026.	1.7	7
1701	MYC Overexpression is Associated with an Early Disease Progression from MDS to AML. Leukemia Research, 2021, 111, 106733.	0.4	6
1702	Rare Case of Multiple Lineage Dysplasia Myelodysplastic Syndrome Presenting with Only Anemia: A Case Report. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 182-188.	0.1	1
1703	Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?. Future Oncology, 2021, 17, 5163-5175.	1.1	23
1704	â€˜We cannot paint them all with the same brushâ€™: the need for a better definition of patients with myelodysplastic syndromes for clinical trial design. British Journal of Haematology, 2022, 196, 268-269.	1.2	4
1707	A Personalized Molecular Pathogenesis of MDS. , 2013, , 97-109.		0
1708	Prognostic Models for Patients with Myelodysplastic Syndromes. , 2013, , 153-167.		0
1709	Hematopoietic Cell Transplantation (HCT). , 2013, , 211-228.		0
1711	The Diagnosis of Myelodysplastic Syndromes. RSC Detection Science, 2013, , 182-200.	0.0	0
1712	Thrombocytosis. , 2014, , 133-150.		0
1715	Iron Overload, Chelation Therapy and Survival in Lower-Risk Myelodysplastic Syndromes: State of the Evidence. International Blood Research & Reviews, 2014, 2, 95-112.	0.1	0
1717	Molecular Testing in Hematologic Malignancies. , 2014, , 135-167.		1
1719	Novel approaches in the classification and risk assessment of patients with myelodysplastic syndromes-clinical implication. Scripta Scientifica Medica, 2014, 46, 62.	0.1	0
1720	Myelodysplastic Syndromes in Older Patients. , 2015, , 49-61.		0
1721	Treatment-Recalcitrant Lower-risk Myelodysplastic Syndrome Successfully Treated with Long-term Azacitidine in an Elderly Male. Kitakanto Medical Journal, 2015, 65, 193-197.	0.0	0
1722	Pre-transplant Medical Evaluation. , 2015, , 43-54.		0

#	Article	IF	Citations
1723	ÐÐ°ÐºÑ‚Ð¾Ñ€Ñ‹ Ð¿Ñ€Ð¾Ð³Ð½Ð¾Ð·Ð° Ð¿Ñ€Ð¸ Ð¼Ð¸ÐµÐ»Ð¾Ð´Ð¸ÑÐ¿Ð»Ð°Ð·Ñ‚Ð¸Ñ‡ÐµÑ…... Ð¼Ð¸ÐµÐ»Ð¾Ð´Ð¸ÑÐ¿Ð»Ð°Ð·Ñ‚Ð¸Ñ‡ÐµÑ. Ñ‚Ð¸Ð½Ð		
1724	The Myelodysplastic Syndromes. , 2015, , 269-277.		0
1725	Neutrophil to Lymphocyte Ratio - Not an Independent Prognostic Factor in Patients with the Myelodysplastic Syndrome. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10883-10885.	0.5	2
1726	Dramatic response in the dependency to transfusion after low doses of lenalidomide treatment in a 5q-syndrome patient: a case report. Â°stanbul Kuzey Klinikleri, 2015, 1, 191-193.	0.1	2
1727	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
1729	Refractory Cytopenia With Multilineage Dysplasia. , 2016, , 5-54-5-57.		4
1730	A Case of Coexistence of Bone Marrow-involved Refractory Marginal Zone B-Cell Lymphoma and Therapy-related Myelodysplastic Syndrome. Laboratory Medicine Online, 2016, 6, 98.	0.0	0
1731	Overview and Classification of MDS. , 2016, , 5-42-5-45.		0
1732	Myelodysplastische Syndrome. , 2016, , 1-9.		0
1733	Myelodysplastic syndromes in 2016. Onkologie (Czech Republic), 2016, 10, 114-119.	0.0	0
1734	Chromosomal Abnormalities in Myelodysplastic Syndromes Detected With Multiplex Ligation Dependent Probe Amplification. IOSR Journal of Dental and Medical Sciences, 2016, 15, 79-82.	0.0	0
1735	Myelodysplastic Disorders, 5q-Syndrome. , 0, , .		0
1736	Cytogenetic Features of Elderly Turkish Myelodysplastic Syndrome Patients. Erciyes Medical Journal, 2016, 38, 95-98.	0.0	0
1737	Hypomethylating Agents in Oncohematology. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 369-382.	0.1	2
1738	Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.2	1
1739	Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML). , 2017, , 87-108.		0
1740	Myelodysplastische Syndrome (MDS). , 2017, , 381-394.		2
1741	Myelodysplastische Syndrome. , 2017, , 1-15.		0

#	Article	IF	Citations
1743	Cord Blood Transplants for Myeloid Malignancies in Adults. , 2017, , 163-179.		0
1744	MDS/AML del(11)(q14) Share Common Morphological Features Despite Different Chromosomal Breakpoints. Anticancer Research, 2017, 37, 645-650.	0.5	1
1745	Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes. Journal of the Advanced Practitioner in Oncology, 2017, 8, .	0.2	2
1746	Identification of Myelodysplastic Syndrome by Flow Cytometry. , 2017, , 105-114.		0
1747	Chronic Myelomonocytic Leukemia: Clinical and Pathologic Features. Molecular Pathology Library, 2018, , 233-247.	0.1	0
1748	The Myelodysplastic Syndromes. , 2018, , 483-508.		0
1749	First Cytogenetic Profile of Omani Patients with de novo Myelodysplastic Syndromes: Comparison with data from Asia, Africa, Europe and North and South America. Sultan Qaboos University Medical Journal, 2017, 17, e286-292.	0.3	1
1750	Synoptic Bone Marrow Reporting. , 2018, , 26-29.		0
1751	Myelodysplastic Syndromes (MDS). Encyclopedia of Pathology, 2018, , 1-12.	0.0	0
1752	Overview and Classification of Myelodysplastic Syndromes. , 2018, , 566-575.		0
1753	Morphology and Flow Cytometry. Hematologic Malignancies, 2018, , 3-13.	0.2	0
1754	Myelodysplastische Syndrome. , 2018, , 183-197.		0
1755	Outcome after azacitidine treatment in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia in the Clinic of Hematology at St. Marina University Hospital, Varna. Scripta Scientifica Medica, 2018, 50, 31.	0.1	2
1756	A Case Report of a Patient with Myelodysplastic Syndrome Who Has Lower Back Pain. The Journal of Internal Korean Medicine, 2018, 39, 230-236.	0.0	1
1757	PatrÃ³n clÃnico y citogenÃ©tico en pacientes con sÃndrome mielodisplÃ¡sico en CÃºcuta (Norte de) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.0	0
1758	Bone Marrow Malignancies and Indications for Hematopoietic Cell Transplantation. , 2019, , 387-400.		0
1760	Liquid biopsies in myeloid malignancies. , 2019, 2, 1044-1061.		5
1762	Myelodysplastic Syndrome. , 2019, , 1-21.		0

#	Article	IF	Citations
1763	Myelodysplastic Syndrome: An Overview. , 2019, , 149-161.		0
1765	Comparative assessment of conventional chromosomal analysis and fluorescence in situ hybridization in the evaluation of suspected myelodysplastic syndromes: A single institution experience. Avicenna Journal of Medicine, 2019, 9, 55-60.	0.3	0
1766	DÃ¼ÅŸÃ¼k riskli miyelodisplastik sendrom hastalarÄ±nda proksismal noktÃ¼rnal hemoglobinÃ¼ri klon varlÄ±ÄŸÄ±nÄ±n deÄŸerlendirilmesi. Mersin Üniversitesi SaÄlÄ±k Bilimleri Dergisi, 0, , 300-309.	0.2	0
1767	Chronic Myeloid Neoplasms. , 2020, , 235-251.		0
1768	Myelodysplastic Syndromes (MDS). Encyclopedia of Pathology, 2020, , 358-369.	0.0	0
1769	Bone Marrow Dyspoiesis and Revised International Prognostic Scoring System- A Comparative Study. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 3146-3150.	0.1	0
1770	Evaluation of azacitidine in patients with transplantâ€'ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasiaâ€'related changes in a Japanese clinical setting. Oncology Letters, 2020, 19, 1317-1321.	0.8	1
1771	Anaemias resulting from defective maturation of red cells. , 2020, , 5450-5456.		0
1772	Lymphohematopoietic Malignancies. , 2020, , 543-559.		0
1774	Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 635-643.	2.3	11
1775	Analysis of Expansion Mesenchymal Stromal Cells in patients with low risk myelodysplastic syndrome. Journal of Bone Marrow Transplantation and Cellular Therapy, 2020, 1, 8-14.	0.1	0
1776	TP53 in Myelodysplastic Syndromes. Cancers, 2021, 13, 5392.	1.7	8
1777	Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?. International Journal of Laboratory Hematology, 2022, 44, 333-341.	0.7	3
1778	From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review. Diagnostics, 2021, 11, 1982.	1.3	6
1779	Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study. Frontiers in Oncology, 2021, 11, 721764.	1.3	1
1780	Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome. Best Practice and Research in Clinical Haematology, 2021, 34, 101332.	0.7	3
1781	The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?. EJHaem, 2022, 3, 301-313.	0.4	9
1782	Roxadustat for the treatment of anemia in patients with <scp>lowerâ€'risk</scp> myelodysplastic syndrome: Openâ€'label, doseâ€'selection, leadâ€'in stage of a phase 3 study. American Journal of Hematology, 2022, 97, 174-184.	2.0	35

#	Article	IF	Citations
1783	Myelodysplastic Syndrome. , 2020, , 479-499.		0
1784	Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts. Journal of Hematology (Brossard, Quebec), 2020, 9, 33-36.	0.4	2
1785	HSCT in Malignancies. Organ and Tissue Transplantation, 2020, , 1-16.	0.0	0
1786	Treatment Algorithms for Lower-Risk Myelodysplastic Syndrome. , 2020, , 131-145.		0
1787	Epidemiology, Etiology, and Clinical Presentation of Myelodysplastic Syndromes. , 2020, , 3-17.		2
1788	Syndromes myÃ©lodysplasiques et leucÃ©mies aiguÃ«s. , 2020, , 270-278.e3.		0
1790	Cytogenetic characteristics of 665 patients with myelodysplastic syndrome in China: A singleâ€'center report. Oncology Letters, 2020, 21, 126.	0.8	4
1791	Some characteristics of patients with myelodysplastic syndrome. Medical Herald of the South of Russia, 2020, 11, 32-42.	0.2	0
1792	Deep learning for bone marrow cell detection and classification on whole-slide images. Medical Image Analysis, 2022, 75, 102270.	7.0	54
1793	A Case of Therapy-related Myeloid Neoplasms (t-MNs) after Adjuvant Chemotherapy for Breast Cancer -a Summary Report of Therapy-related MNs after Treatment for Breast Cancer in Japan. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2020, 81, 1980-1984.	0.0	0
1795	Morphological, Flow Cytometry, and Cytogenetic Diagnosis of MDS. , 2020, , 19-42.		3
1797	CHIPs-A-LOY Loss of Chromosome Y Clusters With CHIP-associated Mutations. , 2020, 17, .		0
1799	Myelodysplastic/Myeloproliferative Neoplasms. , 2020, , 559-594.		0
1800	ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
1801	Relationship between Low Pretreatment Geriatric Nutritional Risk Index and Poor Tolerability of Azacitidine in Patients with Myelodysplastic Syndromes. Annals of Nutrition and Metabolism, 2020, 76, 405-412.	1.0	3
1802	Myelodysplastic Syndromes (MDS). Essentials of Diagnostic Pathology, 2020, , 343-381.	0.0	0
1803	The MEDALIST Trial: Are We on the Podium for Lower-Risk MDS?. , 2020, 17, .		0
1804	A Case of Myelodysplastic Syndrome Diagnosed after Colectomy for Colon Cancer with a Poor Prognosis. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2020, 81, 2297-2302.	0.0	0

#	Article	IF	Citations
1805	Chromosomal Abnormalities in Myelodysplastic Syndrome Patients in Upper Northern Thailand. Asian Pacific Journal of Cancer Prevention, 2020, 21, 639-645.	0.5	0
1806	EXCELLENT PROGNOSIS OF LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DETECTABLE MYELOID-RELATED MUTATIONS. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	0
1807	TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. Cancers, 2021, 13, 5502.	1.7	2
1811	SF3A1 Gene Polymorphism Affects Clinical Features, but not Susceptibility to Myelodysplastic Syndromes. Kitakanto Medical Journal, 2020, 70, 315-323.	0.0	0
1812	The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores. Journal of Medicine and Life, 2014, 7, 335-8.	0.4	0
1814	A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon. American Journal of Blood Research, 2015, 5, 86-90.	0.6	1
1815	Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2013, 23, 109-16.	0.7	1
1816	Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview. International Journal of Hematology-Oncology and Stem Cell Research, 2017, 11, 231-239.	0.3	13
1817	Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes. Journal of the Advanced Practitioner in Oncology, 2016, 7, 707-717.	0.2	1
1818	Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes. Journal of the Advanced Practitioner in Oncology, 2017, 8, 29-39.	0.2	5
1819	Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. Clinical Advances in Hematology and Oncology, 2018, 16, 56-66.	0.3	10
1820	A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center. American Journal of Translational Research (discontinued), 2019, 11, 4533-4541.	0.0	1
1821	Concomitant isochromosome 17q and mutated in a myelodysplastic syndrome patient with a poor prognosis. International Journal of Clinical and Experimental Pathology, 2017, 10, 9786-9792.	0.5	0
1834	The Significance of Purity: Leukaemias Involving the Erythroid Lineage. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020077.	0.5	0
1835	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Advances, 2020, 4, 5716-5721.	2.5	9
1836	Simplified flow cytometry scoring for diagnosis and prognosis of myelodysplastic symptom. American Journal of Translational Research (discontinued), 2020, 12, 7449-7458.	0.0	2
1837	Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-Î± and IL-32 Levels in Myelodysplastic Syndrome Patients. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2949-2953.	0.5	1
1839	Impact of gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. American Journal of Cancer Research, 2021, 11, 955-967.	1.4	0

#	Article	IF	Citations
1841	Concurrence of Myelodysplastic syndromes and large granular lymphocyte leukemia: clinicopathological features, mutational profile and gene ontology analysis in a single center. American Journal of Cancer Research, 2021, 11, 1616-1631.	1.4	2
1843	MicroRNAs in the Myelodysplastic Syndrome. Acta Naturae, 2021, 13, 4-15.	1.7	1
1844	Myelodysplastische Syndrome. , 2022, , 172-178.		0
1845	Myelodysplastic syndromes and myeloproliferative disorders. , 2022, , 391-411.		0
1846	MicroRNAs in the Myelodysplastic Syndrome. Acta Naturae, 2021, 13, 4-15.	1.7	10
1847	Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis. Transplantation and Cellular Therapy, 2022, 28, 158.e1-158.e9.	0.6	4
1848	Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes. Cancers, 2021, 13, 5712.	1.7	6
1849	Haploidentical Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Case Report First Experience. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 250-253.	0.1	2
1850	USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Stillâ€™s Disease in Elderly Patients. Journal of Clinical Medicine, 2021, 10, 5586.	1.0	20
1851	Integrated analysis of genotype and phenotype reveals clonal evolution and cytogenetically driven disruption of myeloid cell maturation in myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2021, , .	0.7	0
1852	Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood, 2022, 139, 624-629.	0.6	12
1853	Why Single-Cell Sequencing Has Promise in MDS. Frontiers in Oncology, 2021, 11, 769753.	1.3	2
1854	Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients. Journal of Blood Medicine, 2021, Volume 12, 1019-1030.	0.7	5
1855	Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure. European Medical Journal Hematology, 0, , 52-64.	0.0	0
1856	Onkologika. , 2021, , 579-638.		0
1857	Is 6-Shogaol an Effective Phytochemical for Patients With Lower-risk Myelodysplastic Syndrome? A Narrative Review. Integrative Cancer Therapies, 2021, 20, 153473542110650.	0.8	7
1858	The transfusion of nonâ€prophylactically RHâ€KEL1 antigenâ€matched red blood cells is feasible in selected myelodysplastic syndrome and acute myeloid leukaemia patients. Vox Sanguinis, 2022, , .	0.7	1
1859	Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients. Antioxidants, 2022, 11, 139.	2.2	1

#	Article	IF	Citations
1860	Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update. Annals of Laboratory Medicine, 2022, 42, 299-305.	1.2	15
1861	Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-Î± and IL-32 Levels in Myelodysplastic Syndrome Patients. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2949-2953.	0.5	3
1864	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	3.4	32
1865	Platelet Doubling After First Decitabine Cycle Predicts Response and Survival of Myelodysplastic Syndrome Patients. Current Medical Science, 2022, 42, 77-84.	0.7	1
1866	Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes. BMC Cancer, 2022, 22, 127.	1.1	3
1867	BMT for Myelodysplastic Syndrome: When and Where and How. Frontiers in Oncology, 2021, 11, 771614.	1.3	7
1868	Identification of a specific immunophenotype associated with a consistent pattern of genetic mutations including <scp>SRFS2</scp> and gene expression profile in <scp>MDS</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 173-182.	0.7	2
1869	Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease. Frontiers in Immunology, 2021, 12, 800149.	2.2	23
1870	How low risk are low risk myelodysplastic syndromes?. Expert Review of Hematology, 2022, 15, 15-24.	1.0	5
1871	Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e467-e476.	0.2	5
1873	What are the risks and benefit of a transplant for elderly patients?. Journal of Illusion, 2022, 11, 22-35.	0.0	0
1874	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. Clinical Cancer Research, 2022, 28, 1614-1627.	3.2	4
1875	Systemic mastocytosis with myeloid sarcoma and B-CLL: molecular and clonal heterogeneity in a rare case of SM-AHN with review of literature. Acta Clinica Belgica, 2022, , 1-9.	0.5	0
1876	Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes. Journal of Cancer Research and Clinical Oncology, 2022, 148, 845-856.	1.2	6
1877	TP53 mutation defines a unique subgroup within complex karyotype deÂnovo and therapy-related MDS/AML. Blood Advances, 2022, 6, 2847-2853.	2.5	87
1878	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>) but not in <scp>MDS</scp>/<scp>MPNâ€RSâ€T</scp>. American Journal of Hematology, 2022, 97, .	2.0	6
1879	Hematopoietic cell transplantation for myelodysplastic syndromes. Journal of Illusion, 2022, 11, 43-52.	0.0	0
1881	Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study. Bone Marrow Transplantation, 2022, 57, 598-606.	1.3	2

#	Article	IF	Citations
1882	Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS). European Journal of Haematology, 2022, 108, 342-353.	1.1	3
1883	Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities. Frontiers in Oncology, 2021, 11, 796477.	1.3	0
1884	Reduced Plasmacytoid Dendritic Cell Output Is Associated With High Risk in Low-grade Myelodysplastic Syndrome. HemaSphere, 2022, 6, e685.	1.2	4
1885	The FLT3 internal tandem duplication mutation at disease diagnosis is a negative prognostic factor in myelodysplastic syndrome patients. Leukemia Research, 2022, 113, 106790.	0.4	0
1886	The value of nextâ€generation sequencing in routine diagnostics and management of patients with cytopenia. International Journal of Laboratory Hematology, 2022, 44, 531-537.	0.7	3
1887	The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. Leukemia and Lymphoma, 2022, 63, 1651-1659.	0.6	5
1888	Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly â€œpromisingâ€?. Blood Advances, 2022, 6, 2854-2866.	2.5	3
1889	Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study. Annals of Hematology, 2022, 101, 855-867.	0.8	19
1890	Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes. Cells, 2021, 10, 3494.	1.8	4
1891	Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. American Journal of Blood Research, 2021, 11, 472-497.	0.6	2
1892	Two Cases of Myelodysplastic Syndrome and Neck Infection After Chemoradiotherapy for Hypopharyngeal Carcinoma. Practica Otologica, 2022, 115, 307-314.	0.0	0
1893	Noncoding RNAs and Their Response Predictive Value in Azacitidine-treated Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-related Changes. Cancer Genomics and Proteomics, 2022, 19, 205-228.	1.0	4
1894	Emergence of t(3;21)(q26.2;q22) during eltrombopag treatment in a patient with relapsed aplastic anemia who received chemotherapy for angioimmunoblastic T-cell lymphoma. Leukemia Research Reports, 2022, 17, 100305.	0.2	1
1895	Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 768-774.	1.3	8
1896	Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes. Nature Communications, 2022, 13, 1038.	5.8	13
1897	Comprehensive and unbiased multiparameter high-throughput screening by compaRe finds effective and subtle drug responses in AML models. ELife, 2022, 11, .	2.8	2
1898	Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA. Blood Advances, 2022, 6, 3178-3188.	2.5	6
1899	EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes. HemaSphere, 2022, 6, e695.	1.2	2

#	Article	IF	Citations
1901	Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes. International Journal of Molecular Sciences, 2022, 23, 2802.	1.8	10
1902	Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine. International Journal of Hematology, 2022, , 1.	0.7	1
1903	Prognostic impact of chromosomal changes at relapse after allogeneic hematopoietic cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. Bone Marrow Transplantation, 2022, , .	1.3	0
1904	Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry. Cytometry Part B - Clinical Cytometry, 2023, 104, 128-140.	0.7	3
1905	Dynamic change in peripheral blood WT1 mRNA levels within three cycles of azacitidine predict treatment response in patients with high-risk myelodysplastic syndromes. Annals of Hematology, 2022, , 1.	0.8	1
1906	Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis. Transplantation and Cellular Therapy, 2022, 28, 323.e1-323.e9.	0.6	2
1907	Phase 1/2 study evaluating the safety and efficacy of DSPâ€7888 dosing emulsion in myelodysplastic syndromes. Cancer Science, 2022, 113, 1377-1392.	1.7	6
1908	Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience. Frontiers in Oncology, 2022, 12, 795955.	1.3	11
1909	VEXAS-like syndrome: a potential new entity?. Annals of Hematology, 2022, 101, 1125-1128.	0.8	3
1910	Unrelated bone marrow transplantation improves Crohn's disease in a patient with myelodysplastic syndrome that developed from aplastic anemia: A case report. World Academy of Sciences Journal, 2022, 4, .	0.4	0
1911	Incidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: no evidence of improvement over time. Leukemia and Lymphoma, 2022, 63, 1964-1969.	0.6	2
1912	Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future. Leukemia Research, 2022, 115, 106820.	0.4	2
1913	Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report. World Journal of Clinical Cases, 2022, 10, 3601-3608.	0.3	2
1914	Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes. Frontiers in Oncology, 2022, 12, 846044.	1.3	4
1915	Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes. Scientific Reports, 2022, 12, 5925.	1.6	6
1916	Evolution of severe (transfusionâ€dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophageâ€associated failure of the eythropoietic niche. British Journal of Haematology, 2022, , .	1.2	3
1917	Outcomes of second allogeneic stem cell transplantation and antiâ€relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis. Hematological Oncology, 2022, 40, 763-776.	0.8	4
1918	Rac GTPases in acute myeloid leukemia cells: Expression profile and biological effects of pharmacological inhibition. Toxicology and Applied Pharmacology, 2022, 442, 115990.	1.3	8

#	Article	IF	Citations
1919	Interleukin-1 (IL-1) and the inflammasome in cancer. Cytokine, 2022, 153, 155850.	1.4	30
1920	Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia and Lymphoma, 2022, 63, 684-693.	0.6	1
1921	Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 307-314.	0.6	4
1922	Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 264-270.	0.6	4
1923	Have we reached a molecular era in myelodysplastic syndromes?. Hematology American Society of Hematology Education Program, 2021, 2021, 418-427.	0.9	23
1924	Room for Improvement: A 20-Year Single Center Experience with Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. Indian Journal of Hematology and Blood Transfusion, 0, , 1.	0.3	0
1925	Therapy-related myeloid neoplasms after transcatheter arterial chemoembolization for hepatocellular carcinoma. Blood Research, 2021, 56, 349-353.	0.5	1
1926	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDSâ€Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	0.7	18
1927	Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes. Leukemia and Lymphoma, 2021, , 1-9.	0.6	0
1928	Clinical, immunophenotypic, and cytogenetic characteristics of highâ€grade myelodysplastic syndromes with <scp>CD41</scp>â€positive progenitor cells. Cytometry Part B - Clinical Cytometry, 2023, 104, 98-107.	0.7	1
1929	In Vitro Generated Dendritic Cells of Leukemic Origin Predict Response to Allogeneic Stem Cell Transplantation in Patients With AML and MDS. Journal of Immunotherapy, 2022, 45, 104-118.	1.2	0
1930	Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile. Leukemia and Lymphoma, 2021, , 1-11.	0.6	1
1931	Lower risk but high risk. Hematology American Society of Hematology Education Program, 2021, 2021, 428-434.	0.9	10
1932	The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2023, 104, 115-127.	0.7	7
1934	New Approaches to Myelodysplastic Syndrome Treatment. Current Treatment Options in Oncology, 2022, 23, 668-687.	1.3	12
1935	A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms. Cancer Research Communications, 2022, 2, 258-276.	0.7	0
1936	A randomised phase <scp>II</scp> study of azacitidine (<scp>AZA</scp>) alone or with Lenalidomide (<scp>LEN</scp>), Valproic acid (<scp>VPA</scp>) or Idarubicin (<scp>IDA</scp>) in <scp>higherâ€Risk MDS</scp> or low blast <scp>AML</scp>: <scp>GFM</scp>'s â€œpick a winnerâ€• trial, with the impact of somatic mutations. British Journal of Haematology, 2022, 198, 535-544.	1.2	12
1937	Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS). Cancers, 2022, 14, 1941.	1.7	6

#	Article	IF	Citations
1938	The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH). Leukemia, 2022, 36, 1451-1466.	3.3	14
1939	Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood, 2022, 139, 2273-2284.	0.6	29
1943	Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes. International Journal of Hematology, 2022, 116, 81-88.	0.7	1
1944	Comparative analysis of Decitabine intensified BUCY2 and BUCY2 conditioning regimen for high-risk MDS patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2022, , .	1.3	1
1963	A phase 1b study of glasdegibâ€‰+â€‰azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. Annals of Hematology, 2022, 101, 1689-1701.	0.8	10
1964	Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes. HemaSphere, 2022, 6, e0713.	1.2	3
1965	Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 670-679.	0.2	2
1966	Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. International Journal of Hematology, 2022, 116, 228-238.	0.7	5
1967	Enhancing our chances of picking a winner in higherâ€risk myelodysplastic syndromes. British Journal of Haematology, 2022, , .	1.2	0
1968	De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old are Enriched for Adverse Risk Features. Leukemia Research, 2022, , 106857.	0.4	4
1969	Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis. Leukemia and Lymphoma, 2022, , 1-16.	0.6	1
1970	Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-21.	1.9	2
1971	RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS. Leukemia, 2022, 36, 1898-1906.	3.3	7
1972	Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Modern Pathology, 2022, 35, 1212-1219.	2.9	10
1974	Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2022, 23, 1107-1116.	0.5	1
1975	DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022030.	0.5	2
1976	Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: emerging data and future insights. Expert Review of Hematology, 2022, 15, 411-421.	1.0	0
1977	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation, 2022, 57, 1217-1239.	1.3	119

#	Article	IF	Citations
1978	The Prognostic Value of Pretherapy Peripheral Blood Inflammatory Indices in Myelodysplastic Syndromes. Frontiers in Oncology, 2022, 12, 877981.	1.3	1
1980	Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lowerâ€risk myelodysplastic syndrome. British Journal of Haematology, 2022, 198, 703-712.	1.2	6
1981	Treosulfan compared with <scp>reducedâ€intensity</scp> busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial. American Journal of Hematology, 2022, 97, 1023-1034.	2.0	17
1982	Bone marrow fibrosis impact on response to azacitidine in myelodysplastic syndromes. Pathology, 2022, 54, 763-767.	0.3	2
1983	A Machine Learning Model of Response to Hypomethylating Agents in Myelodysplastic Syndromes. SSRN Electronic Journal, 0, , .	0.4	0
1984	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Bone Marrow Transplantation, 0, , .	1.3	1
1985	Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e874-e883.	0.2	3
1986	Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. Leukemia, 2022, 36, 1947-1950.	3.3	9
1987	Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation. Hematology, 2022, 27, 620-628.	0.7	0
1988	Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Advances, 2022, 6, 5750-5762.	2.5	20
1989	Clinical features and prognosis of patients with gastrointestinal BehÃ§et's disease-like syndrome and myelodysplastic syndrome with and without trisomy 8. Seminars in Arthritis and Rheumatism, 2022, 55, 152039.	1.6	4
1991	Molecular Mechanisms and Therapies of Myeloid Leukaemia. International Journal of Molecular Sciences, 2022, 23, 6251.	1.8	0
1992	Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome. Cancer Management and Research, 0, Volume 14, 1857-1865.	0.9	0
1993	Application of precision medicine in clinical routine in haematologyâ€”Challenges and opportunities. Journal of Internal Medicine, 2022, 292, 243-261.	2.7	12
1994	Acute and chronic leukemias. , 2023, , 403-411.		0
1995	Quantitative evaluation of treatment response to lenalidomide by applying fluorescence <i>in situ</i> hybridization for peripheral blood granulocytes in a patient with 5qâ€“ syndrome. Journal of Clinical and Experimental Hematopathology: JCEH, 2022, , .	0.3	0
1996	Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum. Blood Advances, 2022, 6, 3921-3931.	2.5	7
1997	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	3.3	1,211

#	Article	IF	Citations
1998	Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome. Cancers, 2022, 14, 2984.	1.7	5
1999	Anemia of geriatric patients. Physiology International, 2022, 109, 119-134.	0.8	5
2000	Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. Leukemia and Lymphoma, 2022, 63, 2671-2678.	0.6	0
2001	Hematological disorders after salvage <scp>PARPi</scp> treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes. International Journal of Cancer, 2022, 151, 1791-1803.	2.3	7
2002	What constitutes meaningful improvement in myelodysplastic syndromes?. Leukemia and Lymphoma, 2022, 63, 2528-2535.	0.6	2
2003	Epidemiologic Evaluation of Clinical Outcomes in Ethnic Minorities with Myelodysplastic Syndromes. Leukemia Research, 2022, , 106907.	0.4	0
2004	Iron overload disorders. Hepatology Communications, 2022, 6, 1842-1854.	2.0	33
2005	Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Advances, 2022, 6, 5132-5145.	2.5	43
2006	Global Proteomics Analysis of Bone Marrow: Establishing Talin-1 and Centrosomal Protein of 55 kDa as Potential Molecular Signatures for Myelodysplastic Syndromes. Frontiers in Oncology, 0, 12, .	1.3	2
2007	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
2008	Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood, 2022, 140, 1408-1418.	0.6	13
2009	Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers. Diagnostics, 2022, 12, 1556.	1.3	6
2010	VEXAS Syndrome: A Novelty in MDS Landscape. Diagnostics, 2022, 12, 1590.	1.3	22
2011	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
2012	Vitamin C Deficiency in Patients With Acute Myeloid Leukemia. Frontiers in Oncology, 0, 12, .	1.3	4
2013	A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation. Frontiers in Oncology, 0, 12, .	1.3	0
2014	Myelodysplastic syndrome: epidemiology, diagnostics and epigenetic disorders. Medical Herald of the South of Russia, 2022, 13, 179-190.	0.2	0
2015	Myelodysplastic Syndrome: Diagnosis and Screening. Diagnostics, 2022, 12, 1581.	1.3	4

#	Article	IF	Citations
2016	G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial. Blood Cancer Journal, 2022, 12, .	2.8	2
2017	Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications. Diagnostics, 2022, 12, 1659.	1.3	1
2018	Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study. Frontiers in Oncology, 0, 12, .	1.3	0
2019	Anemia and Other Hematological Problems. , 2022, , 493-505.		0
2020	New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes. International Journal of Molecular Sciences, 2022, 23, 7542.	1.8	16
2021	Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process. Diagnostics, 2022, 12, 1658.	1.3	6
2022	A Novel Germline Mutation in DDX41 Predisposed to Myelodysplasia/Acute Myeloid Leukemia. Laboratory Medicine Online, 2022, 12, 209-213.	0.0	0
2023	Past, present and future in low-risk myelodysplastic syndrome. Frontiers in Medicine, 0, 9, .	1.2	0
2024	Bone marrow <scp>CD3</scp> ⁺ <scp>CD56</scp> ⁺ regulatory T lymphocytes (<scp> T _{R3} </scp> _{â^'56} cells) are inversely associated with activation and expansion of bone marrow cytotoxic T cells in <scp>IPSSâ€R</scp> veryâ€low/low risk <scp>MDS</scp> patients. European Journal of Haematology, 0, , .	1.1	5
2025	Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes withÂring sideroblasts. Blood, 2022, 140, 2170-2174.	0.6	13
2026	ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial. International Journal of Hematology, 0, , .	0.7	0
2027	Prognostic value of the controlling nutritional status score in patients with myelodysplastic syndromes. Frontiers in Nutrition, 0, 9, .	1.6	2
2028	SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 869-877.	0.2	5
2029	In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemiaâ€"A Narrative Review of Current Knowledge. Journal of Clinical Medicine, 2022, 11, 4283.	1.0	0
2030	Effect of thrombopoietin receptor agonist on health-related quality of life and platelet transfusion burden for patients with myelodysplastic syndromes: a systematic review and meta-analysis. Annals of Hematology, 0, , .	0.8	0
2031	Increased Apoptotic Activity in Low-Risk Myelodysplastic Syndrome. Journal of Clinical Medicine, 2022, 11, 4604.	1.0	0
2032	Association between transfusion status and clinical and economic outcomes in patients with myelodysplastic syndromes from the physicians' perspective. Cancer Reports, 0, , .	0.6	1
2033	Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases. Clinical and Experimental Medicine, 2023, 23, 803-813.	1.9	2

#	Article	IF	Citations
2034	Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a realâ€world setting. American Journal of Hematology, 2022, 97, .	2.0	3
2035	Lowerâ€risk myelodysplastic syndromes: Current treatment options for anemia. EJHaem, 2022, 3, 1091-1099.	0.4	2
2036	Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies. Bone Marrow Transplantation, 2022, 57, 1671-1680.	1.3	2
2037	Extracellular Vesicles in Myeloid Neoplasms. International Journal of Molecular Sciences, 2022, 23, 8827.	1.8	2
2038	Phase Ib study of eltrombopag and azacitidine in patients with highâ€risk myelodysplastic syndromes and related disorders (the <scp>ELASTIC</scp> study). British Journal of Haematology, 0, , .	1.2	0
2039	Immunophenotypic changes of monocytes in myelodysplastic syndrome and clinical significance. Clinical and Experimental Medicine, 2023, 23, 787-801.	1.9	1
2040	Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment. Frontiers in Immunology, 0, 13, .	2.2	2
2041	A machine learning model of response to hypomethylating agents in myelodysplastic syndromes. IScience, 2022, 25, 104931.	1.9	7
2042	Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS. Journal of Clinical Medicine, 2022, 11, 4908.	1.0	4
2043	Renal Leukemic Infiltration Overlapping Acute Focal Bacterial Nephritis during Myelodysplastic Syndrome: An Autopsy Case Report. Medicina (Lithuania), 2022, 58, 1060.	0.8	0
2044	HigherÂRUNX1 expression levels are associated with worse overall and leukaemiaâ€free survival in myelodysplastic syndrome patients. EJHaem, 2022, 3, 1209-1219.	0.4	0
2045	Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia. Bone Marrow Transplantation, 2022, 57, 1716-1718.	1.3	6
2046	High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia, 2022, 36, 2306-2316.	3.3	38
2047	Germ line predisposition variants occur inÂmyelodysplastic syndrome patients of all ages. Blood, 2022, 140, 2533-2548.	0.6	48
2048	Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and IDH1 R132C mutation. Leukemia and Lymphoma, 2022, 63, 3000-3003.	0.6	1
2049	Leukemias, Lymphomas, and Plasma Cell Disorders. , 2023, , 237-300.		0
2050	MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia and Lymphoma, 0, , 1-11.	0.6	0
2051	Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes. Frontiers in Oncology, 0, 12, .	1.3	3

#	Article	IF	Citations
2052	Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients. Blood Cancer Journal, 2022, 12, .	2.8	14
2053	Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1â€“2 study. Lancet Haematology,the, 2022, 9, e756-e765.	2.2	39
2054	Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy. Leukemia Research, 2022, 122, 106947.	0.4	1
2055	Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD. Therapeutic Advances in Hematology, 2022, 13, 204062072211275.	1.1	2
2056	The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?. Therapeutic Advances in Hematology, 2022, 13, 204062072211128.	1.1	4
2057	Clinical, Hematological, and Cytogenetic Profile of Myelodysplastic Syndromes in Adults: A Three Year Cross-sectional Study. Oman Medical Journal, 0, , .	0.3	0
2058	IPSS-M Incorporates Next-Generation Sequencing for a New International Prognostic Scoring System. , 2022, 19, .		0
2059	Myelodysplastic Syndrome: A Real-World Experience from a Developing Country. SSRN Electronic Journal, 0, , .	0.4	0
2061	Haplo-Peripheral Blood Stem Cell Plus Cord Blood Grafts for Hematologic Malignancies Might Lead to Lower Relapse Compared with Haplo-Peripheral Blood Stem Cell Plus Bone Marrow Grafts. Transplantation and Cellular Therapy, 2022, , .	0.6	0
2062	Causes and Pathophysiology of Acquired Sideroblastic Anemia. Genes, 2022, 13, 1562.	1.0	3
2063	SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e1059-e1066.	0.2	2
2064	Clinical Application of Biomarkers for Hematologic Malignancies. , 2022, , 150-212.		0
2066	IMMUNE DEREGULATION IN MYELODYSPLASTIC SYNDROMES - THE ROLE OF CYTOKINES AND SOLUBLE ADHESION MOLECULES. A PILOT STUDY. Military Medical Science Letters (Vojenske Zdravotnicke Listy), 0, , .	0.2	0
2067	Quality of Life in Low-Risk MDS: An Undervalued Endpoint. Journal of Clinical Medicine, 2022, 11, 5699.	1.0	2
2068	Extracellular Vesicles in Haematological Disorders: A Friend or a Foe?. International Journal of Molecular Sciences, 2022, 23, 10118.	1.8	2
2069	Global methylation status of LINE-1 in pediatric myelodysplastic syndrome: a predictive biomarker of prognosis?. Leukemia and Lymphoma, 0, , 1-4.	0.6	0
2070	Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients. American Journal of Hematology, 2022, 97, 1589-1598.	2.0	8
2071	Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory. BMC Cancer, 2022, 22, .	1.1	4

#	Article	IF	Citations
2072	Can Lower-Risk MDS Achieve High Reward with Hypomethylating Agent Therapy?. , 2022, 1, .		0
2074	Diagnosis and Treatment of Myelodysplastic Syndromes. JAMA - Journal of the American Medical Association, 2022, 328, 872.	3.8	44
2075	Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes. Annals of Medicine, 2022, 54, 2627-2636.	1.5	1
2076	Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms â€“ results of the EUROPE trial by EMSCO. Leukemia, 0, , .	3.3	1
2077	Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Experimental Hematology, 2022, 115, 44-53.	0.2	2
2078	Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes. Current Oncology, 2022, 29, 6933-6946.	0.9	0
2079	Healthy-like CD4+ Regulatory and CD4+ Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte Infusion. International Journal of Molecular Sciences, 2022, 23, 10914.	1.8	2
2080	NPM1 mutations are associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype.. Leukemia Research, 2022, , 106965.	0.4	0
2081	Usefulness of Genetic Aberration and Shorter Telomere Length in Myelodysplastic Syndrome: A Pilot Study. Laboratory Medicine, 0, , .	0.8	0
2082	Pediatric nonâ€“Downâ€™s syndrome acute megakaryoblastic leukemia patients in China: A single center's real-world analysis. Frontiers in Oncology, 0, 12, .	1.3	4
2083	Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment. Advances in Biological Regulation, 2023, 87, 100920.	1.4	4
2084	Quantitative Assessment of Bone Marrow Activity Using 18F-FLT PET in Aplastic Anemia and Myelodysplastic Syndromes. Clinical Nuclear Medicine, 0, Publish Ahead of Print, .	0.7	1
2085	Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes. Annals of Hematology, 2022, 101, 2633-2643.	0.8	2
2086	Flow cytometry lyophilised-reagent tube for quantifying peripheral blood neutrophil myeloperoxidase expression in myelodysplastic syndromes (MPO-MDS-Develop): protocol for a diagnostic accuracy study. BMJ Open, 2022, 12, e065850.	0.8	0
2089	Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations. Lancet Haematology,the, 2023, 10, e71-e78.	2.2	6
2090	Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes. European Journal of Haematology, 2022, 109, 772-778.	1.1	3
2092	Treatment of lower-risk myelodysplastic syndrome. Medicinski Pregled, 2022, 75, 32-37.	0.1	0
2093	Treatment of higher-risk myelodysplastic syndrome. Medicinski Pregled, 2022, 75, 38-43.	0.1	0

#	Article	IF	Citations
2094	Diagnosis, classification, and prognosis of myelodysplastic syndromes. Medicinski Pregled, 2022, 75, 25-31.	0.1	0
2097	Allogeneic stem cell transplantation for patients with myelodysplastic syndromes. American Journal of Hematology, 2023, 98, 322-337.	2.0	5
2098	Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation. Diagnostics, 2022, 12, 2493.	1.3	1
2099	Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome. Scientific Reports, 2022, 12, .	1.6	1
2100	Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms. Leukemia, 2022, 36, 2875-2882.	3.3	17
2101	Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine. Clinical Cancer Research, 2022, 28, 5306-5316.	3.2	4
2102	IPSS-M has greater survival predictive accuracy compared with IPSS-R in personsâ€‰â‰¥â€‰60Âyears with myelodysplastic syndromes. Experimental Hematology and Oncology, 2022, 11, .	2.0	17
2103	SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis. Leukemia, 2022, 36, 2894-2902.	3.3	12
2104	The International Consensus Classification of myelodysplastic syndromes and related entities. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2023, 482, 39-51.	1.4	6
2105	Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes. Cancers, 2022, 14, 4941.	1.7	7
2106	Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia. Frontiers in Oncology, 0, 12, .	1.3	5
2107	Paradigm shift in monogenic autoinflammatory diseases and systemic vasculitis: The VEXAS syndrome. Medicina ClÃnica (English Edition), 2022, 159, 489-496.	0.1	0
2108	VEXAS Syndromeâ€”A Review of Pathophysiology, Presentation, and Prognosis. Journal of Clinical Rheumatology, 2023, 29, 298-306.	0.5	5
2109	Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies. Leukemia, 2022, 36, 2734-2738.	3.3	2
2110	The genetics of myelodysplastic syndromes and the opportunities for tailored treatments. Frontiers in Oncology, 0, 12, .	1.3	4
2111	Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia, 2022, 36, 2939-2946.	3.3	14
2112	Over expression of mTOR gene predicts overall survival in myelodysplastic syndromes. Molecular Biology Reports, 0, , .	1.0	0
2113	Germ lineDDX41mutations define a unique subtype of myeloid neoplasms. Blood, 2023, 141, 534-549.	0.6	52

#	Article	IF	Citations
2114	How can we incorporate molecular data into the IPSS?. Best Practice and Research in Clinical Haematology, 2022, 35, 101410.	0.7	1
2116	Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment. Biomedicine and Pharmacotherapy, 2022, 156, 113905.	2.5	5
2117	Predicting Medical Outcomes. , 2022, , 309-342.		0
2118	Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age. Blood Reviews, 2023, 59, 101033.	2.8	5
2119	Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment. Cancers, 2022, 14, 5531.	1.7	4
2120	Cause of death and excess mortality in patients with lowerâ€risk myelodysplastic syndromes (MDS): A report from the European <scp>MDS</scp> registry. British Journal of Haematology, 2023, 200, 451-461.	1.2	5
2123	Azacitidine Monotherapy in Patients With Treatment-NaÃ¯ve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 127-137.	0.2	3
2125	Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. Leukemia Research, 2023, 124, 106999.	0.4	3
2126	Management of Adult Patients with Myelodysplastic Syndromes. European Medical Journal Hematology, 0, , 104-112.	0.0	0
2127	The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms. Cancers, 2022, 14, 5690.	1.7	3
2128	Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transplantation and Cellular Therapy, 2023, 29, 71-81.	0.6	10
2129	Therapeutic approaches for the management of higher risk myelodysplastic syndromes. Leukemia and Lymphoma, 2023, 64, 511-524.	0.6	2
2130	<i>IDH</i> mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy. Haematologica, 2023, 108, 1168-1172.	1.7	2
2131	The use of carbon monoxide breath test to detect the effect of iron overload on erythrocyte lifespan in MDS. Frontiers in Oncology, 0, 12, .	1.3	0
2132	Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts. Annals of Hematology, 0, , .	0.8	1
2133	A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. Lancet Haematology,the, 2023, 10, e117-e128.	2.2	8
2134	Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer Journal, 2022, 12, .	2.8	8
2135	Role of Bclâ€2 inhibition in myelodysplastic syndromes. International Journal of Cancer, 2023, 152, 1526-1535.	2.3	0

#	Article	IF	Citations
2136	Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome. International Journal of Hematology, 0, , .	0.7	1
2137	Transplant for TP53-mutated MDS and AML: because we can or because we should?. Hematology American Society of Hematology Education Program, 2022, 2022, 522-527.	0.9	7
2138	New investigational combinations for higher-risk MDS. Hematology American Society of Hematology Education Program, 2022, 2022, 368-374.	0.9	2
2139	Allogeneic transplantation for advanced acute leukemia. Hematology American Society of Hematology Education Program, 2022, 2022, 534-538.	0.9	1
2140	Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience. Frontiers in Pharmacology, 0, 13, .	1.6	4
2141	Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia. Blood Reviews, 2023, 59, 101039.	2.8	1
2142	Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component. Cancers, 2022, 14, 6244.	1.7	1
2143	SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia. Clinical Epigenetics, 2022, 14, .	1.8	2
2144	Risk stratifying MDS in the time of precision medicine. Hematology American Society of Hematology Education Program, 2022, 2022, 375-381.	0.9	5
2145	Comparison of Molecular International Prognostic Scoring System (M-IPSS) and Revised International Prognostic Scoring System (R-IPSS) in Thai patients with myelodysplastic neoplasms. Hematology, 2022, 27, 1294-1297.	0.7	2
2146	The spectrum of GATA2 deficiency syndrome. Blood, 2023, 141, 1524-1532.	0.6	17
2147	Clinical and Prognostic Impact of STAG2 Mutations in Myeloid Neoplasms: The Mayo Clinic Experience. Blood Advances, 0, , .	2.5	1
2148	Contingent Synergistic Interactions between Non-Coding RNAs and DNA-Modifying Enzymes in Myelodysplastic Syndromes. International Journal of Molecular Sciences, 2022, 23, 16069.	1.8	3
2149	Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues. Cytometry Part B - Clinical Cytometry, 2023, 104, 27-50.	0.7	10
2150	A Rare Case of Extensive Erythrophagocytosis by Pathological Erythroblasts in a Patient With Myelodysplastic Syndrome. Annals of Laboratory Medicine, 2023, 43, 303-306.	1.2	0
2151	Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation. Nature Communications, 2023, 14, .	5.8	9
2152	Clinicoâ€genetic and prognostic analyses of 716 patients with primary <scp>myelodysplastic syndrome</scp> and <scp>myelodysplastic syndrome/acute myeloid leukemia</scp> based on the 2022 International Consensus Classification. American Journal of Hematology, 2023, 98, 398-407.	2.0	5
2153	Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 355-359.	0.2	2

#	Article	IF	Citations
2154	Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2023, 98, 681-689.	2.0	6
2155	Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (<scp>CyTOF</scp>). Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2023, 103, 551-562.	1.1	4
2156	Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes. Future Oncology, 2022, 18, 4017-4029.	1.1	3
2157	Analysis of Immune-Cell Distribution of Bone Marrow in Patients with Myelodysplastic Syndrome. Hematology Reports, 2023, 15, 50-56.	0.3	0
2158	A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features. Modern Pathology, 2023, 36, 100068.	2.9	0
2159	Advances in myelodysplastic syndromes: promising novel agents and combination strategies. Expert Review of Hematology, 0, , 1-13.	1.0	2
2160	Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study. Annals of Hematology, 2023, 102, 311-321.	0.8	2
2161	Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway. Hematology, 2023, 28, .	0.7	3
2162	Clinical significance of prognostic nutritional index in myelodysplastic syndrome. Hematology, 2023, 28, .	0.7	1
2163	Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world. Journal of Geriatric Oncology, 2023, 14, 101418.	0.5	0
2164	Germline Predisposition to Myeloid Neoplasms in Inherited Bone Marrow Failure Syndromes, Inherited Thrombocytopenias, Myelodysplastic Syndromes and Acute Myeloid Leukemia: Diagnosis and Progression to Malignancy. Journal of Hematology Research, 0, 8, 11-38.	0.5	2
2165	Where diagnosis for myelodysplastic neoplasms (<scp>MDS</scp>) stands today and where it will go: The role of flow cytometry in evaluation of <scp>MDS</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 12-14.	0.7	1
2166	Impact of the International Consensus Classification of myelodysplastic syndromes. British Journal of Haematology, 2023, 201, 443-448.	1.2	3
2167	How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms. Clinical Hematology International, 2023, 5, 8-20.	0.7	1
2168	RNA Interference (RNAi): An Effective Way to Develop Rational Combination Therapies with Hypomethylating Agents in Acute Leukaemias and Myelodysplastic Syndrome. European Medical Journal Hematology, 0, , 53-57.	0.0	0
2169	Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea. Yonsei Medical Journal, 2023, 64, 123.	0.9	0
2170	Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes. Blood, 2023, 141, 1768-1772.	0.6	11
2171	Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediateâ€1 risk patients with myelodysplastic syndromes. Oncology Letters, 2023, 25, .	0.8	0

#	Article	IF	Citations
2172	Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia, 2023, 37, 717-719.	3.3	7
2173	Myelodysplastic syndromes, thy name is heterogeneity. British Journal of Haematology, 2023, 201, 381-382.	1.2	2
2175	Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-transplant Follow-Up: The Role of Next-Generation Sequencing. Biomedicines, 2023, 11, 359.	1.4	0
2176	Increased Inflammasome Activation Is Associated with Aging and Chronic Myelomonocytic Leukemia Disease Severity. Journal of Immunology, 2023, 210, 580-589.	0.4	8
2177	Telomere integrated scoring system of myelodysplastic syndrome. Journal of Clinical Laboratory Analysis, 2023, 37, .	0.9	1
2178	High BM plasma S100A8/A9 is associated with a perturbed microenvironment and poor prognosis in myelodysplastic syndromes. Blood Advances, 2023, 7, 2528-2533.	2.5	4
2179	Considerations for Drug Development in Myelodysplastic Syndromes. Clinical Cancer Research, 2023, 29, 2573-2579.	3.2	3
2180	clevRvis: visualization techniques for clonal evolution. GigaScience, 2022, 12, .	3.3	2
2181	Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype. EJHaem, 2023, 4, 446-449.	0.4	2
2182	Introduction to a review series on germ line predisposition to hematologic malignancies: time to consider germ line testing. Blood, 2023, 141, 1509-1512.	0.6	2
2183	Myelodysplastic syndromes: new methods of diagnosis, prognostication, and treatment. Deutsches Ärzteblatt International, 0, , .	0.6	2
2184	The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms. American Journal of Hematology, 2023, 98, .	2.0	1
2185	New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia. Current Research in Translational Medicine, 2023, 71, 103386.	1.2	6
2186	Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes. Current Treatment Options in Oncology, 0, , .	1.3	1
2187	The Proliferation Index of Erythroid Cells Predicts the Development of Transfusion-dependence in Myelodysplastic Syndrome Patients With Mildly Reduced Hemoglobin Levels at Initial Diagnosis. HemaSphere, 2022, 6, e804.	1.2	1
2189	Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes â€“ A potential prognostic marker?. Frontiers in Oncology, 0, 12, .	1.3	0
2191	Risk prediction in MDS: independent validation of the IPSS-Mâ€”ready for routine?. Leukemia, 2023, 37, 938-941.	3.3	12
2192	Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication. Current Opinion in Hematology, 2023, 30, 30-37.	1.2	1

#	Article	IF	Citations
2193	HÃmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
2194	Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation. Nature Communications, 2023, 14, .	5.8	7
2195	Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS. Blood Advances, 2023, 7, 2952-2956.	2.5	7
2196	High Co-Expression of PDCD1/TIGIT/CD47/KIR3DL2 in Bone Marrow Is Associated with Poor Prognosis for Patients with Myelodysplastic Syndrome. Journal of Oncology, 2023, 2023, 1-11.	0.6	0
2197	Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes. JCO Oncology Practice, 2023, 19, e559-e569.	1.4	1
2198	Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. Bone Marrow Transplantation, 2023, 58, 534-543.	1.3	5
2199	Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. Blood Reviews, 2023, 60, 101056.	2.8	2
2200	Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes. Scientific Reports, 2023, 13, .	1.6	1
2201	Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression. Leukemia, 2023, 37, 680-690.	3.3	5
2202	Incidence and predisposing factors of infection in patients treated with hypomethylating agents. Leukemia Research, 2023, 127, 107043.	0.4	2
2203	Molecular Drivers of Myelodysplastic Neoplasms (MDS)â€"Classification and Prognostic Relevance. Cells, 2023, 12, 627.	1.8	2
2204	A Multicenter Phase 2 Clinical Trial of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2023, 29, 328.e1-328.e6.	0.6	2
2205	Extracellular Vesicles and MicroRNA in Myelodysplastic Syndromes. Cells, 2023, 12, 658.	1.8	1
2206	Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidineâ€"A Prospective Cohort Study by the AGMT. Cancers, 2023, 15, 1388.	1.7	3
2207	Hereditary predisposition to malignant myeloid hemopathies: Caution in use of saliva and guideline based on our experience. Frontiers in Oncology, 0, 13, .	1.3	1
2208	Appropriate pre-transplant strategy for patients with myelodysplastic syndromes receiving allogeneic haematopoietic stem cell transplantation after myeloablative conditioning. Frontiers in Immunology, 0, 14, .	2.2	0
2209	Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2023, 24, 5018.	1.8	7
2210	Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases. Hematology Reports, 2023, 15, 180-187.	0.3	1

#	Article	IF	Citations
2211	Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome. Frontiers in Nutrition, 0, 10, .	1.6	0
2213	Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of Clinical Oncology, 2023, 41, 2815-2826.	0.8	35
2214	TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia. Transplantation and Cellular Therapy, 2023, 29, 390.e1-390.e10.	0.6	3
2215	Wilmsâ€™ tumor 1 expression combined with genetic mutations for prognostic assessment in MDS. Leukemia and Lymphoma, 2023, 64, 856-864.	0.6	0
2216	Reconstructing Clonal Evolutionâ€"A Systematic Evaluation of Current Bioinformatics Approaches. International Journal of Environmental Research and Public Health, 2023, 20, 5128.	1.2	0
2217	Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy. Leukemia Research Reports, 2023, 19, 100367.	0.2	0
2218	The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2023, 24, 5734.	1.8	4
2219	Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. Journal of Clinical Oncology, 2023, 41, 2827-2842.	0.8	29
2220	m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis. Molecular Cell, 2023, 83, 1165-1179.e11.	4.5	10
2222	Outcomes of patients with therapyâ€related myeloid neoplasms after treatment with poly() Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Haematology, 2023, 201, .	1.2	2
2224	Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 2023, , .	0.6	0
2225	Clonal haematopoiesis and dysregulation of the immune system. Nature Reviews Immunology, 2023, 23, 595-610.	10.6	18
2226	Discriminant Principal Component Analysis of ToFâ€SIMS Spectra for Deciphering Compositional Differences of MSCâ€Secreted Extracellular Matrices. Small Methods, 2023, 7, .	4.6	3
2227	Recombinant human thrombopoietin promotes platelet recovery in DCAG-treated patients with intermediate-high-risk MDS/hypoproliferative AML. Medicine (United States), 2023, 102, e33373.	0.4	0
2228	Updates in molecular genetics of therapy-related myeloid neoplasms. Seminars in Diagnostic Pathology, 2023, , .	1.0	0
2229	Some results of a pilot study of mutations in ASXL1 and DNMT3A genes in myelodysplastic syndrome. Ã›Å¾no-Rossijskij Å¾urnal TerapevtiÄeskoj Praktiki, 2023, 4, 97-105.	0.1	0
2230	Raising the bar for lower-risk myelodysplastic syndromes. Leukemia and Lymphoma, 2023, 64, 1082-1091.	0.6	0
2231	Statin use in myelodysplastic syndromes is associated with a better survival and decreased progression to leukemia. Blood Advances, 2023, 7, 3838-3841.	2.5	2

#	Article	IF	Citations
2233	Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents. Current Hematologic Malignancy Reports, 0, , .	1.2	0
2234	Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group. Cancers, 2023, 15, 2305.	1.7	2
2235	Epigenetic regulation by ASXL1 in myeloid malignancies. International Journal of Hematology, 2023, 117, 791-806.	0.7	4
2236	An Assessment of the Three Popular Prognostic Scoring Systems for Chronic Myelomonocytic Leukemia (CMML) in an Indian Context. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.1	0
2237	A View on Drug Development for Cancer Prevention. Cancer Discovery, 2023, 13, 1058-1083.	7.7	2
2238	Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clinical Hematology International, 2023, 5, 143-154.	0.7	7
2239	Myelodysplastic syndrome: Approach to diagnosis in the era of personalized medicine. Seminars in Diagnostic Pathology, 2023, 40, 172-181.	1.0	1
2240	STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)Â+Âazacitidine in higher risk MDS and CMML-2. Future Oncology, 2023, 19, 631-642.	1.1	6
2241	Improving the diagnosis of myelodysplastic syndrome by red blood cell parameters. Clinical and Translational Oncology, 0, , .	1.2	0
2244	Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature. Bone Marrow Transplantation, 0, , .	1.3	0
2249	Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome Patients. , 2024, , 263-277.		0
2294	Venetoclax-based salvage for management of relapsed acute leukaemia after allogeneic haematopoetic stem cell transplant: durable remissions only seen following consolidation with donor lymphocyte infusion or second transplant. Bone Marrow Transplantation, 0, , .	1.3	0
2298	Chronic neutrophilic leukemia preceded by myelodysplastic syndromes. International Journal of Hematology, 0, , .	0.7	0
2303	Stem Cell Transplant for Acute Myeloid Leukemia. , 2023, , 501-534.		0
2322	MDS. , 2023, , 75-79.		0
2339	Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC. Leukemia, 2023, 37, 2138-2141.	3.3	2
2358	Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia, 0, , .	3.3	0
2360	Novel Strategies to Manage Cytopenia in Low-Risk MDS. , 2023, , 461-467.		0

#	Article	IF	Citations
2361	Prognostic Indicators in MDS and CMML. , 2023, , 421-435.		0
2364	Hematologic Disorders. , 2023, , 1-31.		0
2365	Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patientsâ€™ outcome?. Leukemia, 0, , .	3.3	0
2373	Molecular testing in myelodysplastic syndromes. , 2024, , 589-596.		0
2390	Case report: Pediatric acute lymphoblastic leukemia with trisomy 5 as sole cytogenetic abnormality. IP Journal of Diagnostic Pathology and Oncology, 2023, 8, 234-236.	0.0	0
2409	Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M. Blood Cancer Journal, 2023, 13, .	2.8	0
2423	AnÃ©mies. , 2023, , 369-374.		0
2425	Ancillary Tests. , 2024, , 97-120.		0
2426	Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort. Frontiers in Immunology, 0, 15, .	2.2	0
2437	Genomic technologies for detecting structural variations in hematologic malignancies. Blood Research, 2024, 59, .	0.5	0
2438	Myelodysplastic Syndrome. , 2024, , .		0
2440	Hematologic Disorders. , 2024, , 511-541.		0
2443	HÃmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0